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Abstract 
The ovary is one of the most dynamic organs in the human body.   Ovaries have a 
finite pool of follicles during fetal life.  On-going follicular atresia significantly 
contributes to a quantitative and qualitative decline in ovarian reserve.   Only a tiny 
number of follicles are released between puberty and menopause in the form of 
ovulation.  Reproductive outcome following assisted conception significantly depends 
upon the quality and quantity of oocytes.  Ovarian reserve is a significant predictor of 
ovarian response during the assisted conception treatment cycle.  It not only 
determines the number of oocytes to be collected but also controls the pregnancy 
outcome.  The first two publications evaluate the prediction of ovarian reserve and 
management of the poor ovarian reserve.  The third and fourth publications analyse 
use of donor oocyte as a treatment option and the pregnancy complications associated 
with donor oocyte.   The fifth publication examines the factors affecting fertilisation 
rates in assisted conception and strategies to improve the fertilisation process.  Poor 
quality oocytes and the resultant poor-quality embryo is one of the primary causes for 
miscarriage in natural and assisted conception.  The sixth and seventh publications 
discuss the diagnosis and management of miscarriages.  These publications have 
significant clinical and research implications which are discussed in results and 
discussion chapter.  Especially sixth publication contributed to changing the national 
guideline on the diagnosis of missed miscarriage.  Recent research updates that 
occurred after our research period are discussed in a separate chapter.   Further 
research is required to manage the reproductive outcomes related to the poor quantity 
and quality of oocytes.      
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Chapter 1: Introduction 
 
“Formulation of a problem is often more essential than its solution, which may be 
merely a matter of mathematical or experimental skills. To raise new questions, new 
possibilities, to regard old problems from a new angle requires creative imagination 
and marks real advances in science.”  
Albert Einstein (Einstein and Infeld, Evolution of Physics, 1938, page 92). 
 
This year is the 40th birth anniversary of the first human born following in-vitro 
fertilisation (IVF), a milestone in human history and the landmark achievement for 
Reproductive Science.  It has opened the path for new scientific breakthroughs and 
clinical success, enabling the creation of new families and treatment for subfertility.  
More than 8 million babies have been born using IVF since 1978 (Niederberger et al., 
2018).  Although the advancements in Reproductive Science have helped many 
patients, IVF still is unsuccessful for more than half of patients undergoing treatment.  
Each failed approach to improve the success rate of the treatment resulted in the seeds 
of further research and technological advances.  Reproductive Science continues to 
build on failures.  Each stage in the IVF pathway, from obtaining good quality gametes 
to the birth of a healthy child, can result in challenges for health-professionals and 
patients.  Finding solutions to overcome these challenges through rigorous and robust 
research is essential.  In the words of Albert Einstein, the underlying problems require 
robust analysis before searching for solutions.  The current work presented here is a 
systematic analysis of some of the critical challenges in Reproductive Medicine with 
the central theme of the ovum.   
 
1.1: Human ovarian physiology and physiology of conception 
Ovaries are dynamic structures that are composed of multiple compartments.  
Primordial germ cells originate in the endoderm of the yolk sac, hindgut, and allantois.  
The maximum number of oocytes, around 6-7 million in both ovaries (Baker, 1963), 
is reached at 16-20 weeks of gestation.  The ovaries undergo a regular monthly cycle 
consisting of follicular growth, ovulation, and formation of corpus luteum.  If 
pregnancy does not occur then, the corpus luteum is lysed resulting in the onset of in 
the onset of menses.  Follicular recruitment and subsequent growth are a complex 
process that is coordinated by multiple hormones.  At puberty, follicular recruitment 
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begins at the beginning of monthly menstrual cycles.  Every month the ovaries 
produced a single egg, which is ready to be fertilised by sperm.  The female body is 
adapted for conception and implantation of fertilised egg in the form of an embryo by 
coordinated secretion of hormones.  If fertilisation fails, then luteolysis begins and the 
cycle is terminated.  The average time for ovulation and next luteolysis with the onset 
of another period is average of 28 days.  The entire cycle consists of three distinct 
phases that include the selection of the dominant follicle, establishment of the 
ovulatory phase and corpus luteum maintenance or its lysis (Gougeon, 1986).   
 
Follicular development is usually seen in both the ovaries.  The time required from a 
primary follicle to ovulation is approximately 85 days (Oktay et al., 1998).  Most of 
time needed during this development is gonadotropin independent.  Many small 
follicles start developing in response to gonadotrophic hormones.  All these small 
follicles become mitotically active and start growing at the same time.  The number of 
small follicles that mature is dependent on the amount of follicle stimulating hormone 
FSH available and the sensitivity of the follicles to the gonadotropins.  In healthy 
women who are cycling naturally, only one of the follicles is destined to release the 
oocyte.  This single follicle is known as the dominant follicle (Goodman and Hodgen, 
1983).  The intraovarian environment governs the choice of dominant follicle.  
Hormones secreted during each phase play a distinct role in the whole process.  
Follicle stimulating hormones is the hormone responsible for the development of 
multiple follicles at the same time.  FSH levels fall after choice of the dominant follicle 
because of negative feedback mechanism.  Granulosa cells start releasing oestrogen.  
Oestrogen produces cyclic changes in the uterine endometrium and vaginal 
epithelium.  It prepares the endometrium for implantation.  Oestrogen production from 
the developing follicle leads to the luteinizing hormone (LH) surge that results in 
ovulation.  Luteinising hormone plays an important role and serves as the essential 
maker for ovulation.  Once LH levels show a surge, then ovulation happens within 36-
38hrs of LH peak.  If fertilisation does not occur, then the corpus luteum disappears.  
Fall in oestrogen and progesterone levels result in the initiation of menses (McNatty 
et al., 1979, McNatty, 1979).   
To summarise the events, initial follicular development occurs independent of 
hormone influence, FSH stimulation drives follicles to the preantral stage, FSH 
induced aromatisation of androgen in the granulosa results in the production of 
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oestrogen, and FSH and oestrogen both together increases the number of FSH receptor 
of the follicle.  The next step is a choice of a dominant follicle.  Dominant follicle is 
established by day 5-7.  This selection process is the result of oestrogen action within 
the maturing follicle, which is a positive influence of FSH action and negative 
feedback at the hypothalamic-pituitary level.  LH levels rise steadily during the late 
follicular phase stimulating androgen production in the theca.  FSH induces LH 
receptors.  LH initiate luteinisation and progesterone production in the granulosa layer.  
LH surge stimulates luteinisation, synthesis of progesterone and prostaglandins within 
the follicles (McNatty, 1979).  Progesterone enhances the activity of proteolytic 
enzymes and with prostaglandins digestion and rupture of follicle wall.   
 
If the released oocyte is fertilised by sperm, early pregnancy human chorionic 
gonadotropin HCG rescues the corpus luteum.  It continues to maintain luteal function 
until placental steroidogenesis is well established.  Spermatozoa require 
approximately 72 days for production and maturation.  Only a few hundred sperm 
reach the oocyte.  They are stored at the cervix for up to 72 hours (Bedford, 1994).  
After ovulation, oocyte starts to travel through the fallopian tubes.  Tubal transport 
depends on smooth muscle contraction and ciliary action.  Sperm penetration depends 
on acrosomal proteinase and binding of sperm receptors to zona ligands (Katz et al., 
1989).  The capacitation and following acrosome reaction results in activated sperm 
that discharges the nucleus into the oocyte cytoplasm.  The fertilization triggers cell 
division that result in the formation of the embryo.  The early embryo enters the uterine 
cavity as a morula.  It develops further to blastocyst stage before implantation.  The 
implantation window is when the endometrium is receptive for an embryo.  A complex 
activity of cytokines, lipids and growth factors modulated by progesterone progresses 
endometrium to the receptive stage.  Adhesion molecules integrins and cytokines play 
a crucial role in implantation.  Transient expression of the leukaemia-inhibitory factor 
in mice is essential for implantation (Stewart et al., 1992).  Other vital cytokines are 
colony stimulating factor-1 and interleukin-1 (Simon et al., 1996).   
Thus, if the fertilisation and implantation are successful, it results in maintained levels 
of progesterone for gestation.  Human chorionic gonadotropin secretion is ensured to 
continue the relevant process.   
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1.2: The quantitative and qualitative decline in oocyte with age and reproductive 
implications 
Age alone has a significant impact on fertility.  The average age of first-time mothers 
has increased worldwide; this delay in childbearing contributes to an increasing 
incidence of subfertility.  A primordial follicle is a non-growing follicle (NGF).  These 
follicles continue to have growth and atresia under all circumstances continuously.  
Therefore, the number continues to decline with age.  The rate of decline is 
proportional to the total number present.  Most rapid drop occurs before birth.  
Approximately 2 million oocytes present at birth and 300,000 at puberty as compared 
to 6-7 million at 16-20 weeks.  Out of all these follicles, 400 will ovulate throughout 
reproductive years.  Figure 1 shows a model of non-growing follicle numbers based 
upon several histological studies of the human ovary (Wallace and Kelsey, 2010). 
   
 
Figure 1:  The age-related decline in NGF 
 
The gradual decrease in oocyte number is associated with an increase in circulating 
levels of follicle stimulating hormones and increased atresia of follicles.  The early 
growth of follicles takes several months.  This growth is not dependent on the 
hormone.  The cohort of follicles reaches a stage when if it is not recruited by FSH 
action, it undergoes atresia.   
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Age not only results in the quantitative decline in oocyte but it also reduces the quality 
of oocytes.  Aged oocytes display increased chromosomal abnormality and 
dysfunction of cellular organelles, both of which factor into oocyte quality(Igarashi et 
al., 2015).  This age-related decline in fecundity is strongly dependent on oocyte 
quality, which is critical for fertilization and subsequent embryo development.  Aging 
oocyte negatively influence fertilization and development (Miao et al., 2009).   
 
There is a marked increase in the risk of aneuploidy, miscarriage, and birth defects 
with increasing maternal age.  Although the aetiology of such pathologies is 
complicated, there is a well-established causative relationship between the age-related 
decline in oocyte quality and oxidative stress (Mihalas et al., 2017).  Chromosomal 
errors during human conception have an astonishingly high rate, and the most of these 
errors are derived from the oocyte (Hassold and Hunt, 2001).  Aneuploidy rate 
increases exponentially from 30 to 35 years from baseline 20% of oocytes to on 
average 80% by 42 years (Capalbo et al., 2017).  Thus, the accelerated decline in 
genetic quality of oocytes starts from 30 years of age.  There is a high chance of non-
disjunction of spindle poles in oocytes that is associated with higher chances of 
attrition (Ottolenghi et al., 2004).  An age-related increase in meiotic non-disjunction 
suggested causing chromosomal aneuploidy and early pregnancy loss (te Velde and 
Pearson, 2002).  Women who delay their pregnancies post 30’s can have issues with 
both conceiving and maintenance of pregnancies. Such age-related rapid decline is not 
seen in men as sperm production and maturation is a continuous process.  
    
1.3: Research gap and evidence synthesis to bridge the gap 
Although quantity and quality are interlinked and could be dependent upon each other, 
ovarian reserve tests predict the amount and not the quality.  Antral follicle count 
(AFC) and anti-Müllerian hormone (AMH) are good predictors of ovarian reserve.  A 
diminished ovarian reserve is not associated with increased aneuploidy or an increase 
in miscarriage rate among younger women (Bishop et al., 2017).  Therefore, clinicians 
require an appropriate tool to predict both quantitative and qualitative reserve.  The 
most widely used and consistent predictor of the quality of oocytes is maternal age.  
AMH is a more direct and independent measure of the growing preantral and antral 
follicular pool.  Such prediction is crucial in especially poor responder groups. 
15 
 
Publication 1 attempts to bridge the research gap using a novel approach of combining 
age and AMH for poor responder group (Jeve, 2013).   
 
Poor ovarian reserve results in poor ovarian response during IVF cycle.  Researchers 
have explored various strategies to treat poor ovarian response.  Women with 
diminished ovarian reserve are one of the most challenging groups to manage in 
assisted conception.  There are various observational studies, randomized controlled 
trials, and systematic reviews reported (Kyrou et al., 2009, Sunkara et al., 2011a, 
Polyzos and Devroey, 2011, Narkwichean et al., 2013, Gonzalez-Comadran et al., 
2012).  However, the published literature has been shown to have qualitative 
limitations.  Many of the published studies are too specific to evaluate one approach 
(Kyrou et al., 2009, Bosdou et al., 2012) or too inexplicit with cohort and randomised 
data combined (Narkwichean et al., 2013).  There was a need for more comprehensive 
good quality synthesis of all available evidence at one place. 
 
Publication 2 is a systematic review and meta-analysis of all good quality randomised 
trials to find out effective treatment protocol for poor responders(Jeve and Bhandari, 
2016).  
 
Donor oocyte IVF is an alternative treatment option for women with diminished 
oocyte quantity and quality.  There is a substantial increase in the number of donor 
oocyte recipients in recent years (Kupka et al., 2014).  However, donor oocyte 
pregnancy is not risk-free.  Advanced maternal age in itself can cause pregnancy 
complications (Michalas et al., 1996, Simchen et al., 2006).  Pregnancies achieved by 
IVF or by intracytoplasmic sperm injection (ICSI) are at a higher risk for pregnancy 
complications compared with spontaneous pregnancies (Wang et al., 1994, Maman et 
al., 1998).  Therefore, the question is whether increased risks with donor oocyte IVF 
is due to the biological origin of oocyte or maternal age or IVF technology.  
Publication 3 is a cohort study, which compares donor oocyte IVF with natural 
conception and autologous oocyte IVF conception (Jeve et al., 2016b). Publication 4 
is a systematic review and meta-analysis of all published evidence on the obstetric 
outcome of donor oocyte conception (Jeve et al., 2016a).   
Poor fertilisation rates and miscarriage rates could be the result of poor quality of 
gametes (Braude and Rowell, 2003, Hourvitz et al., 2006).  Fertilisation rate has an 
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impact on the outcome of the treatment cycle. Fertilisation rates of 60% or over are 
expected (Braude and Rowell, 2003).  When oocytes collected during IVF cycle are 
few, which occur with diminished ovarian response group, it is far more critical to 
have a maximum number of oocytes fertilised.  Researchers have attempted various 
interventions to improve fertilisation rates (Mokanszki et al., 2014, La Sala et al., 
2015, Chansel-Debordeaux et al., 2015, Nakagawa et al., 2001, Beck-Fruchter et al., 
2014). 
 
Publication 5 critically appraises the existing evidence on multiple causes of failed 
fertilization and strategies to achieve a higher fertilisation rate (Jeve et al., 2017).  
Miscarriage is one of the most devastating pregnancy outcomes.  The incidence of 
early embryonic demise is high as compared with other early pregnancy complications 
(Wilcox et al., 1988).  The chromosomal anomaly is the most prevalent cause for 
spontaneous miscarriage (Cunningham et al., Lathi et al., 2011).  When it comes to 
diagnosis of any miscarriage, high-quality accuracy is required to prevent the wrong 
diagnosis for apparent reason.  In Publication 6, a critical appraisal of the available 
evidence was undertaken to find out the accuracy of ultrasound diagnosis of 
miscarriage based on existing national guideline (Jeve et al., 2011).  It was the first 
review to investigate the evidence on ultrasound criteria.  Recurrent miscarriage is one 
of the most debated and researched areas in early pregnancy.  Recurrent miscarriages 
have substantial psychological, financial and clinical impact (Stirrat, 1990).  Different 
investigations and treatments are a constant source of debate among professionals.  
Finally, Publication 7 is on evidence-based management of recurrent miscarriage 
(Jeve and Davies, 2014b).   
 
Figure 2 provides a diagrammatic summary of the structure and content of this thesis. 
It illustrates how each of the seven publications relate to one another. 
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Figure 2: Diagrammatic summary of structure and contents of present thesis to explain 
role of ovum in reproductive outcomes 
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Chapter 2: Aims and objectives 
 
Oocyte quality and quantity are closely related with each other.  The reproductive 
outcome cannot be attributed to only one factor.  To simplify, we have divided the 
aims and objectives as below.   
 
2.1: To investigate the reproductive outcomes related to the oocyte quantity  
 
Objectives: 
a) To predict the ovarian response using serum AMH and age in the poor responder 
group (publication 1) 
b) To evaluate all the existing protocols and strategies applied to poor responders by 
including evidence generated from only good quality randomised controlled trials 
(publication 2) 
c) To investigate the obstetric outcome of pregnancies conceived using donor oocyte 
IVF compared with pregnancies conceived using autologous-oocyte IVF or natural 
conceptions (publication 3) 
d) To analyse whether donor oocyte IVF acts as an independent risk factor for 
pregnancy complications (publication 4) 
 
2.2: To investigate the reproductive outcomes related to the oocyte quality 
 
Objectives: 
a) To classify and analyse the factors affecting fertilisation and strategies to improve 
the fertilisation rates (publication 5) 
b) To evaluate, by a systematic review of the literature, the accuracy of first-trimester 
ultrasound in diagnosing early embryonic demise publication 6) 
c) To produce evidence‑based guidance on the clinical management of recurrent 
miscarriage (publication 7) 
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Chapter 3: Methods 
 
3.1:   A mixed methods approach was used to investigate the reproductive outcomes 
related to the oocyte quantity.   
 
Methods included: 
a) A cohort study of women undergoing controlled ovarian stimulation for IVF or 
ICSI cycle.  These women were treated for either primary or secondary infertility 
at a teaching hospital.  All women included were predicted reduced responders 
with serum AMH value between one and five pmol/L (publication 1). 
 
b) Evaluation of the existing literature with systematic review and meta-analysis.  
Poor responders to ovarian stimulation formed the study population.  All types of 
intervention subjected to randomised controlled trials were included in the 
systematic review.  Two or more trials with identical design and interventions were 
analysed by meta‑analysis.  Our outcome measures were the number of oocytes 
retrieved per cycle, live birth rates, and clinical pregnancy rates (publication 2).  
 
c) A cohort study to compare outcome in women conceived with donor oocyte and 
delivered a live neonate after 24 weeks of pregnancy with two age-matched control 
groups, including omen who conceived after autologous IVF and the other group 
formed by women conceived spontaneously.  The primary study outcome was 
hypertensive disorders of pregnancy (pregnancy-induced hypertension and pre-
eclampsia).  Multivariate analysis was performed by logistic regression 
(publication 3).   
 
d) Systematic review and meta-analysis of published literature.  All observational 
studies comparing pregnancy outcomes in donor oocyte pregnancies with a 
predefined control group were included.  The control group included women who 
had assisted conception using IVF or ICSI with autologous oocytes.  The primary 
outcome was any hypertensive disorder in pregnancy; secondary outcome 
measures included the risk of caesarean section, development of gestational 
diabetes, and small for gestational age, preterm delivery, and intrauterine death 
(publication 4). 
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3.2:  To investigate the reproductive outcomes related to the oocyte quality, qualitative 
and quantitate synthesis of existing evidence was performed.  
 
a) A systematic review of all studies analysing factors affecting fertilisation and 
strategies to improve the fertilisation rates.  Various strategies used for improving 
fertilisation rates formed the intervention.  The comparison group had no such 
intervention under research.  The primary outcome measure was fertilisation rates.  
No secondary outcome measures.  All types of study designs including case-
control, cohort, and randomised studies were included (publication 5).   
 
b) Systematic review used to investigate the accuracy of existing diagnostic criteria 
to diagnose early miscarriage.  Studies which evaluated the accuracy of first-
trimester ultrasonography in pregnant women for the diagnosis of early embryonic 
demise were included.  Accuracy measures including sensitivity, specificity and 
likelihood ratios for abnormal and normal test results were calculated for each 
study and each test threshold (publication 6).   
 
c) The evidence was sought for all current recommendations as well as all 
unanswered questions on investigating and managing recurrent miscarriages.  The 
evidence was searched using the individual subclass of the aetiology of recurrent 
pregnancy loss.  The recommendations are based on evidence which was graded 
based on quality (publication 7).   
 
3.3:  Recent research updates published following our research  
 
For all submitted systematic reviews (2, 4, 5 and 6th publications), the update on 
current evidence was searched systematically with defined search strategy.  The 
literature search strategy used for updates is described in detail in Appendix B.  The 
limitations applied were human, English language and publication date.  The titles and 
abstracts were screened to include relevant evidence.  Full text of the article was 
reviewed and critically appraised to produce the updates for submitted publications.  
Update review was performed by the author only.  Meta-analysis was not updated.  
Scoping literature search for relevant updates was performed for the first, third and 
seventh publications. 
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Chapter 4:  Results and discussion 
 
4.1: Publication 1: The combined use of antimullerian hormone and age to predict the 
ovarian response to controlled ovarian hyperstimulation in poor responders: A novel 
approach (Jeve, 2013). 
 
Results 
Our cohort study showed clinical pregnancy rate per embryo transfer was 20.  33%, in 
poor responder group.  AMH and age were analysed using linear regression model 
which produced an equation to give predicted oocyte count if AMH and age are 
known.   
 
Discussion 
The number of oocytes retrieved during an IVF cycle is a crucial step.  After 
fertilisation of oocytes, embryos are formed.  The number of embryos allows statically 
higher chances of good quality embryos and resultant pregnancy.  It also gives an 
opportunity to have frozen embryos for future use.  The number of eggs in IVF is a 
robust surrogate outcome for clinical success.   Live birth rate found to rise with an 
increasing number of eggs up to fifteen oocytes (Sunkara et al., 2011b).  An inadequate 
response could be associated with multiple factors.  The diminished ovarian reserve is 
the most common cause of poor response.  The use of follicle stimulating hormone as 
an indicator of follicular health has not been very successful in predicting the 
outcomes.  Anti-Mullerian hormone (AMH) was first discovered to be essential for 
the development of Mullerian tubules in infants for a male reproductive system.  This 
hormone was later known to be important in understanding the follicular growth.  The 
hormones are expressed in the preantral and antral stages and play an essential role in 
follicular development until a single dominant follicle is selected.  In 2002, van Rooij 
suggested AMH can be used as a marker for ovarian ageing (van Rooij et al., 2002).  
Subsequently, Tremellen showed AMH assessments are superior to FSH in identifying 
women with reduced ovarian reserve.  Anti-mullerian hormone assessment should be 
considered as a useful adjunct to FSH levels and antral follicle count when estimating 
ovarian reserve (Tremellen et al., 2005).  The AMH levels are direct indicators of the 
size of the preantral and antral follicular pool.  With further research work, AMH 
emerged as a better predictor of ovarian reserve (Kwee et al., 2008).  The sensitivity 
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and specificity of detecting the poor responders with AMH were between 72-93%.  At 
the same time, few researchers questioned its clinical usefulness (La Marca et al., 
2009).  Our study used a novel approach of using both AMH levels and age as two 
factors to predict for the success of pregnancy in poor responders.  All the earlier 
studies undertaken have used AMH as a parameter and predicted age to have a 
significant contribution.  However, no one used both predictors together and 
developed a simple formula for predicting the outcome.  Our results show increasing 
AMH value is associated with increasing oocyte yield in this reduced responders group 
which is consistent with previous data (Nelson et al., 2007).  Our results demonstrated 
that combining two strong predictors allow clinicians to develop a model for 
predicting ovarian response.  Such an approach will help clinicians to counsel patient, 
design protocol for optimal outcome.  Clinicians could offer other options like oocyte 
donation and adoption, without subjecting ovarian stimulation.  Individualisation of 
treatment is possible with the use of accurate prediction (Nelson et al., 2007).   
 
This study has a small population size and conducted at the single centre; these are 
limitations of this study.  None the less, this study demonstrated an approach to model 
two good predictors together accessing quantity and quality while predicting ovarian 
response. It could be used very effectively for personalised treatment approaches.   
 
4.2: Publication 2: Effective treatment protocol for poor ovarian response: A 
systematic review and meta‑analysis (Jeve and Bhandari, 2016). 
 
Results 
We found 61 randomised controlled trials including 4997 cycles.  We divided these 
trials into 10 different management strategies based on interventions.  Limited 
evidence on growth hormone supplementation and transdermal testosterone 
supplementation showed improved clinical pregnancy rates and live birth rates in poor 
responders.  Various other strategies did not show significant improvement in 
outcome.   
 
Discussion 
Our study supplies the most comprehensive review for investigating effective 
treatment for poor responders.  It included only randomised trials.  Kyrou and team 
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reviewed twenty-two studies and found insufficient evidence to recommend any 
treatment approach proposed to improve pregnancy rates in poor responders (Kyrou 
et al., 2009).  Bosdou, in 2012, investigated use of androgens and androgen modulating 
agents in poor responders undergoing IVF.  The study was not conclusive with a 
probable indication that use of testosterone could enhance the live birth rate.  No other 
androgen or androgen-related agents had any effect on outcome (Bosdou et al., 2012).  
A systematic review and meta-analysis on the role of dehydroepiandrosterone in 
improving the outcome in poor responders clearly showed that 
dehydroepiandrosterone did not affect the outcome (Narkwichean et al., 2013).  Our 
meta-analysis shared the same view of the insufficient evidence to recommend any 
treatment choice to improve reproductive outcome in poor responders.  These meta-
analyses published before us had a methodological limitation of using data from 
observational studies and nonrandomized studies in their meta‑analysis (Bosdou et al., 
2012, Kyrou et al., 2009, Narkwichean et al., 2013).  Our limitations include 
heterogeneity in the definition of poor responders in these trials conducted before 
Bologna consensus criteria (Ferraretti et al., 2011).  Although some adjuvant 
supplementations like growth hormone and androgens may appear to improve ovarian 
response and reproductive outcome, we recognise that the numbers are small to 
recommend their routine use in poor responders.   
 
4.3: Publication 3: Three-arm age-matched retrospective cohort study of obstetric 
outcomes of donor oocyte pregnancies (Jeve et al., 2016b) 
 
Results 
Hypertensive disorders in pregnancy affected 33% of women in the study group as 
compared with 7% women who conceived after autologous IVF or conceived 
spontaneously.  The risk of hypertensive disorders in pregnancy was significantly 
higher in the donor oocyte group.   
 
Discussion 
Although IVF using oocyte donation has enabled women at an advanced age or with 
ovarian failure to  achieve pregnancy successfully, pregnancy following oocyte 
donation can subject them to a higher risk of maternal morbidity and mortality (Karnis 
et al., 2003).  Danish national cohort study showed an increased risk of preeclampsia 
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and preterm labour in donor oocyte pregnancies as compared with pregnancies after 
autologous IVF (Malchau et al., 2013).  The immunologic theory of pre-eclampsia 
might explain the risk of obstetric complications for women with conceiving after 
oocyte donation.  Advanced maternal age is associated with a significantly increased 
risk of perinatal complications (Laskov et al., 2012).  Therefore, it is necessary to 
eliminate bias caused by maternal age and other risk factors.  Our study has a limited 
population size, as a significant limitation, to address other variables.    
 
4.4: Publication 4: Donor oocyte conception and pregnancy complications: a 
systematic review and meta-analysis (Jeve et al., 2016a). 
 
Results 
We included total, 11 studies (n = 81 752).  The risk of developing hypertensive 
disorders during pregnancy was significantly higher for donor oocyte pregnancy (odds 
ratio 3.92; 95% confidence interval, 3.21–4.78).  Further subgroup analysis showed 
for a singleton, and twin pregnancies showed that the risk was significantly higher for 
donor oocyte pregnancy in each group.  Secondary outcomes including small for 
gestational age, caesarean section and preterm delivery were significantly higher with 
oocyte donation pregnancy.  Meta-regression for the covariate of age suggested that 
risk was independent of age.   
 
Discussion  
Our findings are consistent with some previous observational studies (Serhal and 
Craft, 1989, Abdalla et al., 1998, Wiggins and Main, 2005).  A previous systematic 
review discussed the immunological pathogenesis of complications but did not include 
meta‐analysis(van der Hoorn et al., 2010).  Immunologic intolerance between the 
mother and the fetus may play an essential role in the pathogenesis of preeclampsia 
due to donor oocyte conception (Levron et al., 2014).  Ours is the first meta‐analysis 
and meta‐regression to quantify the risk of pregnancy complications in women with 
donor oocyte pregnancy.  Small values for I2 and narrow confidence intervals, low 
statistical heterogeneity are significant strengths of our meta‐analysis.  Our significant 
limitation is difficult to conclude that the obstetric risks are entirely independent of 
variables like age from any meta‐analysis and systematic review.  We made every 
attempt to neutralise the effects of confounding factors such as age by performing 
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subgroup analysis and meta‐regression.  Ideally, individual participant data (IPD) 
meta‐analysis would be the best design.  Secondary outcomes are not entirely 
independent of hypertensive disorders.  We did not have the information on 
preventative measures such as the use of low‐dose aspirin or ultrasound assessment 
for fetal growth.   
 
4.5: Publication 5: Strategies to improve fertilisation rates with assisted conception: a 
systematic review (Jeve et al., 2017). 
 
Results  
Factors affecting fertilisation were allocated as sperm-related and oocyte-related 
factors.  We divided the methods to improve fertilisation rates based on the 
intervention used.  Various interventions are used to improve fertilisation rates 
including assisted oocyte activation, physiological intracytoplasmic sperm injection 
(PICSI) and intracytoplasmic morphologically selected sperm injection (IMSI).  
Optimal laboratory condition and improved procedural effects in techniques result in 
higher fertilisation rates.   
 
Discussion  
The most frequent cause of failed fertilisation is no availability of appropriate sperm 
or failed oocyte activation.  Quality of oocytes is a critical factor.  Delayed cytoplasmic 
maturation with unsynchronised nuclear maturity can lead to morphological changes 
in the oocyte.  Oocyte maturity can influence fertilisation rates.  Based on current 
evidence, we divided the causes influencing fertilisation rates such as gamete related, 
procedure related, and laboratory related.  Due to the nature of the research question 
and vast differences between study designs, it was not possible to do a quantitative 
synthesis of the evidence.  Various promising interventions are being studied; further 
evidence is awaited before recommending their use in clinical practice.   
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4.6 Publication 6: Accuracy of first-trimester ultrasound in the diagnosis of early 
embryonic demise: a systematic review (Jeve et al., 2011). 
 
Results 
We screened 720 citations, 23 were reviewed in detail.  Eight primary papers with four 
different categories of tests (18, 2 × 2 tables) involving 872 women were included in 
this systematic review.  We found a paucity of high-quality, prospective data to 
recommend guideline criteria for the accurate diagnosis of early miscarriage.  We 
demonstrated an urgent need for an appropriately powered, prospective study using 
current ultrasound technology and an agreed reference standard for pregnancy before 
any guidelines are formulated.   
 
Discussion  
Ultrasonography is the most routinely used method to study the development of the 
foetus.  It was used as early as in 1972 to predict abnormal foetus.  Later many studies 
were done in the early 1980's and 1990's to study for any abnormalities in the foetus.  
Confirmation of non-viable pregnancy is very critical.  Any error in judgment could 
be emotionally and physically disastrous to the mother.   
 
The criteria for diagnosing a non-viable pregnancy should have a predictability rate of 
100%.  The national guideline at the time of publication of this paper recommended 
ultrasound criteria to diagnose miscarriage as CRL 5 or more and no fetal heartbeats 
or MSD 20 or more with no fetal poles.  Our findings showed that the above 
recommendations are based on inadequate evidence.  This review has identified many 
studies and various criteria for the identification of inevitable early pregnancy demise.  
An empty gestational sac of ≥25 mm diameter and a missing yolk sac with a 
gestational sac diameter of ≥20 mm appear to be the most accurate thresholds for the 
diagnosis of miscarriage, with an estimated specificity of 1.00.  However, clinicians 
should note that both thresholds had a 95% CI of 0.  96–1.00, indicative of up to four 
in every 100 diagnoses may be a false positive.  The significant limitation of these 
studies is the use of various reference standards.  Most of the studies did not use 
rigorous standards for the diagnosis of miscarriage.  None of the studies evaluated the 
reproducibility and repeatability of early pregnancy measurements on ultrasound.  The 
reviewed studies did not stipulate if a policy of two independent examiners confirming 
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the diagnosis was undertaken routinely to avoid operator errors.  If in doubt, repeating 
scans at an interval is emphasised.   
 
A cohort study published at the same time of our publication suggested that criteria to 
diagnose miscarriage based on growth in MSD and CRL are potentially unsafe.  
However, finding an empty gestational sac on two scans more than seven days apart 
is highly likely to indicate miscarriage, irrespective of growth (Abdallah et al., 2011a).  
Other group agreed with our view that current national guidelines should be reviewed 
to avoid inadvertent termination of wanted pregnancies.  An MSD cut-off of > 25 mm 
and a CRL cut-off of > 7 mm could be introduced to minimise the risk of a false-
positive diagnosis of miscarriage (Abdallah et al., 2011b).  A study showed MSD 
measurement of 20 mm by the first observer, the prediction interval for the second 
observer was 16.8-24.5 mm.  For a CRL measurement of 6 mm, the prediction interval 
for the second observer was 5.4-6.7 mm (Pexsters et al., 2011).   
Inter-observer variation is a well-accepted concept in medicine.  Pexsters’s study 
signifies why we should account for inter observer’s variations while establishing cut-
offs for ultrasound diagnosis. 
 
4.7 Publication 7: Evidence‑based management of recurrent miscarriages (Jeve and 
Davies, 2014a).   
 
Results 
We critically appraised the evidence to produce a concise answer for clinical practice.  
The pathophysiology was discussed in detail along with the mechanism of proposed 
treatment options.  We endeavoured to make clinical recommendations based on 
graded evidence to guide clinical practice.  We graded the evidence to support 
management strategy so that clinicians and patients can make an informed choice for 
the treatment.  The most common cause for single sporadic miscarriage was a 
chromosomal anomaly which indicates qualitative errors in gametes or during the 
process of fertilisation and cell division.  Recurrent miscarriage may be the first 
presentation of some of the haematological or endocrine disorders.  The evidence does 
not support investigations for inherited thrombophilia.  No evidence to recommend 
low dose aspirin and low molecular weight heparin treatment for recurrent 
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miscarriages seen in inherited thrombophilia patients.  Idiopathic recurrent 
miscarriage remains a challenge.   
 
Discussion  
The literature supports only a few therapeutic interventions.  The progesterone act as 
immunomodulator which is favourable and pregnancy protective (Raghupathy et al., 
2009).  The results from multicentre trials (PROMISE) were awaited.  Treatment of 
antiphospholipid syndrome with heparin and aspirin confers a significant benefit in 
live births (Branch et al., 2010, Ziakas et al., 2010). 
  
Further evidence is needed for debated treatment options such as use of progesterone, 
use of thyroxine for sub-clinical hypothyroidism, and treatment of inherited 
thrombophilia.  There is no conclusive evidence to support prenatal genetic screening 
for unexplained recurrent miscarriages as well as for structural chromosome 
abnormality (Simpson, 2012). 
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Chapter 5: Recent research updates that occurred after our research period 
 
In this chapter we will discuss whether: a) any added evidence has been identified 
following an update of the searches used in the publications, and b) the impact any 
added evidence has on the conclusions reported in these publications.  To ease the 
comparison of new evidence across the publications, we will tabulate the findings. 
 
5.1 Publication 1 and 2 : The combined use of antimullerian hormone and age to 
predict the ovarian response to controlled ovarian hyperstimulation in poor 
responders: A novel approach (Jeve, 2013) and  
Effective treatment protocol for poor ovarian response: A systematic review and 
meta-analysis (Jeve and Bhandari, 2016). 
 
The recent update on literature as discussed in method and appendix B showed 
following randomised control trials using various approaches to treat poor responders 
are published after our study. 
 
Table 1: Update on strategies used to treat poor responders following our publication  
 
Intervention Strategy Study Conclusion 
Growth hormone 
adjuvant therapy   
Dakhly (Dakhly et al., 
2018),  Choe 2018 (Choe et 
al., 2018), Dakhly 2016 
(Dakhly et al., 2016) 
Norman 2016 (Norman et 
al., 2016) 
No significant 
difference in the 
outcome   
Transdermal 
testosterone 
Bosdou 2016 (Bosdou et al., 
2016), Escriva 2015 
(Escriva et al., 2015) 
No significant 
difference in the 
outcome   
Transdermal 
testosterone  
Singh 2016 (Singh et al., 
2016)   
The clinical pregnancy 
rates were also 
significantly higher 
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Dehydroepiandrosterone 
(DHEA) 
supplementation 
Narkwichean (Narkwichean 
et al., 2017), Viardot-
Foucault 2015 (Viardot-
Foucault et al., 2015) 
No significant 
difference in the 
outcome  
DHEA 25 mg three 
times daily for 12 weeks 
as an adjuvant in short 
antagonist cycle 
Kotb 2016 (Kotb et al., 
2016) 
DHEA increases the 
number of oocytes, 
fertilisation rate, 
fertilised oocytes, and 
clinical pregnancy rate 
and ongoing pregnancy 
rate 
A delayed start protocol 
with gonadotropin-
releasing hormone 
(GnRH) antagonist and 
microdose flare-up 
GnRH agonist protocol   
Davar 2018 (Davar et al., 
2018)  
No significant 
difference in clinical 
pregnancy rate, and 
ongoing pregnancy rates 
Effect of antioxidant 
treatment with 
coenzyme Q10 
Xu 2018 (Xu et al., 2018b) No significant 
difference in the 
outcome 
mid-follicular phase 
recombinant LH  
supplementation in 
(GnRH) antagonist 
protocol 
Mak 2017 (Mak et al., 2017) No significant 
difference in the 
outcome 
Corifollitropin alfa 
followed versus 
recombinant FSH 
Drakopoulos 2017 
(Drakopoulos et al., 2017), 
Blasco 2017 (Blasco et al., 
2017), Kolibianakis 2015 
(Kolibianakis et al., 2015) 
No significant 
difference in the 
outcome 
Adjuvant sildenafil 
therapy 
Ataalla 2016 (Ataalla et al., 
2016) 
No significant 
difference in the 
outcome 
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Individualised dosing in 
predicted poor 
responders 
Van Tilborg 2016 (Van 
Tilborg et al., 2016) 
AFC-based 
individualised 
gonadotropin dosing in 
does not improve live 
birth rates 
Mild ovarian stimulation Siristatidis 2016 (Siristatidis 
et al., 2016) 
Mild ovarian 
stimulation is inferior to 
conventional regimes 
Short gonadotropin-
releasing hormone 
agonist versus flexible 
antagonist versus 
clomiphene citrate 
regimens 
Schimberni 2016 
(Schimberni et al., 2016)  
The GnRH agonist 
protocol showed a 
significantly higher 
pregnancy rate than the 
clomiphene and the 
GnRH antagonist 
protocol 
450 IU versus 600 IU 
gonadotropin 
Lefebvre 2015(Lefebvre et 
al., 2015)  
No difference was found 
between the outcomes 
 
 
Table 2: Further evidence published on AMH following our publication 
 
Study Conclusion 
Fleming et al., 2015 
Review (Fleming et 
al., 2015).    
AMH established as the gold-standard biomarker to 
evaluate ovarian reserve and predict ovarian response to 
stimulation  
Systematic review by 
Iwase et al., 2014   
(Iwase et al., 2014)  
AMH proved to be a useful biomarker outside infertility 
treatment, for other conditions, such as endometriosis and 
ovarian tumour, as well as surgical interventions, such as 
cystectomy and uterine artery embolisation 
Meta-analysis by 
Iliodromiti et al., 2014 
(Iliodromiti et al., 
2014) 
The diagnostic odds ratio for women with unknown 
ovarian reserve 2.39 (95% confidence interval (CI): 1.85-
3.08).  AMH, independently of age, has some association 
with predicting live birth 
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Cohort study by Zheng 
et al., 2017 (Zheng et 
al., 2017) 
 Patients with low levels of AMH may achieve successful 
treatment outcomes.  Low AMH levels in isolation do not 
represent an appropriate marker for withholding fertility 
treatment. 
Steiner 2017, (Steiner 
et al., 2017) 
Among women aged 30 to 44 years without a history of 
infertility who had been trying to conceive biomarkers 
indicating diminished ovarian reserve compared with 
normal ovarian reserve were not associated with reduced 
fertility. 65% of women with low AMH were predicted to 
get pregnant within six cycles, compared with 62% with 
normal AMH, the chances of getting pregnant in any given 
cycle was no different for women with low and normal 
levels of AMH (hazard ratio 1.19, 95% confidence 
interval CI 0.88 to 1.61). This suggest the limitation of 
AMH  as a marker of reproductive potential in natural 
conception 
 
Clinical and research implications 
In recent years, further research demonstrated AMH, independently of age, has some 
association with predicting the outcome.  The predictive accuracy is improved when 
it is combined with other biomarkers such as age, antral follicle count and FSH.   
Ageing of the women plays a vital role.  IVF stimulations protocols are based on these 
biomarkers to achieve optimal response. 
Further research is based on these biomarkers are their predictive potential.   It raises 
further research questions such as a value of AMH in other endocrine conditions such 
as premature ovarian insufficiency, prediction of menopause, benign gynaecological 
conditions including endometriosis.   AMH could provide further insight into the rate 
of ovarian follicular depletion.  Findings from Steiner study showed the limitations of 
ovarian reserve markers including AMH in natural conception. Biomarkers of 
diminished ovarian reserve (low AMH or high FSH) were not associated with reduced 
fecundability or a lower cumulative probability of conceiving. The most important 
limitation of this study was, the primary outcome as conception not live birth. 
Diminished ovarian reserve could affect fecundity by increasing the risk of 
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miscarriage, perhaps through an effect on egg quality. Although various AMH cut-off 
values were explored, the study was not powered to look at very low (≤0.1 ng/mL) 
AMH values. This study shows the importance of our approach discussed in the first 
paper where we have suggested to use biochemical marker, serum AMH along with 
age to predict the reserve. AMH alone may not be enough marker for reproductive 
outcome.  
Our study on the treatment of poor responders and literature published following our 
publication did not answer the best treatment strategy for poor ovarian response.  The 
treatment stays a challenge.  The clinicians can provide evidence-based information 
to all women who request for any adjuvant therapy.  Further research could be focused 
on specific approaches such as DHEA, testosterone or GH supplementation.   
 
Limitations 
Small population size is one of the significant limitations of our study to develop a 
predictor model using AMH and age.   IVF outcome is a result of many variables along 
with ovarian reserve.   Due to limited numbers, we could not perform further analysis 
to address variables.   
Before the Bologna criteria, heterogeneity of the definition on poor responders was a 
significant limitation.  Our study, although tried to address this issue with careful 
inclusion Included studies have a small population size.  Therefore, the outcome 
difference does not reach statistical significance.  Two researchers did not perform the 
updated literature search, inclusion of studies and analysis.  The meta-analysis was not 
performed using new data.   
 
5.2 Publication 3 and 4: Three-arm age-matched retrospective cohort study of obstetric 
outcomes of donor oocyte pregnancies (Jeve et al., 2016b).    
Donor oocyte conception and pregnancy complications: a systematic review and meta-
analysis (Jeve et al., 2016a) 
 
The recent update on literature as discussed in method and appendix B, showed the 
following studies compared donor oocyte (DO) pregnancy outcomes 
 
Table 3: Studies comparing donor oocyte pregnancy outcome following our 
publication 
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Study Result Conclusion 
Kamath  2017 (Kamath et 
al., 2017) 5929 DO and 
127,856 autologous IVF  
adjusted odds ratio (aOR) 
1.56, 99.5% confidence 
interval (CI) 1.34 to 1.80 
for preterm and aOR 1.43, 
99.5% CI 1.24 to 1.66 for 
low birth weight  
Significantly higher risk 
of preterm and low birth 
weight after DO 
conception 
Elenis 2016 (Elenis et al., 
2016) Donor oocyte n= 76 
Spontaneous n= 149 
Autologous oocyte IVF 
n= 63  
DO higher odds for 
premature delivery (OR 
2.36, 95 % CI 1.02-5.45), 
for being small for 
gestational age (OR 4.23, 
95 % CI 1.03-17.42)  
Significantly higher risk 
of preterm and low birth 
weight after DO 
conception 
Simeone 2016(Simeone et 
al., 2012)  
136 consecutive patients 
divided into DO IVF and 
autologous IVF. The risk 
of preeclampsia was 27% 
in the DO group and 5.6% 
in the autologous IVF 
group, (p=0.0024, OR 
6.17) 
Significantly higher risk 
of Pregnancy-induced 
hypertension, caesarean 
section, with donor 
oocyte IVF 
Banker  2016(Banker et 
al., 2016)  
Autologous oocytes 
n=691, donor oocytes 
n=810 
Pre-term delivery highest 
in Donor oocyte 
(42.58%), autologous 
oocyte (29.52%) 
Significantly higher risk 
of preterm 
Yu et al., 2018(Yu et al., 
2018)  
SART CORS data,  
Donor oocyte n= 2703 
Autologous oocyte 
n=4402 
Preterm delivery adjusted 
odds ratio (aOR) 1.33 
(95% CI 1.02-1.75), small 
for gestational age baby 
aOR 1.75 (95% CI 0.85-
3.7) 
Significantly higher risk 
of preterm and no 
significant difference for  
small for gestational age 
baby after DO 
conception 
35 
 
 
Clinical and research implications 
Based on our publications and these studies, data further strengthen our conclusion 
that donor oocyte conception can cause significant pregnancy complications.   There 
is an addition of a few more pregnancy complications such as low birth weight.   
Simeone et al showed significantly increased risk of pre-eclampsia which was 
consistent with our findings. Kamath and Elenis showed increased risk of preterm and 
low birth weight babies after DO conception. Banker and Yu showed high risk of 
preterm births.  Preventative strategies such as low dose aspirin and growth monitoring 
with ultrasound could reduce the risks during pregnancy.   Further research could be 
focussed on the understanding pathophysiology of these complications and 
preventative measures.   
 
Limitations 
The definitions used for preterm delivery, small baby, intra-uterine growth restriction 
was not uniform in original publications.   These definitions evolved over a period.  
Some of the measured the outcomes such as mode of delivery, preterm or small for 
gestational age baby may be the result of hypertensive disorders during pregnancy.   
The information was not available on any preventative measures used to reduce the 
risk of complications.  5.3 Publication 5: Strategies to improve fertilisation rates with 
assisted conception: a systematic review (Jeve et al., 2017). 
 
The recent update on literature as discussed in method and appendix B, showed 
following studies to analyse strategies to improve fertilisation rates 
 
Table 4: Update on strategies to improve fertilisation rates following our publication  
 
Study Results Conclusion 
Yovich et al., 2018 
(Yovich et al., 2018)  
The use of ICSI to improve the 
fertilisation rate for non-male 
factor subfertility significantly 
more ICSI-generated embryos 
were utilised (2.5 vs 1.8; 
Reduction in failed 
fertilisation rates was 
seen. The first 
treatment for 
unexplained infertility 
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p < 0.003) with productivity 
rates of 67.8% for pregnancy 
and 43.4% for livebirths. 
could be undertaken 
within the IVF-ICSI 
Split model 
Xu  2018 (Xu et al., 
2018a)  
The predictive value of 
acrosomal enzymes was 
studied, spontaneous  acrosome 
reaction rate is significant 
predictor of fertilization 
outcome 
(OR= 0.68, 95% CI 0.53-0.88, 
P =  0.68) 
Lower acrosomal 
enzymes levels ( 
<25muIU/106) were 
predictive of total 
fertilisation failure 
Kirman-Brown 2019 
(Kirkman-Brown et al., 
2019)  
Hyaluronic Acid Binding 
Sperm Selection (HABSelect 
Trial), Live birth rate (OR 1.12, 
95% CI 0.94 to 1.34; p = 0.18) 
PICSI offered no clear 
advantage in relation 
to the primary 
outcome. 
Cui  2018 (Cui et al., 
2018)  
Spermatozoa PIWI-interacting 
RNAs (piRNAs) levels , There 
were significant increases in 
the levels of all 
3 piRNAs in spermatozoa from 
the group with higher 2PN rates 
(for piR-31704, P = .002; for 
piR-39888, P < .001; for piR-
40349, P < .001; respectively) 
Spermatozoa levels of 
piR-31704 and piR-
39888 were decreased 
in male factor 
infertility group 
piRNAs plays a role in 
fertilisation process 
Ahmed  2018(Ahmed et 
al., 2018) 
The study analyses the 
influence of extended 
incubation time on sperm 
chromatin condensation and 
DNA strand breaks and their 
effect on the fertilisation 
rate,  Fertilisation rate in the 
(Group 1- no extended time) 
No influence on 
fertilisation rates. 
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was 62.45% and 69.17% 
(Group 2-extened incubation). 
de Moura  2017(de Moura 
et al., 2017) 
 Randomized trial analysed 
using diluted hyaluronidase 
8IU/mL (n=104) versus normal 
concentration 80IU/mL(n=88) 
used for denudation of sibling-
oocytes  
Diluted group showed 
better results in 
fertilisation rates 
(92.3% vs.  80.6%), 
Bartoli  2017(Bartoli et 
al., 2017) 
Study to examine the impact of 
advanced paternal age (mean 
51.0+/-5.7 years),  14.9±7.7 
normally fertilized zygotes 
(60%) observed on day 1 of 
embryonic development which 
are significantly lower than 
non-advanced paternal age 
male (Control = 82%; 
p<0.0001) 
Fertilisation rates were 
significantly reduced 
utilising advanced 
paternal age sperm 
Morin 2017  Retrospective cohort study of a 
total of 8345 cycles, on linear 
regression analysis, 
Fertilization Rate was 
correlated with Total motile 
sperm count (r2 ¼ 0.13, 
regression coefficient: 3.63, 
p=0.02) 
 Total motile sperm 
count is correlated 
with fertilisation rates 
in IVF/ICSI cycles 
Stanhiser 2017 (Stanhiser 
et al., 2017)  (n= 3,281) 
Study compared the 
fertilisation, implantation, and 
pregnancy rates following ICSI 
versus conventional 
insemination for unexplained 
infertility, ICSI reduced the 
probability of pregnancy by 
ICSI significantly 
reduces fertilisation, 
pregnancy, and 
implantation rates 
compared to 
conventional 
fertilisation for 
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10% (relative risk [RR] 0.90 
95% CI 0.82 – 0.99) 
couples with 
unexplained 
subfertility. 
Zheng 2016 (Zheng et al., 
2016)  
966 cycles with severe 
oligozoospermia ( count <= 
5x106/mL and motile 
spermatozoa <2x 106/ml) 
analysed  
The rates of 
fertilisation are 
reduced (p < 
0.001) with reduced 
motile spermatozoa in 
severe 
oligozoospermia  
Lesoine  2016 (Lesoine 
and Regidor, 2016)  
Myoinositol group 136/ 233 
oocytes collected were 
fertilised and 128/300 oocytes 
in the placebo group were 
fertilised.   
Myoinositol therapy in 
women with PCOS 
resulted in better 
fertilisation rates 
Modarres  2016(Modarres 
et al., 2016)  
The fertilisation rate was 44% 
in the group requiring surgical 
sperm extraction and 49% in 
the Sildenafil only group  
No significant 
improvement in the 
semen analysis, 
fertilisation rates or 
pregnancy outcomes 
with Sildenafil 
Rodriguez-Purata 2016 
(Rodriguez-Purata et al., 
2016) 
Use of ICSI versus 
conventional IVF in donor 
sperm, low fertilization rate 
was higher with ICSI when 
compared to conventional 9.1% 
(25/389) vs. 7.9% (35/681) and 
failed fertilization was also 
higher with ICSI than in 
conventional insemination 
3.3% (13/389) vs. 2.5% 
(17/681).  
This study shows that 
fertilisation rates are 
correlated with 
patient's age and with 
the numbers of the 
oocytes inseminated, 
but not with the 
method of 
insemination. 
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Clinical and Research implications 
Based on very few further publications, the results and conclusion from this 
publication remain unchanged.  The most important addition on this topic was HAB 
select trial. The trial did not show clear advantage with PICSI in relation to the primary 
outcome. The trail has some limitations. Embryologists were not blinded, and limited 
data were available from poorer samples and non-random sample selection in the 
mechanistic cohort. Prepared rather than raw semen was used for tests of DNA 
integrity. The interesting finding was PICSI showed a reduced miscarriage risk. 
Therefore, it opened a new question to re-evaluate PICSI focusing on miscarriage rates 
and consider aspects of sperm quality that PICSI favours. Assisted oocyte activation 
and sperm selection using IMSI and PICSI remain widely studied interventions.   
 
 
5.4 Publication 6: Accuracy of first-trimester ultrasound in the diagnosis of early 
embryonic demise: a systematic review (Jeve et al., 2011). 
 
An updated literature search (as described in methods section and detailed in appendix 
B) showed following studies that have published after our study 
 
Table 5: Update on studies to analyse ultrasound diagnosis of early miscarriage 
following our publication 
 
Study Results Conclusion 
Abuelghar  2013
 (Abuelghar et 
al.) 
A CRL of 2 SD or less from that 
expected for gestational age as a 
cut-off point had a sensitivity of 
56.6, specificity of 81.9, the 
positive predictive value of 36.6, 
the negative predictive value of 
91.1 
Small for gestational age 
CRL was associated with a 
higher probability of a 
miscarriage  
Tan 2014 (Tan 
et al.)  
N= 305 with a gestational age of 
6 to 9 weeks  
The pregnancies with a 
yolk sac diameter >/= 5 
mm had a significantly 
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higher risk of miscarriage 
(p = 0.005). 
Wie  2015 (Wie 
et al.) N= 188  
Miscarriage=30 
(16.0%) 
Fetal heart rate below the 5th 
percentile (OR, 6.43), MSD 
below the 5th percentile (OR, 
4.87), gestational sac volume 
below the 5th percentile (OR, 
5.25), and yolk sac diameter 
below the 2.5th or above the 
97.5th percentile (OR, 15.86) 
were significant predictors of 
miscarriage  
A small-for-gestational-
age gestational sac 
volume, fetal bradycardia, 
a small gestational sac 
diameter, and a small or 
large yolk sac diameter are 
significant sonographic 
predictor of miscarriage. 
Plevakova 2015 
(Plevakova et 
al., 2015)  
A retrospective cohort study No correlation between the 
volume of gestational sac 
and the development of the 
pregnancy 
Preisler et al., 
2015 (Preisler et 
al., 2015)  
They found mean gestational sac 
diameter ≥25 mm with an empty 
sac (specificity: 100%,), embryo 
with crown-rump length ≥7 mm 
without visible embryo heart 
activity (specificity: 100%), 
mean gestational sac diameter 
≥18 mm for gestational sacs 
without an embryo presenting 
after 70 days’ gestation 
(specificity: 100%), embryo with 
crown-rump length ≥3 mm 
without visible heart activity 
presenting after 70 days’ 
gestation (specificity: 100%) 
This study concluded, 
changed the cut-off values 
of gestational sac and 
embryo size defining 
miscarriage are 
appropriate.   They noted 
that the timing between 
scans and expected 
findings on repeat scans 
are still too liberal.    
Gabbay-Benziv 
et al., 
IVF pregnancies with a live 
embryo, a 
Small CRL <10th centile 
can predict miscarriage 
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2017(Gabbay-
Benziv et al., 
2017)  
small CRL (CRL ≤tenth 
percentile for gestational age) at 
40-80 days' gestation may 
predict miscarriage 
Datta  2017 (Dat
ta and Raut) N= 
800 Miscarriage 
=140 (17.5%) 
CRL, MSD, and fetal heartbeat 
values below the 5th percentile 
(odds ratio 26.48, 26.94, and 
100.63, respectively), and YSD 
above the 95th percentile (OR 
1.04)  
First-trimester ultrasound 
measurements are 
predictors of early 
miscarriage.   
 
Clinical and research implications 
Before our publication, various international societies used clear cut off values and 
parameters to diagnose miscarriage in their guidelines (Bickhaus et al., 2013).  Our 
publication demonstrated that the cut off used were based on poor quality evidence.   
The academics and professionals widely acclaimed our paper.  The royal college of 
Obstetricians and Gynaecologists (RCOG) accepted the findings and released a 
statement to welcome the research and to declare amendment in their guideline 
(RCOG, 2011).  Our paper, along with other publications made headlines in national 
media which attracted more extensive public attention (BBC, 2011, Telegraph, 2011, 
Mail, 2011, Time, 2011, Medscape, ScienceDaily, 2011).  To explain the results to the 
member of public following media stories NHS released its statement (NHS, 2011).     
 It is axiomatic that decisions about embryonic viability must not be open to doubt.   
So it is surprising how little evidence exists to support previous guidance (Bourne and 
Bottomley, 2012).   Review published in the New England Journal of Medicine, 
Recent research has shown the need to adopt more stringent criteria for the diagnosis 
of nonviability to minimise or avoid false positive test results.    
Regarding the diagnostic criteria for nonviable pregnancy during the 1st trimester, a 
previous study used the following guideline for EPL: an MSD ≥ 25 mm and either no 
embryo or a CRL ≥ 7 mm and no heartbeat (Doubilet et al., 2013).  This view is 
strengthened by the BMJ (the British Medical Journal) editorial on the diagnosis of 
miscarriage (McCarthy and Tong, 2015).   Preisler study added strong evidence to 
support our suggested cut-off points for CRL (≥7 mm) and MSD (≥25MM) 
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measurements. These values are widely used at present.  Further research is being 
focused upon development of predictor models following accuracy of cut off values. 
 
Limitations 
Literature search on updates was carried out and analysed by only one researcher, the 
author.  Small population size, single centre studies and unaddressed inter-observer 
variations are limitations of included studies.  Technological advances in ultrasound 
machines over the period was not addressed. 
 
 
5.5 Publication 7: Evidence‑based management of recurrent miscarriages (Jeve and 
Davies, 2014a).    
 
A recent scoping literature review showed following studies that have published after 
our study.    
 
Table 6: Update on the management of recurrent miscarriage following our 
publication 
Study  Results Conclusion 
Iews et al., 2018 
(Iews et al., 
2018) 
A systematic review to study 
preimplantation genetic diagnosis, the 
primary outcome was live birth rate 
(LBR), and a pooled total of 847 
couples who conceived naturally had 
an LBR ranging from 25-71% 
compared with 26.7-87% among 562 
couples who underwent IVF and 
PGD. 
Preimplantation genetic 
diagnosis does not 
improve reproductive 
outcome in couples 
with recurrent 
pregnancy loss 
Kangatharan et 
al., 2017 
(Kangatharan et 
al., 2017).    
 
A systematic review and meta-
analysis to analyse inter-pregnancy 
interval (IPI). 
Sixteen studies (n=1043840) were 
included. With an IPI of less than 6 
Inter-pregnancy 
interval of fewer than 
six months following 
miscarriage is not 
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months, the overall risk of further 
miscarriage (Risk ratio (RR) 0.82 
95% CI 0.78-0.86) and preterm 
delivery (RR 0.79 95% CI 0.75-0.83) 
were significantly reduced.  
associated with adverse 
outcomes 
Saccone et al., 
2017 (Saccone 
et al., 2017) 
Pooled data from the ten trials (1,586 
women) on use of progesterone. 
Studies span more than 60 years. Use 
of progestogens lowers risk of 
recurrent miscarriage (RR 0.72, 95% 
CI 0.53-0.97) and higher live birth 
rate (RR 1.07, 95% CI 1.02-1.15) 
Supplementation with 
progestogens might 
reduce the incidence of 
recurrent miscarriages 
Santos et al., 
2017 (Santos et 
al., 2017).    
 
A systematic review and meta-
analysis anti-phospholipid syndrome 
the meta-analysis of 9 studies showed 
association between antiphospholipid 
antibodies (aPLs) and/or APS 
compared to the patients with RM  
(OR: 0.279; 95% CI: 0.212-0.366) 
Positive association 
between 
antiphospholipid 
antibodies and 
antiphospholipid 
syndrome in patients 
with recurrent 
miscarriage 
Pils et al., 2016 
(Pils et al., 2016)  
A study to evaluate AMH and 
estradiol , Anti-Mullerian hormone 
and estradiol were significantly lower 
in women with idiopathic recurrent 
miscarriage (median 1.2 ng/ml, IQR 
0.6-2.1, and median 36.5 pg/ml, IQR 
25.8-47.3, respectively) than in 
women with explained recurrent 
miscarriage (median 2.0 ng/ml, IQR 
1.1-2.7, and median 42.5 pg/ml, IQR 
32.8-59.8, respectively; p<0.05). 
Idiopathic 
recurrent miscarriage is 
associated with lower 
basal estradiol and anti-
Mullerian hormone 
levels compared to 
explained 
recurrent miscarriage 
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Maraka et al., 
2016 (Maraka et 
al., 2016).    
A meta-analysis to investigate use of 
thyroxine, eighteen cohort studies at 
low-to-moderate risk of bias were 
included. Compared with euthyroid 
pregnant women, pregnant women 
with Subclinical hypothyroidism 
were at higher risk for pregnancy loss 
(relative risk [RR] 2.01 [confidence 
interval (CI) 1.66-2.44]),  
Subclinical 
hypothyroidism during 
pregnancy is associated 
with multiple adverse 
outcomes, however the 
value of levothyroxine 
therapy in preventing 
these adverse outcomes 
remains uncertain 
Skeith et al., 
2016 (Skeith et 
al., 2016)  
A meta-analysis to study inherited 
thrombophilia, Analysis of Eight 
trials and 483 patients  (relative risk, 
0.81; 95% confidence interval, 0.55-
1.19;P= .28), 
No benefit of LMWH in 
preventing recurrent 
pregnancy loss in 
women with inherited 
thrombophilia 
Grimstad and 
Krieg 2016 
(Grimstad and 
Krieg, 2016) 
A review article , Larger database 
studies are needed with stricter 
control criteria before reasonable 
conclusions can be drawn. 
No further evidence to 
support any treatment in 
inherited thrombophilia 
treatment 
Zhang et al., 
2015 (Zhang et 
al., 2015).    
A meta-analysis to examine the role 
of LMWH and aspirin. A total of 
2391 patients were included in this 
analysis (OR 1.45 CI 0.84-2.79)  
Patients without the 
antiphospholipid 
syndrome, the use of 
combined low 
molecular weight 
heparin (LMWH) and 
aspirin cannot be 
supported 
Egerup et al., 
2015 (Egerup et 
al., 2015).    
A meta-analysis on the use of 
intravenous immunoglobulins in 
women with recurrent miscarriages. 
11 trials analysed, (RR 0.92, 95% CI 
0.75-1.12, p = 0.42). 
No significant benefit 
but increase the risk of 
adverse events 
Coomarasamy et 
al., 2015 
A multicentre randomised PROMISE 
trial on Progesterone treatment, 
There is no evidence to 
support first-trimester 
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(Coomarasamy 
et al., 2015) 
progesterone used in 404 women and  
placebo 432 women, (RR 1.04; 95% 
CI- 0.94 to 1.15) 
progesterone therapy to 
improve outcomes in 
women with a history of 
unexplained recurrent 
miscarriage 
Tang et al., 2013 
(Tang et al., 
2013).    
A feasibility trial of screening women 
with idiopathic recurrent miscarriage 
for high uterine natural killer cell 
density and randomising to 
prednisolone or placebo. The live 
birth rate was 12/20 (60%) with 
prednisolone and 8/20 (40%) with 
placebo (Risk Ratio 1.5, 95% CI 0.79-
2.86) 
No significant 
difference 
Dhillon-Smith et 
al. 2019 
(Dhillon-Smith 
et al., 2019) 
A double-blind, placebo-controlled 
(TABLET) trial to investigate 
whether levothyroxine treatment 
would increase live-birth rates among 
euthyroid women who had thyroid 
peroxidase antibodies and a history of 
miscarriage or infertility (RR- 0.97; C 
0.83 to 1.14, P=0.74) 
Levothyroxine in 
euthyroid women with 
thyroid peroxidase 
antibodies did not result 
in a higher rate of live 
births 
 
Clinical and research implications 
Our publication provides an evidence-based approach managing recurrent miscarriage 
clinically.   The guidance is graded based on the hierarchy of the evidence.   Further 
updates do not change the original recommendations made.   Much awaited PROMISE 
trial did not show any benefit of using progesterone for unexplained recurrent 
miscarriage (RR 1.04; 95% CI- 0.94 to 1.15). However, this trial has some limitations. 
The progesterone treatment was started after confirmed pregnancy, and thus this study 
cannot address whether progesterone supplementation could be more effective in 
reducing the risk of miscarriage if administered during the luteal phase of the cycle, 
before the confirmation of pregnancy. The preparation used was vaginal, it is 
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suggested that intramuscular preparations of progesterone may provide greater 
therapeutic benefit than vaginal preparations. Treatment of subclinical 
hypothyroidism, inherited thrombophilia associated with recurrent miscarriage did not 
show any benefit.  Recent TABLET trial showed that the use of levothyroxine in 
euthyroid women with thyroid peroxidase antibodies did not result in a higher rate of 
live births than placebo ,(RR-0.97; CI- 0.83 to 1.14, P=0.74).  The significant 
limitation of this trial was inclusion of women with history of miscarriage or infertility, 
which is a heterogeneous population. Zhang reported no role of low molecular weight 
heparin (LMWH) and aspirin to reduce the risk of miscarriage in women without 
antiphospholipid syndrome. Further research is focussed upon idiopathic recurrent 
miscarriage as it is still a big challenge.   
 
Limitations 
This publication was structured to be clinically relevant and, every attempt was made 
to perform the comprehensive literature search.   However, this is not a systematic 
review and meta-analysis of original studies.   We have accepted the evidence-based 
on the hierarchy of evidence in evidence-based medicine pyramid.   This is the major 
limitation of this publication.  The literature search for updates was performed as a 
scoping search for the individual debated topic and idiopathic recurrent miscarriage.   
Therefore, we cannot be sure that all relevant literature is being included and 
evaluated.  None the less, this publication and updates provide a clear guidance on the 
most controversial issues in the management of the recurrent miscarriage and 
evaluates all major publications. 
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Chapter 6:  Conclusion 
 
The ovary is the critical organ in human reproduction which controls reproductive 
lifespan, pregnancies, and their outcomes.  Prediction of ovarian qualitative and 
quantitative reserve, number of quality of oocytes remaining in the ovaries, is one of 
the critical aspects in assisted conception.  Age is the significant predictor for the 
quality of oocytes and reproductive outcome.  Serum AMH is widely accepted as the 
most accurate biochemical marker of ovarian reserve.  Age and serum AMH together 
offer the better prediction.  Such prediction is vital for choosing appropriate treatment 
strategies to optimise the reproductive outcome in assisted conception.  Quantity and 
quality of the oocytes and resultant ovum determines the successful reproductive 
outcome, a healthy live baby.  Poor ovarian reserve markers including low serum 
AMH may not predict poor outcome in natural fertility.   The researchers have trialled 
various strategies to treat poor responders, but unfortunately, no single strategy has 
shown a promising success.  The ongoing research is focussed on testosterone 
supplementation to improve the quantity and quality of follicles recruited during 
ovarian stimulation.  Other option to treat the women with low or no ovarian reserve 
is with the use of donor oocyte assisted conception. Donor oocyte pregnancy is the 
high risk of many obstetric complications.  Therefore, the ovum, whether it is 
autologous or from the donor, it significantly impacts the reproductive outcome.  Poor 
quality oocytes result in lower fertilisation rates, lower implantation rates and higher 
miscarriage rates.  Accurate diagnosis and management of miscarriage are crucial to 
optimising the reproductive outcome.   
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Literature search strategy and inclusion of studies in updated reviews 
 
1. Effective treatment protocol for poor ovarian response: A systematic review 
and meta‑analysis 
 
Database: AMED (Allied and Complementary Medicine) <1985 to September 2018>, 
Books@Ovid <September 10, 2018>, Full text journals from OVID, PsycARTICLES 
Full Text, Embase Classic+Embase <1947 to 2018 September 14>, International 
Political Science Abstract <1989 to June 2018>, Ovid MEDLINE(R) and Epub Ahead 
of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to 
September 14, 2018>, PsycINFO <1806 to September Week 2 2018>, PsycTESTS 
<1910 to September 2018> 
 
Search Strategy: 
1     (poor responders* or Diminished ovarian response* or low Responders* or 
inadequate ovarian response* or low ovarian reserve*).mp. [mp=ab, hw, ti, tx, bt, ct, tn, 
ot, dm, mf, dv, kw, fx, dq, an, jn, tt, nm, kf, px, rx, ui, sy, tc, id, tm, td] (8987) 
2     limit 1 to human [Limit not valid in AMED,Books@Ovid,Your 
Journals@Ovid,Journals@Ovid,International Political Science Abstract; records were 
retained] (6965) 
3     limit 2 to yr="2015 -Current" (1590) 
4     (Low AMH* or low anti-mullerian hormone* or the Bologna Criteria*).mp. 
[mp=ab, hw, ti, tx, bt, ct, tn, ot, dm, mf, dv, kw, fx, dq, an, jn, tt, nm, kf, px, rx, ui, sy, tc, 
id, tm, td] (705) 
5     limit 4 to human [Limit not valid in AMED,Books@Ovid,Your 
Journals@Ovid,Journals@Ovid,International Political Science Abstract; records were 
retained] (604) 
6     limit 5 to yr="2015 -Current" (336) 
7     3 or 6 (1843) 
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8     (IVF* or Assisted conception* or ICSI* or In-vitro fertilization*).mp. [mp=ab, hw, 
ti, tx, bt, ct, tn, ot, dm, mf, dv, kw, fx, dq, an, jn, tt, nm, kf, px, rx, ui, sy, tc, id, tm, td] 
(96142) 
9     limit 8 to human [Limit not valid in AMED,Books@Ovid,Your 
Journals@Ovid,Journals@Ovid,International Political Science Abstract; records were 
retained] (77484) 
10     limit 9 to yr="2015 -Current" (16578) 
11     7 and 10 (527) 
12     remove duplicates from 11 (384) 
13     limit 12 to (clinical trial or randomized controlled trial or controlled clinical trial or 
multicenter study) [Limit not valid in AMED,Books@Ovid,Your 
Journals@Ovid,Journals@Ovid,International Political Science 
Abstract,PsycINFO,PsycTESTS; records were retained] (99) 
14     limit 13 to humans [Limit not valid in AMED,Books@Ovid,Your 
Journals@Ovid,Journals@Ovid,International Political Science 
Abstract,PsycINFO,PsycTESTS; records were retained] (99) 
15     limit 14 to yr="2015 -Current" (99) 
 
Included 21 citations after screening full text. 
Reasons for exclusions include: non randmosied trails, absence of appropriate outcome 
measure, poor description of study design. 
 
2. Donor oocyte conception and pregnancy complications: a systematic review 
and meta-analysis 
Database: AMED (Allied and Complementary Medicine) <1985 to September 2018>, 
Books@Ovid <September 10, 2018>, Full text journals from OVID, PsycARTICLES 
Full Text, Embase Classic+Embase <1947 to 2018 September 14>, International 
Political Science Abstract <1989 to June 2018>, Ovid MEDLINE(R) and Epub Ahead 
of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to 
September 14, 2018>, PsycINFO <1806 to September Week 2 2018>, PsycTESTS 
<1910 to September 2018> 
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Search Strategy: 
1     (oocyte* or ovum* or ova* or egg*).mp. [mp=ab, hw, ti, tx, bt, ct, tn, ot, dm, mf, 
dv, kw, fx, dq, an, jn, tt, nm, kf, px, rx, ui, sy, tc, id, tm, td] (1264648) 
2     limit 1 to human [Limit not valid in AMED,Books@Ovid,Your 
Journals@Ovid,Journals@Ovid,International Political Science Abstract; records were 
retained] (630493) 
3     limit 2 to yr="2016 - 2018" (76311) 
4     (Assisted Conception* or IVF* or ICSI).mp. [mp=ab, hw, ti, tx, bt, ct, tn, ot, dm, 
mf, dv, kw, fx, dq, an, jn, tt, nm, kf, px, rx, ui, sy, tc, id, tm, td] (73844) 
5     limit 4 to yr="2016 - 2018" (12062) 
6     Donor*.mp. [mp=ab, hw, ti, tx, bt, ct, tn, ot, dm, mf, dv, kw, fx, dq, an, jn, tt, nm, 
kf, px, rx, ui, sy, tc, id, tm, td] (774325) 
7     3 and 6 (1767) 
8     4 and 7 (588) 
9     remove duplicates from 8 (479) 
10     ((Obstetric* or Pregnancy*) and Complications*).mp. [mp=ab, hw, ti, tx, bt, ct, tn, 
ot, dm, mf, dv, kw, fx, dq, an, jn, tt, nm, kf, px, rx, ui, sy, tc, id, tm, td] (328613) 
11     limit 10 to yr="2016 - 2018" (30841) 
12     9 and 11 (33) 
 
Full text screened 13 
Studies included 5 
Reasons for exclusion- absence of comparison group, absence of well-defined obstetric 
complications and review articles. 
 
3. Strategies to improve fertilisation rates with assisted conception: a 
systematic review Database: Embase <1974 to 2018 September 14>, Ovid 
MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and 
Daily <1946 to September 14, 2018> 
Search Strategy: 
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1     (IVF* or Assisted conception* or ICSI* or In-vitro fertilization*).mp. [mp=ti, ab, 
hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, px, rx, an, ui, sy] (93000) 
2     limit 1 to human (74502) 
3     limit 2 to yr="2016 -Current" (11521) 
4     ((Fertilisation* or Fertilization*) and rate*).m_titl. (2148) 
5     limit 4 to human (1602) 
6     limit 5 to yr="2016 -Current" (156) 
7     3 and 6 (148) 
8     remove duplicates from 7 (113) 
Title screened 113 
Abstracts screened 20 
Studies included 13. 
 
4. Accuracy of first-trimester ultrasound in the diagnosis of early embryonic 
demise: a systematic review  
Database: Embase <1980 to 2018 Week 38>, Ovid MEDLINE(R) and Epub Ahead of 
Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 14, 
2018> 
Search Strategy: 
1     (ultrasound* or ultrasonography* or ultrasound or Scan* or Sonography*).mp. 
[mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, px, rx, an, ui, sy] (2205961) 
2     (miscarriage* or abortion* or pregnancy loss*).mp. [mp=ti, ab, hw, tn, ot, dm, mf, 
dv, kw, fx, dq, nm, kf, px, rx, an, ui, sy] (195503) 
3     limit 2 to human (160319) 
4     1 and 3 (13894) 
5     limit 4 to "diagnosis (best balance of sensitivity and specificity)" (2049) 
6     limit 5 to human (2049) 
7     limit 6 to embryo <first trimester> [Limit not valid in Ovid MEDLINE(R),Ovid 
MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) 
Publisher; records were retained] (750) 
8     limit 7 to English (676) 
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9     limit 8 to (clinical study or clinical trial, all or comparative study or observational 
study) [Limit not valid in Embase; records were retained] (186) 
10     limit 9 to yr="2012 -Current" (54) 
11     limit 4 to "diagnosis (best balance of sensitivity and specificity)" (2049) 
12     limit 11 to human (2049) 
13     limit 12 to embryo <first trimester> [Limit not valid in Ovid MEDLINE(R),Ovid 
MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) 
Publisher; records were retained] (750) 
14     limit 13 to English (676) 
15     limit 14 to (clinical study or clinical trial, all or comparative study or observational 
study) [Limit not valid in Embase; records were retained] (186) 
16     limit 15 to yr="2012 -Current" (54) 
17     remove duplicates from 16 (53) 
Title screened 53, Abstracts screened 9 
Included: 7, Reason for exclusion: reviews 2 
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a better marker of ovarian responsiveness, 
as it reflects the size of the larger resting 
pool of prefollicle‑stimulating hormone 
(FSH)‑dependent follicles. AMH is a more 
direct and independent measure of the growing 
preantral and antral follicular pool.[4‑6] Thus 
age and serum AMH are the most successful 
predictors of reduced ovarian response. Our 
aim was to evaluate the role of age and AMH 
influencing outcome of assisted reproduction 
in women with predicted reduced response 
(AMH between 1 and 5 pmol/L) and to 
develop a model using of AMH and age 
together to predict the number of oocytes 
in poor responders. Such model will help 
clinicians to predict the response and design 
appropriate protocol. It will also help in 
patient counselling and advice on alternative 
management options.
INTRODUCTION
Failed‑assisted conception cycle causes 
considerable amount of emotional and 
economical loss. There are various attempts 
made to predict reduced response. Evidence 
has shown convincingly that poor ovarian 
response is a first sign of ovarian ageing.[1] The 
Bologna criteria[2] define the poor response as 
presence of two or more features (i) advanced 
maternal age or any other risk factor for 
poor ovarian response; (ii) a previous poor 
ovarian response; and (iii) an abnormal 
ovarian reserve test. Two episodes of poor 
ovarian response after maximal stimulation 
deemed sufficient to define a patient as poor 
responder in the absence of other criteria. 
Ovarian ageing can occur independently of 
chronological age.[3] AMH suggested being 
The combined use of antimullerian hormone and 
age to predict the ovarian response to controlled 
ovarian hyperstimulation in poor responders: A novel 
approach
ABSTRACT
CONTEXT: Reduced ovarian response to stimulation represents one of the most 
intractable problems in infertility treatment. As failed cycle can cause considerable 
amount of emotional and economical loss, there are various attempts made to predict 
ovarian response. AIMS: To evaluate different factors influencing outcome of assisted 
reproduction in women with predicted reduced response (antimullerian hormone between 
1 and 5 pmol/L) and to develop a model using of AMH and age to predict the number 
of oocytes in poor responders. SETTINGS AND DESIGN: Retrospective study in a 
teaching hospital. MATERIALS AND METHODS: We analyzed 85 cycles (57 women) 
with predicted reduced response with serum AMH value between 1 and 5 pmol/L. 
Standard ovarian stimulation protocol was used. Primary outcome measures were clinical 
pregnancy rates and oocytes retrieved. STATISTICAL ANALYSIS USED: Data were 
analyzed using Microsoft excel and MetlabR software. RESULTS: Clinical pregnancy 
rate/ET was 20.33%, in this group. AMH and age was analyzed using linear regression 
model which produced an equation to give predicted oocyte count if AMH and age are 
known. (Oocytes = age × (‑ß) + Serum AMH × α) (Constant ß=0.0102 and α = 1.0407). 
CONCLUSIONS: Combined use of serum AMH and age to predict ovarian response 
within reduced responder group should be further evaluated. For first time, we suggested 
combining both factors to predict ovarian response using a simple equation which allow 
developing tailored strategy.
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MATERIALS AND METHODS
We have analyzed 85 cycles undergoing controlled ovarian 
stimulation for IVF or ICSI cycle. These women were treated 
for either primary or secondary infertility at teaching hospital. 
All women included were predicted reduced responders 
with serum AMH value between 1 and 5 pmol/L. We defined 
reduced responders based on AMH level between 1 and f5 
pmol/L based on previous study by.[7] There was no age cut 
off. Population was from different ethnic background. We 
have excluded all cases with AMH 5 pmol/L and above as 
they proved to have normal response and different strategies 
were used in these cases. We have excluded women with 
AMH of less than 1 pmol/L, as they demonstrated to have 
maximum cycle cancellation and no pregnancy occurred 
in this group. Ovarian stimulation was performed with 
exogenous gonadotropins initiated on the third or forth cycle 
day in the form of either Menogon (Ferring Pharmaceuticals, 
Langley, UK) or Gonal‑F (Serono, Feltham, UK). The 
starting daily dose of FSH was either 225 or 300 IU each day. 
Ovarian follicular responses were monitored with serum 
E2 concentrations and transvaginal ultrasound assessment 
of follicular growth. The GnRH antagonist Cetrotide 0.25 
mg/day s.c. (Merck Serono Feltham, U.K.) or Ganirelix was 
commenced on days 4‑7 if serum E2 exceeded 200 pg/mL. 
Follicular responses were monitored with serum E2 and 
transvaginal ultrasound assessment of follicular growth. 
Ovulation was induced with 6500 IU HCG (Ovitrelle, Serono, 
Feltham, UK), provided that three follicles were 17 mm 
in diameter and serum E2 was 200 pg/ml. Trans‑vaginal 
oocyte retrieval was performed under ultrasound guidance 
38 h after HCG administration and the number of oocytes 
retrieved were recorded. Women were either offered IVF‑ET 
or ICSI‑ET. The study analysis includes only fresh cycles.
Primary outcome studied was clinical pregnancy rates and 
secondary outcomes were positive pregnancy rate, oocytes 
retrieved, and cancellation rate, duration of stimulation, and 
FSH drug consumption.
The AMH assay was performed in batches one month before 
treatment cycle using the enzyme‑linked immunosorbent 
assay provided by DSL in study period 2011 (Webster, Texas, 
USA), with values presented as pmol/L (conversion factor to 
pmol/L ¼ ng/mL _ 7.143). The Reduced responders are defined 
as predicted with low serum AMH (serum AMH between 1 
and 5 pmol/L) and cycle cancellation is defined as less than 
two matured sized follicles after 2 weeks of stimulation with 
maximum dose of gonadotropins. Embryo cryopreservation 
was done with more than one high grade embryo remained 
after fresh embryo transfer. Data were analyzed using 
Microsoft excel and MetlabR software.[8,9] Data were 
presented in descriptive statistic. The factors influencing 
outcome of assisted conception were analysed using linear 
regression model. A simple matrix formula was derived to 
calculate predictive response when these factors are known.
RESULTS
The baseline demographic characteristics and outcome are 
shown in Table 1. The AMH level was ranging from 1.1 to 
4.9 as per inclusion criteria. Among 44 eggs retrieved, two 
failed to fertilize in IVF cycle. A total of 29 (34.1%) cycles 
were treated by ICSI. Thus, fertilization rate was 91.6% in 
ICSI cycles. Duration of stimulation was from 4‑14 days 
and from 675 IU to 5100 IU FSH was used. Out of 85 cycles 
started, eight (9.41%) were cancelled due to poor response. 
A total of 59 embryos were transferred; two embryos were 
frozen along with ET in those women. All cancelled cycles 
are shown in Table 2. Clinical pregnancy was achieved in 
12 cases. Characteristics are discussed in Table 3.
Thus, there was no significant difference between 
these groups. Lower AMH value showed trend toward 
cancellation and higher AMH value showed trend toward 
clinical pregnancy in this group. We have analyzed age and 
AMH, using linear regression model.
The factors Age and AMH were put in linear regression 
model to produce a solution.
Table 1: Demographic characters
Number of patients
cycles 85
Age at stimulation (years) 39 (31‑46)
BMI (kg/m^2) 24.7±4.6
AMH (pmol/L) 2.9 (1.1‑4.9)
Procedure
IVF (%) 56 (65.9)
ICSI (%) 29 (34.1)
Length of stimulation (days) 10 (4‑14)
Total dose (IU) 2100 (675‑5100)
Cancelled cycles ** 8 (9.41%)
Number of oocytes 3 (0‑15)
Number of embryos transferred 59
Normal fertilization rate %
IVF (%) 37 (94.8)
ICSI (%) 22 (91.6)
Cohort outcomes
No transferß 26 (30.5%)
Not pregnant 42 (49.4%)
Positive pregnancy testδ 17 (20%)
Clinical pregnancy 12 (14.1%)
Clinical pregnancy per OR 16%
Clinical pregnancy per ET 20.33%
Clinical pregnancy per cycle 14.11%
Values are presented as median (interquartile range) or mean±standard deviation 
**Percentage per cycle started, (n=85). ßIncludes women with cancelled cycle; no eggs 
or failed fertilisation; δIncludes clinical and biochemical pregnancy. AMH=Antimullerian 
hormone; BMI=Body mass index; ET= Embryo transfer; IU=International units; ICSI=Intra-
cytoplasmic sperm injection; IVF= In vitro fertilization; OR=Odds ratio
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The solution is ( ) 1βˆ −= T TYX XX where X is a 2 × 85 matrix 
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Finally we got 
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β
− 
=   
Thus with this model when age and AMH is known (�∗ ), 
oocytes yield can be predicted by formula: ˆ xβ∗ = Ty ∗ .
For example, woman with age 33 years and AMH value 2, 
the predicted response (oocyte yield) can be calculated as
 
33 0.0102ˆx
2 1.0407
β
−   
= =      
and∗
 ˆoocytes xβ∗= = Ty ∗
so oocytes = 33× (‑ 0.0102) + 2 × 1.0407
Thus this model, with use of simple calculator, gives 
approximate numbers of oocytes number two or three.
DISCUSSION
The evaluation and tailored treatment strategy for poor 
responder group is important to improve overall pregnancy 
rates. Unfortunately, lack of uniform criteria to define this 
group, lack of evidence to predict outcome in this particular 
group, and debated treatment strategy are major influencing 
factors on outcome. This group of women are usually with 
older age and more anxious to get pregnant than younger age 
group. Previous failed treatment cycles add in frustration of 
couple and clinician. Predicting response allows tailoring 
individual treatment strategy. This approach was suggested 
by.[7] We have further extended it for poor responder group. 
Our results show increasing AMH value is associated with 
increasing oocyte yield in this reduced responders group 
which is consistent with previous study.[7] Our results show 
that combining two strong predictors allow clinicians to 
develop a model for predicting ovarian response. This 
will help clinicians to counsel patient, design protocol for 
optimal outcome. Reduced responders with predicted poor 
response using various factors including age and AMH 
will allow opting for natural cycle IVF. Other options like 
oocyte donation, adoption, could be discussed with couple 
without subjecting ovarian stimulation. At same time 
predicted reasonable response will allow to go ahead with 
antagonist and stimulation protocols. Systematic review 
supported antagonist protocol in this group Pandian and 
Marci et al.[10,11] Hence, prediction of response is significant.
Age is always labelled as significant factor affecting 
fertility[12,13] but biological aging and ovarian aging are not 
always same.[3] Various attempts to develop ideal predictive 
test for ovarian reserve were failed.[14] At same time, AMH 
emerged as a promising option for predicting both oocyte 
number and quality.[15] AMH showed definitive advantages 
over other bio markers.[5,6] It has linear relationship 
with age.[4] Previous studies clearly established linear 
relationship between AMH and oocyte yield using AMH 
and age to develop a linear regression model for oocyte 
yield is a justified approach based on past evidence. The 
accuracy of multivariate models for the prediction of 
ovarian reserve and pregnancy in women undergoing IVF 
compared with the antral follicle count (AFC) as single test 
was reviewed by Verhagen et al.[16] He reviewed age + FSH, 
age + inhibin B, age + AFC and different combinations for 
predictive model. He concluded the use of more than one 
single test for the assessment of ovarian reserve cannot 
be supported. Thus, the models incorporating inhibin B, 
FSH, ovarian volume, clomiphene challenge test, and so 
on failed to deliver successful prediction. Further evidence 
is required to support the multivariate model of AMH and 
age to predict ovarian response.
Other factors like body mass index, procedure, previous 
pregnancy, and duration of pregnancy were analyzed but 
failed to establish any significant relationship. There are 
various factors suggested to be significant predictors of 
clinical pregnancy such as age, serum E (2) concentration on 
the day of hCG administration, embryo quality, and number 
of embryos transferred sperm motility and ICSI operator.[17] 
It is practically impossible to establish relationship between 
all factors at a time. Hence, we considered most significant 
Table 2: Cancelled cycle and all cycles characters
Characteristics All Cancelled cycles
Total 85 8
Age 39 (31‑46) 39.9 (35‑45)
BMI 24.7±4.6 25.9±4.6
Amh 2.9 (1.1‑4.9) 2.2 (1.1‑3.3)
Total dose of FSH 2100 (675‑5100) 1162.5 (675‑4200)
Duration of FSH 10 (4‑14) 7.5 (7‑10)
BMI=Body mass index; FSH=Follicle-stimulating hormone
Table 3: Clinical pregnancy and all cycle characteristics
Characteristics All Clinical pregnancy
Total 85 12
Age 39 (31‑46) 37 (35‑39)
BMI 24.7±4.6 24.5±6
AMH 2.9 (1.0‑4.9) 3.15 (1.2‑4.7)
Total dose of FSH 2100 (675‑5100) 2287.5 (1350‑3600)
Duration of FSH 10 (4‑14) 10 (8‑14)
Number of oocyte retrieved 3 (0‑15) 4 (2‑8)
AMH=Antimullerian hormone; BMI=Body mass index; FSH=Follicle-stimulating hormone
262
Jeve: The combined use of anti‑mullerian hormone and age
Journal of Human Reproductive Sciences / Volume 6 / Issue 4 / Oct - Dec 2013
factors particularly affecting subgroup of women labelled 
as reduced responders and analysed to get a user friendly 
predictive model.
This study evaluated the relationship between two 
important factors, age, and AMH, influencing outcome of 
assisted reproduction in reduced responder group. The 
relationship between age and AMH is shown in Figure 1. As 
figure shows the value of AMH is not same within same age 
group. Hence it is crucial to have both predictors taken into 
the consideration whilst predicting ovarian response. This 
figure illustrates the importance of having both predictors 
that is age and AMH calculated together to predict 
more accurate response. All previous studies analyzing 
predictive potential were done in normal, reduced, and high 
responders with many variables at same time. In present 
study, we analyzed combined predictive potential of AMH 
and age affecting outcomes. This study has relatively small 
population size and it is a major limitation. There is a need 
to focus on this particular group of women to improve 
outcome without adding any financial burden or emotional 
stress. This can be achieved only with good prediction of 
response and individualizing therapy accordingly. Current 
evidence favors antagonist approach to treat reduced 
responder group. Current evidence supports AMH and age 
as good predictors of ovarian response over any other single 
or multiple available predictors. We have tried to introduce 
new approach of combining both factors using a simple 
equation. We accept the limitation of having small number 
of study subjects to draw any conclusions based on this 
study alone. Hence, further studies are required to establish 
strong evidence before recommending combination of age 
and AMH prediction model and consequent individualized 
treatment strategy in practice.
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suggested incidence of POR ranges from 
9% to 25%.[3] Various controlled ovarian 
hyperstimulation protocols and strategies 
have been used in this group of women 
to improve reproductive outcome, but the 
success rate still remains low.
To date, there are various observational 
studies, randomized controlled trials (RCTs), 
and systematic reviews reported on this 
subject.[4-9] However, either the studies are 
too specific by trying to address only one 
treatment strategy,[4,7-10] or they include 
observational studies and nonrandomized 
studies in their meta-analysis.[9] The aim of 
INTRODUCTION
Poor ovarian response (POR) is a challenging 
situation in assisted reproduction. There is 
a lack of consensus on the definition of POR 
and a huge variation in treating women with 
previous POR.[1] However, the most common 
criterion to diagnose POR is retrieval of 
low number of oocytes despite adequate 
ovarian stimulation in an assisted conception 
cycle. The ESHRE working group on POR 
definition (the Bologna criteria) reached a 
consensus on the minimal criteria needed 
to define POR by the presence of two of 
the following three features: (i) Advanced 
maternal age (≥40 years) or any other risk 
factor for POR; (ii) a previous characterized 
POR cycle (≤3 oocytes with a conventional 
stimulation protocol); (iii) an abnormal 
ovarian reserve test (antral follicle count <5–7 
follicles or anti-Mullerian hormone (AMH) 
<0.5–1.1 ng/ml).[2] It was also proposed by 
the working group that two episodes of poor 
ovarian response after maximum stimulation 
deemed sufficient to define a patient as 
POR in the absence of other criteria. The 
Effective treatment protocol for poor ovarian 
response: A systematic review and meta‑analysis
ABSTRACT
Poor ovarian response represents an increasingly common problem. This systematic review 
was aimed to identify the most effective treatment protocol for poor response. We searched 
MEDLINE, EMBASE, and The Cochrane Library from 1980 to October 2015. Study quality 
assessment and meta‑analyses were performed according to the Cochrane recommendations. 
We found 61 trials including 4997 cycles employing 10 management strategies. Most 
common strategy was the use of gonadotropin‑releasing hormone antagonist (GnRHant), 
and was compared with GnRH agonist protocol (17 trials; n = 1696) for pituitary down‑
regulation which showed no significant difference in the outcome. Luteinizing hormone 
supplementation (eight trials, n = 847) showed no difference in the outcome. Growth 
hormone supplementation (seven trials; n = 251) showed significant improvement in 
clinical pregnancy rate (CPR) and live birth rate (LBR) with an odds ratio (OR) of 2.13 (95% 
CI 1.06–4.28) and 2.96 (95% CI 1.17–7.52). Testosterone supplementation (three trials; 
n = 225) significantly improved CPR (OR 2.4; 95% CI 1.16–5.04) and LBR (OR 2.18; 95% 
CI 1.01–4.68). Aromatase inhibitors (four trials; n = 223) and dehydroepiandrosterone 
supplementation (two trials; n = 57) had no effect on outcome.
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our systematic review is to appraise all the existing protocols 
applied to poor responders by including evidence generated 
from RCTs.
METHODS
The review was formulated using population, intervention, 
comparison, outcome, and design structure. Poor responders 
to ovarian stimulation formed the study population. All 
types of intervention subjected to RCTs were included in 
the review. The interventions were analyzed and compared 
with the control group used in the study. Two or more trials 
with identical design and interventions were analyzed 
by meta-analysis. Our outcome measures were number 
of oocytes retrieved per cycle, live birth rates (LBR), and 
clinical pregnancy rates (CPR).
We searched the literature on MEDLINE (1980-October 
2015), EMBASE (1980-October 2015), and The Cochrane 
Library (2015) for relevant citations using the keywords, 
“poor responders, controlled ovarian hyperstimulation, 
reduced ovarian response, diminished ovarian response, low 
AMH, assisted conception, and in vitro fertilization (IVF).” 
The reference lists of all known primary and review articles 
were examined to identify cited articles not captured by the 
electronic searches. Language restrictions were not applied. 
A systematic search for all RCTs was carried out. Reference 
lists from retrieved articles and related articles were checked 
for relevant studies. All studies addressing the research 
question and satisfying our inclusion criteria were included 
in the review. The review protocol was registered with the 
PROSPERO Registry (CRD42013004190).
Data collection and analysis
The electronic searches were scrutinized, and full 
manuscripts of all citations that were likely to meet the 
predefined selection criteria were obtained. Two review 
authors (Yadava Bapurao Jeve and Harish Malappa 
Bhandari) independently assessed trial quality and 
extracted data. Studies which met the predefined and 
explicit criteria regarding population, interventions, 
comparison, outcomes, and study design were selected 
for inclusion in this review. When discrepancies occurred, 
they were resolved by consensus (Yadava Bapurao Jeve and 
Harish Malappa Bhandari). We performed meta-analysis 
when two or more trials were comparable in design and 
protocol. Data were analyzed using Review Manager 
(RevMan) [Computer program]. Version 5.1. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014. For each study, the treatment effect was measured 
with an odds ratio (OR) for dichotomous outcomes and 
mean differences for continuous outcomes and random 
effect models that were presented with their corresponding 
95% confidence intervals (CI).
Inclusion criteria
Only RCTs that used suitable definition for POR and used 
different therapeutic approaches for ovarian stimulation of 
poor responders in assisted conception were included in the 
study. The trials reported after publication of the Bologna 
criteria for poor responders were analyzed as per this criteria.[2]
Exclusion criteria
All observational studies or quasi-randomized studies and 
studies in which poor responders were not defined were 
excluded from the study.
Intervention groups
The interventions were grouped as below:
1. Gonadotropin-releasing hormone antagonist (GnRHant) 
protocols
2. Protocols using luteinizing hormone (LH) as an adjuvant
3. Protocols using growth hormone (GH) as an adjuvant
4. Protocols using transdermal testosterone as an adjuvant
5. Protocols using aromatase inhibitors as an adjuvant
6. Protocols using dehydroepiandrosterone (DHEA) as an 
adjuvant
7. Protocols using recombinant human chorionic 
gonadotropin as an adjuvant
8. Natural cycle
9. Protocols using various other adjuvants
10. Various modifications to GnRH agonist (GnRHa) 
protocol.
Types of outcome measures
To bring uniformity in assessment, we analyzed the most 
relevant primary outcomes of LBR and CPR per cycle. The 
secondary outcome measure was the number of oocytes 
retrieved per cycle.
Quality and risk of bias of included studies
We included only RCTs in this systematic review – some 
were blinded and/or placebo-controlled, but others were 
not. Quality analysis was performed using internationally 
accepted Cochrane tools. GRADEpro. [Computer program 
on www.gradepro.org]. Version [2014]. McMaster 
University, 2014, was used to produce a summary of 
findings, tables for meta-analysis; this shows significant 
effects with interventions. A risk of bias table was produced 
using Review Manager (RevMan) [Computer program]. 
Version 5.1. Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2014, and is summarized 
in  Figure 1. Using these tools, we have classified overall 
quality of evidence as moderate to high grade.
RESULTS
A total of 61 RCTs (4997 assisted conception cycles) were 
included in this study. The treatment approaches were 
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categorized into 10 groups (as mentioned above), the most 
common being the use of GnRHant versus GnRHa for 
pituitary downregulation in 17 RCTs. The characteristics 
of the included studies are described in Table 1.
1. GnRHa versus GnRHant for pituitary downregulation: 
Seventeen RCTs (n = 1696) that met the criteria were 
subjected to meta-analysis [Figure 2]. The results 
suggested no significant difference in the number of 
oocytes retrieved (mean difference 0.09; 95% CI 0.53–0.36) 
and no difference in CPR with an OR of 1.24 (95% CI 
0.88–1.73)
2. LH supplementation: Eight RCTs (n = 847) assessed the 
role of supplementation to ovarian hyperstimulation but 
found no difference in CPR (OR 1.32; 95% CI 0.93–1.87)
3. GH supplementation: None of the seven RCTs (n = 251) 
individually had shown benefit of GH supplementation 
in improving CPR, but the pooled data from these 
studies showed a significant improvement in CPR (OR 
2.13; 95% CI 1.06–4.28). Of these, only four studies 
(n = 27) reported LBR and the pooled data showed 
Figure 2: Gonadotropin-releasing hormone agonist (control) versus GnRH antagonist down-regulation protocols
Figure 1: Methodological quality graph
Figure 3: Use of growth hormone supplement
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Table 1: Different therapeutic approaches for poor responders
Study Population Intervention Comparison Outcome Remark
GnRHant protocols
Martinez (2003) n=44 
(21 and 23)
Multiple dose (cetrorelix) Short, multiple dose 
(triptorelin)
Number of oocytes 
3.7 versus 5.6
CPR 5 versus 3
GnRHant and short, 
multiple GnRHa
Cheung (2005) n=66 
(31 and 32)
GnRHant protocol- cetrorelix 
0.25 mg daily as a fixed 
protocol starting on day 6 of 
the stimulation until the day 
of hCG
GnRHa - Buserelin 
acetate nasal spray 
dose of 600 µg from 
mid-luteal phase, and 
co-administered with 
the final week of OCP 
pretreatment
Number of oocytes 
5.89 versus 5.62
CPR 5 versus 3
Unblinded study: 
Fixed, multi-dose 
GnRHant versus - a 
long GnRHa protocol
Marci (2005) n=60 
(30 each)
GnRHa long protocol GnRHant Number of oocytes 
4.3 versus 5.6
CPR 5 versus 2
Unblinded study: 
GnRHant versus 
GnRHa long protocol
Schmidt (2005) n=48 
(24 each)
Ganirelix acetate group 
(received 300 IU of 
recombinant FSH s.c.+150 
IU HMG for 5 days)
21 days of OCP and the 
microdose leuprolide 
flare group
Number of oocytes 
8.9 versus 9.0
CPR 5 versus 4
Unblinded study: 
Microdose GnRHa 
versus GnRHant
Malmusi (2005) n=55 
(30 and 25)
rFSH was started on the D1 
ganirelix 0.25 mg daily until 
the hCG injection
Triptorelin 0.1 mg 
was initiated on D1 
followed by rFSH D2 of 
menstruation
Number of oocytes 
3.5 versus 2.5
CPR 3 versus 6
Unblinded study: 
GnRHa flare‑up 
protocol versus 
GnRHant
De Placido (2005) n=133 
(67 and 66)
Multiple dose (cetrorelix) 
and flare up
Multiple dose 
(triptorelin)
Number of oocytes 
6.79 versus 6.54
CPR 17 versus 14
Multiple dose 
GnRHant and flare 
up, multiple dose
Tazegül (2008) n=89 
(44 and 45)
Multiple dose (cetrorelix/
ganirelix)
Long, multiple dose 
(leuprorelin)
Number of oocytes 
5.44 versus 5.44
CPR 10 versus 11
Multiple dose 
GnRHant versus 
GnRHa long protocol
Tian (2008) n=44 (21 
and 23)
Multiple dose (cetrorelix) Short, multiple dose 
(triptorelin)
Number of oocytes 
3.25 versus 3.79
CPR 8 versus 2
Multiple dose 
antagonist versus 
GnRHa short 
protocol
Wang (2008) n=121 
(63 and 58)
OCP/multiple 
dose (cetrorelix)
OCP/long, microdose 
GnRHa (triptorelin)
Number of oocytes 
4.40 versus 5.41
CPR 22 versus 18
OCP Multiple dose 
GnRHant versus 
microdose GnRHa
Demirol (2009) n=90 
(45 each)
Combined OCP for 21 days. 
On day 3 of menstruation, 
40 µg s.c./bid of leuprolide 
followed by 450 IU/day 
HMG on day 3
GnRHant multiple 
dose - 450 IU/day HMG 
starting on day 3 and 
0.25 mg cetrorelix daily
Number of oocytes 
4.3 versus 3.1
CPR 6 versus 12
Unblinded study: 
GnRHa microdose 
flare‑up versus 
GnRHant multiple 
dose
Kahraman (2009) n=42 
(21 and 21)
Multiple dose (cetrorelix) Flare-up, microdose 
(leuprorelin)
Number of oocytes 
5.60 versus 5.80
CPR 2 versus 3
Multiple dose 
GnRHant and 
GnRHa flare up
Liu (2009) n=118 
(58 and 60)
Multiple dose (cetrorelix) Short, multiple dose 
(triptorelin)
Number of oocytes 
4.12 versus 3
CPR 18 versus 8
Multiple GnRHant 
and GnRHa short 
protocol
Devesa (2010) n=172 
(92 and 80)
OCP/multiple 
dose (ganirelix)
OCP/flare‑up, 
(leuprolide)
Number of oocytes 
4.89 versus 5.91
CPR 13 versus 12
OCP Multiple 
GnRHant and 
GnRHa flare‑up
DiLuigi (2011) n=54 
(28 and 26)
GnRHant protocol Microdose leuprolide 
acetate
Number of oocytes 
5.2 versus 5.4
CPR 9 versus 8
LBR 6 versus 7
GnRHant versus 
GnRHa microdose 
protocol
Karimzadeh (2011) n=159 
(79 and 80)
Clomiphene citrate, 
gonadotropin and GnRHant
Microdose GnRHa flare Number of oocytes 
6.34 versus 4.1
CPR 19 versus 13
Mild protocol and 
microdose GnRHa 
flare protocols
Contd...
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Prapas (2013) n=330 
(168 and 
162)
Fixed GnRHant protocol Long GnRHa protocol Number of oocytes 
3.01 versus 2.64
CPR 53 versus 68
GnRHant (fixed) 
versus GnRHa long 
protocol
Sunkara (2014) n=74 
(37 and 37)
GnRHant GnRHa long protocol Number of oocytes 
3.3 versus 4.42
GnRHant versus 
GnRHa long protocol
Protocols using LH as an adjuvant
Ferraretti (2004) n=104 
(54 and 50)
Recombinant LH in addition 
to the increased dose of FSH
An increased dosage of 
FSH
Number of oocytes
CPR 22 versus 11
Demirol (2005) n=106 
(53 and 53)
Recombinant LH in addition 
to the increased dose of FSH
Increased dosage of FSH Number of oocytes 
5.89 versus 5.62
CPR 5 versus 3
Fernández 
Ramírez (2006)
n=34 
(16 and 18)
rLH 75 IU b.i.d. 
(150 IU/day) starting on the 
day of GnRHant initiation 
until hCG trigger
GnRHant without rLH CPR 2 versus 3
Polidoropoulos (2007) n=136 
(68 and 68)
rLH 75-150 IU/day until 
hCG criteria were met
GnRHa protocol CPR 17 versus 15
Berkkanoglu (2007) n=97 
(46 and 51)
600 IU of rFSH plus daily 
supplementation with 75 IU 
of rLH
600 IU of rFSH as the 
control group
Number of oocytes 
4.8 versus 5.6
CPR 13 versus 14
Three-arm study 
with addition of 
r LH and hCG 
supplementation
Ruvolo (2007) n=42 
(24 and 18)
rLH 75‑150 IU/day from 8th 
day of ovarian stimulation 
until hCG criteria were met
GnRHa and rFSH 
without further LH 
addition
Clinical pregnancy 
10 versus 4
Barrenetxea (2008) n=84 
(42 each)
GnRHa and rFSH and rLH GnRHa and rFSH 
without further LH 
addition
Number of oocytes 
5.43 versus 5.66
CPR 10 versus 9
Unblinded study
Musters (2012) n=116 and 
128
rFSH and rLH (2:1 ratio) rFSH alone CPR 16 versus 15
Protocols using GH as an adjuvant
Owen, (1991) n=25 
(13 and 12)
GH 24 IU i.m./day on 
alternate days, starting 
simultaneously with HMG 
until the day of hCG 
administration
Use of placebo CPR 4 versus 1
LBR 4 versus 0
Zhuang (1994) n=27 
(12 and 15)
GH 12 IU i.m./day on 
alternate days
No placebo CPR 5 versus 2
LBR 4 versus 2
Hughes (1994) n=33 
(21 and 12)
In addition to commencing 
HMG, a second daily 
injection
of GH 12 IU i.m. daily for 
up to 12 days or until hCG
Placebo Number of oocytes 
5 versus 5
Placebo-controlled 
double-blind
Bergh (1994) n=40 
(20 each)
GH 0.1 IU/kg body weight 
per day was given s.c. as 
pretreatment and during 
stimulation with HMG
Placebo CPR 3 versus 2 Double-blind, 
placebo-controlled
Dor (1995) n=14 
(7 and 7)
GNRHa/HMG/GH 
(18 IU on alternate days, 
total dose 72 IU)
GnRHa/HMG/placebo CPR 0 both groups Placebo-controlled 
double-blind 
Suikkari (1996) n=22 
(16 and 6)
GnRHa, gonadotropin in a 
”boost” flare‑up protocol for 
4, or 12 IU of human GH
Placebo CPR 2.4 versus 2 Double-blind 
placebo-controlled
Howles (1999) n=196 (96 
and 100)
Long luteal buserelin 
0.5 mg, 1 mg/day GH 
releasing factor s.c. with 
HMG 300 IU/day i.m. from 
the day of down‑regulation
No supplement CPR 8 versus 8 
LBR 5 versus 4
Multicenter 
double-blind, 
placebo-controlled 
study
Contd...
Jeve and Bhandari: Treatment for poor ovarian response
75Journal of Human Reproductive Sciences / Volume 9 / Issue 2 / Apr - Jun 2016
Table 1: Contd...
Study Population Intervention Comparison Outcome Remark
Kucuk (2007) n=61 
(31 and 30)
GH co-treatment, daily s.c. 
injection of 4 mg from day 
21 of preceding cycle along 
with GnRHa
No supplement Number of oocytes 
6.5 versus 3.2
GH co-stimulation to 
long luteal GnRHa 
regimen
Eftekhar (2013) n=82 
(40 and 42)
GH and GnRHant protocol GnRHant protocol (no 
placebo)
CPR 5 versus 5
Number of oocytes 
6.1 versus 4.8
Protocols using testosterone as an adjuvant
Massin (2006) n=53 
(27 and 26)
Transdermal application of 
testosterone 15 days before 
FSH
Placebo CPR 4 versus 1, 
LBR 2 versus 1
Number of oocytes 
3.17 versus 3.56
Double-blind, 
placebo-controlled 
study
Fábregues (2009) n=62 
(31 and 31)
Testosterone 20 µg/kg/day 
for 5 days transdermal 
application preceding 
ovarian stimulation
High-dose gonadotropin 
in association with 
a minidose GnRHa 
protocol
CPR 6 versus 4, 
LBR 6 versus 4
Number of oocytes 
4.1 versus 3.6
Kim (2011) n=110 
(55 and 55)
12.5 mg transdermal 
testosterone daily for 21 days 
in the cycle preceding 
ovarian stimulation
No placebo CPR 17 versus 8, 
LBR 15 versus 7
Number of oocytes 
4.6 versus 3.2
Protocols using aromatase inhibitors as an adjuvant
Goswami (2004) n=38 
(13 and 25)
Let 2.5 mg daily from day 3 
to 7, and rFSH 75 IU/day on 
days 3 and 8
Long GnRHa protocol 
and rFSH (300-
450 IU/day)
CPR 3 versus 6
Number of oocytes 
1.6 versus 2.1
Unblinded study, 
Let-FSH group 
versus GnRHa-FSH 
group
Kashyap (2005) n=55 
(29 and 26)
Let and GnRHant No placebo, GnRHant 
protocol
CPR 3 versus 1
Ozmen (2009) n=70 
(35 and 35)
Let 5 mg/day for 5 days and 
GnRHant 0.25 μg/day
No placebo, GnRH 
GnRHant 0.25 μg/day
CPR 8 versus 5
Mohsen (2013) n=60 
(30 and 30)
Let supplementation GnRHa protocol (micro 
dose flare)
CPR 4 versus 5
Protocols using DHEA as an adjuvant
Artini (2012) n=48 
(24 each)
25 mg three times a day of 
DHEA supplementation for 
3 months previous to IVF 
cycle
No adjuvant CPR 6 versus 4
Number of oocytes 
3.58 versus 2.67
Prospective, 
randomized, 
controlled
Wiser (2010) n=51 
(26 and 25)
75 mg DHEA orally, once a 
day, at least 6 weeks before 
GnRHa long protocol
No adjuvant CPR 7 versus 3
Number of oocytes 
4.6 versus 3.2 3.2 
and 3.5
Prospective, 
randomized, 
controlled
Protocols using rhCG as an adjuvant
Berkkanoglu (2007) n=99 
(48 and 51)
600 IU of rFSH plus daily 
supplementation with 75 IU 
of rhCG
600 IU of rFSH CPR 10 versus 14
Number of oocytes 
3.8 versus 5.6
Three-arm study 
recombinant 
LH, hCG 
supplementation
Natural cycle
Morgia (2004) n=215 (114 
and 101)
Natural cycle IVF Microdose GnRHa flare 
from day 1 and 600 IU 
FSH
CPR 17 versus 10
Number of oocytes 
0.79 versus 2.1
Unblinded study
Protocols using other adjutants
Jinno (1997) n=162 
(82 and 80)
Oral 1.25 mg/day 
bromocriptine from day 4 to 
6 in preceding cycle and then 
4.5 mg/day, discontinued 
7 days before the beginning 
of HMG administration
GnRHa long protocol CPR 25 versus 13
Number of oocytes 
9.5 versus 8.4
Unblinded, 
controlled trial: 
Bromocriptine 
rebound method
Contd...
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Chung Hoon (1999) n=70 
(35 each)
Triptorelin 0.1 mg from 
day 21; HMG/FSH 300 
IU/day i.m. from day of 
downregulation plus 120 mg/
day pyridostigmine until hCG
No adjuvant CPR 9 versus 4
Number of oocytes 
5.9 versus 3.7
Double-blind, 
placebo-controlled 
study
Battaglia (1999) n=34 
(17 each)
GNRHa + daily 
supplemented (16 g) with 
oral L-arginine
No adjuvant CPR 0 versus 2 
number of oocytes 
1.6 versus 4.1
Oral L-arginine + 
GnRHa
Lok (2004) n=60 
(30 in 
each)
Low-dose aspirin (80 
mg daily) at the time of 
commencement of GnRHa 
in the preceding cycle and 
continuing until hCG
Placebo CPR 3 versus 2
Number of oocytes 
4 versus 3
Double-blind, 
placebo-controlled 
study 
Various modifications to GnRHa protocols
Dirnfeld (1991) n=54 
(28 and 26)
600 µg/day of buserelin 
nasal spray on day 1 till hCG
1000 µg/day of 
buserelin nasal spray 
15‑30 days before 
ovulation induction, then 
600 µg/day till hCG
CPR 3 versus 2
Number of oocytes 
7.0 versus 5.6
Unblinded 
Von Hoof (1993) n=47 
(25 and 22)
225 IU/day i.m. HMG from 
day 3 for 5 days, increasing 
to 450 IU/day
Unchanged dose Unblinded study
Rombauts (1998) n=40 
(18 and 20)
GnRHa from day 2. FSH 
(150 IU) from day 25 of 
previous cycle
GnRHa from day 2. 
FSH 150 IU from day 3 
of treatment cycle
Number of oocytes 
4.5 versus 6
Controlled study 
Dirnfeld (1999) n=78 
(40 and 38)
GnRHa - started in the 
midluteal phase and stopped 
before administration of 
gonadotropins
GnRHa from the 
midluteal phase and was 
continued throughout 
the follicular phase
CPR 5 versus 9 
number of oocytes 
6.46 versus 7.73
Unblinded study
Raga (1999) n=30 
(15 and 15)
300 IU/day rFSH + 
150 IU/day HMG
Purified FSH CPR 4 versus 1 
number of oocytes 
7.2 versus 5.6
Prospective 
randomized study
Garcia-Velasco (2000) n=70 
(34 and 36)
Leuprolide acetate 1 mg/d 
SC till menstruation and then 
stopped. 3 Amp HMG + 5 
Amp FSH on days 1 and 2, 2 
Amp HMG + 3 Amp FSH on 
days 3,4 and 5 from D6
No stop protocol, high 
dose protocol Long 
GnRH suppression and 
gonadotropins
CPR 5 versus 6 
number of oocytes 
4.1 versus 6.9
Unblinded study
Akman (2000) n=40 
(20 each)
Ovarian stimulation with 
no GnRHa or GnRHant 
administration
0.25 mg of Cetrorelix 
daily till hCG
CPR 1 versus 4 
number of oocytes 
3.46 versus 3.25
Unblinded study
Akman (2001) n=48 
(24 in 
each)
Low-dose oral contraceptive 
on cycle day 1 for 21 days. 
On day 2 of menstruation 
leuprolide acetate 
(40 µg s.c./day) followed by 
gonadotropins
Gonadotropins from day 
2 and later 0.25 mg of 
cetrorelix daily
CPR 6 versus 5 
Number of oocytes 
5.5 versus 4.5
Unblinded study
Marci (2003) n=38 
(19 each)
short flare up protocol 
using GnRHa 0.1 mg/day 
triptorelin from day 2
Daily dose of 0.25 mg 
Cetrotide and 375 IU/
day rFSH
CPR 3 and 2 Unblinded study
Mohamed (2006) n=30 
(15 and 13)
Buserelin 500 µg/day s.c. 
from day 1 of cycle and 
ovarian stimulation from day 3
Ovarian stimulation from 
day 3 and GnRHant 0.25 
mg/day from day 8
Number of oocytes 
6 each
Unblinded study
Kucuk (2007) n=42 
(21 each)
Long protocol triptorelin 
0.1 mg, 150 IU rFSH, 
triptorelin was halved to 
0.05 mg and the rFSH was 
increased to 450 IU
Flare‑up regimen of 
triptorelin. Along with 
triptorelin, 450 IU rFSH
Number of oocytes 
6.8 versus 3.8
Long protocol flare 
up regimen
Contd...
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Lainas (2008) n=270 
(180 and 
90)
Ganirelix 0.25 mg and 
including the day of hCG 
administration
0.05 mg/day triptorelin 
from day 2 of the cycle 
including the day of 
hCG administration
CPR 29 versus 
7 number of 
oocytes 3 and 3
CPR=Clinical pregnancy rate, LBR=Live-birth rate, GnRH=Gonadotropin-releasing hormone, GnRHa=Gonadotropin-releasing hormone agonist, GnRHant=GnRH antagonist, FSH=Follicle-stimulating 
hormone, rFSH=Recombinant FSH, HCG=Human chorionic gonadotropin, rhCG=Recombinant hCG, OCP=Oral contraceptive pill, HMG=Human menopausal gonadotropin, LH=Luteinizing 
hormone, rLH=Recombinant LH, GH=Growth hormone, Let=Letrozole, DHEA=Dehydroepiandrosterone, s.c=subcutaneous, IVF=In vitro fertilization
significantly improved LBR (OR 2.96; 95% CI 1.17–7.52) 
with GH supplementation [Figure 3 and Table 2]
4. Testosterone supplementation: A relatively smaller 
number of trials tested transdermal testosterone 
Table 2: Summary of findings for use of growth hormone supplementation
Growth hormone supplementation to gonadotropins compared to placebo or no supplementation for poor responders
Patient or population: Patients with poor responders
Settings: Randomized controlled trials
Intervention: Growth hormone supplementation to gonadotropins
Comparison: Placebo or no supplementation
Outcomes Illustrative comparative risks* (95% CI) Relative effect 
(95% CI)
Number of 
participants 
(studies)
Quality of the 
evidence (grade)
Comments
Assumed risk Corresponding risk
Placebo or no 
supplementation
Growth hormone 
supplementation to 
gonadotropins
Study population
Clinical 
pregnancy rates
123 per 1000 230 per 1000 (129-375) OR 2.13 (1.06-4.28) 251 (7 studies) ⊕⊕⊕⊕High
Moderate
Live birth rates 111 per 1000 270 per 1000 (128-485) OR 2.96 (1.17-7.52) 135 (4 studies) ⊕⊕⊕⊕High
Moderate
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI). CI=Confidence interval, OR=Odds ratio. Grade working group grades of evidence ‑ High quality=Further research 
is very unlikely to change our confidence in the estimate of effect, Moderate quality=Further research is likely to have an important impact on our confidence in the estimate of effect and may 
change the estimate, Low quality=Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate, Very low quality=We 
are very uncertain about the estimate
Table 3: Summary of findings for the use of transdermal testosterone supplementation
Transdermal testosterone supplementation to gonadotropins compared to placebo or no supplementation for poor responders
Patient or population: Patients with poor responders
Settings: Randomized controlled trials
Intervention: Transdermal testosterone supplementation to gonadotropins
Comparison: Placebo or no supplementation
Outcomes Illustrative comparative risks* (95% CI) Relative effect 
(95% CI)
Number of 
participants 
(studies)
Quality of the 
evidence (grade)
Comments
Assumed risk Corresponding risk
Placebo or no 
supplementation
Transdermal testosterone 
supplementation to 
gonadotropins
Study population
Clinical 
pregnancy rates
116 per 1000 240 per 1000 (132-398) OR 2.41 (1.16-5.04) 225 (3 studies) ⊕⊕⊕⊕
High
Low
Moderate
Live birth rates 107 per 1000 207 per 1000 (108-360) OR 2.18 (1.01-4.68) 225 (3 studies) ⊕⊕⊕⊕
High
Moderate
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI). CI=Confidence interval, OR=Odds ratio. Grade working group grades of evidence ‑ High quality=Further research 
is very unlikely to change our confidence in the estimate of effect, Moderate quality=Further research is likely to have an important impact on our confidence in the estimate of effect and may 
change the estimate, Low quality=Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate, Very low quality=We 
are very uncertain about the estimate
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supplementation in assisted conception cycles (three 
RCTs; n = 225). The meta-analysis showed significantly 
improved CPR (OR 2.41; 95% CI 1.16–5.04) and 
LBR (OR 2.18; 95% CI 1.01–4.68), but the number of 
oocytes retrieved was not statistically significant (mean 
difference 0.94; 95% CI 0.24–1.64), [Figure 4 and Table 3]
5. DHEA supplementation: Two RCTs (n = 99). DHEA 
supplementation was found to have no significant 
effect on the number of oocytes (mean difference 0; 95% 
CI − 1.07–1.07) and CPR (OR 2.10; 95% CI 0.75–5.85)
6. Use of aromatase inhibitors: Letrozole supplementation 
was used in four trials (n = 223) and the pooled data 
failed to find any statistically significant CPR (OR 1.28; 
95% CI 0.60–2.73)
7. Natural cycle: The natural cycle IVF was tested by only 
one trial (n = 215).[11] The CPR and number of oocytes 
retrieved were statistically similar in both groups
8. Other interventions: Various authors modified the 
GnRHa protocols or used various supplementations 
such as bromocriptine, pyridostigmine, L-arginine, 
and low-dose aspirin which are described in Table 1. 
None of these interventions showed any significant 
improvement in outcomes.
DISCUSSION
Our systematic review updates on the evidence on various 
strategies to improve reproductive outcome for POR. We 
analyzed 61 RCTs and 4997 assisted conception cycles which 
were divided into 10 categories based on the interventions used.
The use of GnRHant protocol for pituitary downregulation 
is a commonly used approach for poor responders. 
GnRHant protocol offers several advantages. They 
cause immediate, rapid gonadotropin suppression by 
competitively blocking GnRH receptors in the anterior 
pituitary gland, thereby preventing endogenous premature 
release of LH and FSH. Our meta-analysis of 17 RCTs did 
not show any significant difference in CPR or number of 
oocytes retrieved with the use of GnRHant.[12-28]
LH aids maintain adequate concentrations of intraovarian 
androgens and promote steroidogenesis and follicular 
growth. It has been proposed that addition of LH to 
ovarian stimulation protocol may benefit poor responders. 
Meta-analysis of eight trials[13,29-33] did not show significant 
improvement in CPR with use of recombinant LH.
GH, insulin-like growth factor-1, and GH-releasing 
hormone increase the sensitivity of ovaries to gonadotropin 
stimulation and enhance follicular development. GH 
enhances oocyte quality by accelerating and coordinating 
cytoplasmic and nuclear maturation. There are some 
suggestions that GH-releasing factor supplementation may 
improve pregnancy rates in poor responders. The pooled 
data from eight RCTs in this review show significantly 
improved CPR and LBR with GH supplementation.[13,29-36] 
There was no significant heterogeneity in the included 
studies (τ2 = 0.00, χ2 = 0.98, df = 3 [P = 0.81]; I2 = 0%). 
However, none of the studies had independently found 
any significant benefit with GH supplementation. The 
Figure 4: Use of testosterone supplement
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total numbers in the meta-analysis are small to draw any 
definitive conclusions.
Androgen stimulates early stages of follicular growth and 
increases the number of preantral and antral follicles by the 
proliferation of granulosa and thecal cells and reduction in 
granulosa cell apoptosis. It is hypothesized that positive 
change in microenvironment in the ovaries may lead to 
an increase in the number and the maturity of oocytes in 
poor responder group.[37] Three randomized trials[38-40] have 
tested this approach and the meta-analysis shows significant 
improvement in LBR and CPR.
Aromatase inhibition was proposed to improve ovarian 
response to FSH in poor responders. Our meta-analysis 
included four RCTs and failed to show any improvement 
in outcome with the use of aromatase inhibitors.
It is proposed that DHEA changes the follicular 
microenvironment by reducing hypoxic inducible factor-1, 
thus improving the quality of oocytes. Pooled data from 2 
RCTs showed no significant difference in CPR with DHEA 
supplementation.[41]
Natural cycle IVF offers several advantages such as low cost 
and low risk of multiple pregnancies and most importantly 
eliminates the risk of ovarian hyperstimulation syndrome. 
Morgia et al.[11] randomized natural cycle IVF and microdose 
GnRHa flare along with FSH. It was found that natural cycle 
IVF may be as effective as IVF using controlled ovarian 
hyperstimulation. No further trials with this approach were 
found for meta-analysis.
Strengths and limitations
Our study provides most comprehensive and up-to-date 
review on the topic of assessing most effective treatment 
for poor responders and included only RCTs. We divided 
different approaches into 10 categories and performed 
meta-analysis as appropriate. Previous reviews were very 
specific in addressing one treatment strategy, and they 
failed to provide any conclusive answer. Some reviews were 
methodologically limited as they included observational 
studies and nonrandomized studies in their meta-analysis.[4,7,9]
The major limitation of this review is related to its small 
population size. Although some adjuvant supplementations 
may appear to improve ovarian response and reproductive 
outcome, we recognize that the numbers are small to 
recommend their routine use in poor responders. There 
was significant heterogeneity in the definition of poor 
responders in these trials conducted before Bologna 
consensus criteria were recommended.
Interpretation
Our meta-analysis showed no difference in the number 
of oocytes retrieved or the CPRs with use of GnRHant. 
The pooled data from seven studies show significantly 
improved CPR and LBR with GH supplementation in 
the previous review.[4] Our meta-analysis adds a further 
RCT[36] (n = 82) which results in a 48% increase in sample 
size. GH supplementation showed some promising results; 
however, the numbers are small to draw any convincing 
conclusion. Our results for testosterone supplementation 
are consistent with the results of previous meta-analyses 
as there were no new RCTs.[5,7] Letrozole supplementation 
may result in improved FSH sensitivity and concentration, 
but this beneficial effect was not reflected in the results. 
A systematic review by Bosdou et al.[7] previously showed 
no difference in outcome with the use of letrozole. Two 
more RCTs have been undertaken[37,42] since the previous 
review, and we added a total of 68 cycles (43%) to the sample 
size in our review. However, the pooled data showed no 
significant difference in outcome with use of letrozole. The 
anti-aging effect of the adrenal androgen DHEA is thought 
to be the mechanism to improve ovarian response. Recent 
meta-analysis did not show significant improvement with 
the use of DHEA.[9] Only two RCTs were eligible for our 
meta-analysis, which failed to demonstrate any benefit.
CONCLUSION
Evidence from this review suggests that GH supplementation 
or transdermal testosterone supplementation to assisted 
conception treatment cycles is associated with an improved 
CPR and LBR in poor responders. However, it is essential to 
recognize that this evidence is derived from a small number of 
studies; hence, we feel that the current evidence is insufficient to 
recommend the routine use of either of these approaches. Other 
treatment strategies are not found to be useful in improving 
clinical outcome in poor responders. We recommend that the 
empirical use of adjuvants should be avoided pending good 
quality evidence from well-designed studies.
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Objective: To evaluate and compare obstetric complications between women who conceived after oocyte dona-
tion and age-matched control womenwho conceived spontaneously or by autologous in vitro fertilization (IVF).
Methods: In a retrospective cohort study, data were assessed from all women who conceived after oocyte dona-
tion and delivered a live neonate after 24weeks of pregnancy between January 2007 and December 2014 at a UK
hospital. Two age-matched control groups—one containing women who conceived after autologous IVF and the
other containingwomenwho conceived spontaneously—were used for comparison. The primary study outcome
was hypertensive disorders of pregnancy (pregnancy-induced hypertension and pre-eclampsia). Multivariate
analysis was performed by logistic regression. Results: Each group included 45 women. Hypertensive disorders
in pregnancy affected 15 (33%) women in the study group, 3 (7%) women who conceived after autologous IVF,
and 3 (7%) who conceived spontaneously. The risk of hypertensive disorders in pregnancy was significantly
higher in the donor oocyte group (odds ratio 5.85, 95% confidence interval 1.42–23.9; P = 0.01). Conclusion:
Women who conceived after oocyte donation had an increased risk of hypertensive disorders. Oocyte donation
should be managed as an independent risk factor, and couples should be counselled appropriately.
© 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Oocyte donation has become widely used as a treatment option for
infertile couples. In 2009, 21 604 treatment cycles using egg donation
were reported in Europe alone [1]. The demand for donor oocytes has
grown steadily with the trend of delayed childbearing [1]. Increasing
maternal age is a social trend that is likely to continue in the years to
come [2]. Other causes for the increase in oocyte donation include ovar-
ian failure, diminished ovarian reserve,multiple failures of in vitro fertil-
ization (IVF), availability of advanced reproductive technology, and
diagnosis of genetic conditions with risk of inheritance to offspring [3].
Advanced maternal age is an independent risk factor for obstetric
complications [4], particularly hypertensive disorders of pregnancy
[5]. It is also associated with an increased risk of adverse neonatal
outcomes [6]. Women with pregnancy after oocyte donation are at in-
creased risk of pre-eclampsia, fetal growth restriction, preterm labor,
cesarean delivery, and postpartum hemorrhage [7–9]. Therefore, for
studies investigating adverse perinatal outcomes in pregnancies
conceived after oocyte donation, advanced maternal age is likely to be
a significant confounding factor.
The few available studies report conflicting evidence about the risk
of hypertensive disorders in donor oocyte pregnancies after adjusting
for maternal age [10,11], and it is unclear whether pregnancy complica-
tions and obstetric risks are due to oocyte donation or to confounding
factors such as maternal age. The aim of the present study was to eval-
uate and compare obstetric complications between women who con-
ceived after oocyte donation and age-matched control women with
spontaneous conception or autologous IVF conception.
2. Materials and methods
The present retrospective study was conducted as a three-armed,
age-matched cohort study. The study group comprised all women
who conceived after oocyte donation and delivered a live neonate
after 24 weeks of pregnancy at a teaching hospital in Leicester, UK, be-
tween January 1, 2007, and December 31, 2014. The two control groups
comprised age-matchedwomenwho conceived after IVF via autologous
oocytes, and age-matched women with spontaneous conception. The
age-matched control women were identified by selecting pregnancies
recorded immediately after donor oocyte pregnancies in the maternity
electronic database. Pregnancies after preimplantation genetic diagno-
sis, or after surgical sperm retrieval or use of donor sperm were not in-
cluded in the study. As per local protocol, ethical approval and
individual patient consent were not required to analyze anonymized
hospital data.
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All women in the study group were seen in a dedicated prenatal
clinic. For the present analysis, a retrospective service review was un-
dertaken to determine the obstetric outcomes. Data were collated
from booking, prenatal, and intrapartum records, and the maternity
electronic database system. For each patient, demographic data and de-
tails of assisted conception were collected at the booking visit. Data col-
lection was completed for individual women in the study group using a
prepared template.
The primary study outcomewas hypertensive disorders of pregnancy,
including pregnancy-induced hypertension and pre-eclampsia.
Pregnancy-induced hypertension was defined as blood pressure above
140/90 mm Hg on two or more occasions at least 6 hours apart, without
proteinuria, and presenting after 20 weeks of pregnancy. Pre-eclampsia
was defined as blood pressure above 140/90 mm Hg on two or more
occasions at least 6 hours apart, with proteinuria of 0.3 g/day or higher,
after 20 weeks of pregnancy. Fetal growth restriction (FGR) was defined
as a birthweight below the fifth centile for gestational age. Preterm labor
was defined as delivery before 37 completed gestational weeks.
Gestational age was calculated from the day of oocyte collection, which
was defined as day 14 of the cycle. The gestational age for natural concep-
tionwas based on booking prenatal ultrasonography performed between
8 and 13 weeks of pregnancy.
All data were analyzed via Stata version 13 (StataCorp, College
Station, TX, USA). Descriptive data were compared among the three
groups, including age, body mass index (BMI, calculated as weight in
kilograms divided by the square of height inmeters), smoking, and par-
ity. Histograms were produced to ascertain the distribution, and data
with a normal distribution are presented as mean ± SD. Multivariate
analysis was conducted by conditional logistic regression and adjusted
for age, BMI, smoking, previous medical history, parity, and multiple
pregnancy. P b 0.05 was considered to be statistically significant.
3. Results
During the study period, 45 women who conceived after oocyte do-
nationmet the study criteria andwere included in the analysis. The two
control groups therefore each also contained 45 age-matched women.
There was no difference in characteristics between the three groups
(Table 1). The parity of women in the study group ranged from 0 to 4,
that in the autologous IVF control group ranged from 0 to 4, and that
in spontaneous conception group ranged from 0 to 3.
The pregnancy complications are summarized in Table 2. In the lo-
gistic regression model, there was no difference in the incidence of
FGR, preterm delivery, prepartum hemorrhage, mean birth weight, or
cesarean delivery among the groups. Notably, the likelihood of hyper-
tensive disorders in pregnancy was significantly higher in the study
group than in either control group after adjusting for age, BMI, multiple
gestation, and smoking status (odds ratio 5.85, 95% confidence interval
1.42–23.90; P = 0.01). There was a significant difference in the inci-
dence of FGR among the three groups (χ2 = 6.85, P = 0.03); after in-
cluding other covariates in the regression model, however, this
difference was not significant (P= 0.25).
4. Discussion
The present results showed an increased risk of hypertensive disor-
ders among women with donor oocyte pregnancies as compared with
age-matched control women with spontaneous or assisted conception.
By contrast, the results did not show a significant association between
oocyte donation and FGR, preterm labor, or cesarean delivery rate.
This might be explained by the small sample size, which is a significant
limitation of the study.
Two studies of obstetric outcomes in donor oocyte pregnancies [7,12]
have shown an increased risk of preterm labor, pre-eclampsia, prolonged
labor, and cesarean delivery. However, another study [13] failed to find
any association of adverse outcomes with conception after oocyte dona-
tion. ADanish national cohort study [14] showed an increased risk of pre-
eclampsia and preterm labor in donor oocyte pregnancies as compared
with pregnancies after autologous IVF, intracytoplasmic sperm injection,
and spontaneous conception. However, these two complications overlap
with cofounders such as multiple pregnancies, advanced age, underlying
polycystic ovary syndrome, assisted conception, and other pre-existing
medical conditions [15].
Advanced maternal age is associated with a significantly increased
risk of perinatal complications [16]; therefore, it is necessary to elimi-
nate bias caused by maternal age and other risk factors. Levron et al.
[11] recently showed that oocyte donation was independently associat-
edwith a higher rate of hypertensive diseases of pregnancy after adjust-
ment for maternal age, gravidity, parity, and chronic hypertension. The
present findings are consistent with a few studies reporting high com-
plication rates with donor oocyte pregnancies independent of recipient
age, parity, plurality, and the age of the donor [17,18].
The risk of obstetric complications for women with conceiving after
oocyte donationmight be explained on the basis of the immunologic the-
ory of pre-eclampsia. Although the underlying cause of pre-eclampsia is
unknown, an immunologic component is clearly involved in the patho-
physiology of this disorder [19], and parental human leukocyte antigen
sharing is thought to have a role in the etiology of pre-eclampsia [20].
The success of pregnancy depends on appropriate implantation, and
any insult during this process can cause obstetric complications such as
spontaneous abortion, intrauterine growth restriction, or preterm birth,
in addition to pre-eclampsia [21]. By definition, the fetus is allogeneic to
the gestational carrier in donor oocyte pregnancies. As a result, themoth-
er faces a higher degree of antigenic dissimilarity as comparedwith spon-
taneously conceived pregnancies [22]. One study [23] has reported
increased immune activity and fibrinoid deposition at the maternal–
fetal interface of donor oocyte pregnancies, representing a host-versus-
graft rejection-like process. Thus, these pregnancies are at higher risk of
perinatal complications. Further research is required to explain the
pathogenesis of donor oocyte pregnancies and placental complications.
On one hand, assisted reproductive technology using oocyte donation
has enabledwomen at advanced age orwith ovarian failure to successful-
ly achieve pregnancy. On the other hand, conception after oocyte dona-
tion can subject them to a higher risk of maternal morbidity and
mortality [24]. The risk of complications resulting from oocyte donation
highlights the importance of preconception counseling. Although
Table 1
Characteristics of the study women by group.a
Characteristic Oocyte donation (n = 45) Autologous oocyte IVF (n = 45) Spontaneous conception (n = 45) P valueb
Age, y 40.23 ± 5.64 39.23 ± 1.71 39.69 ± 0.71 0.40
Body mass indexc 25.11 ± 4.42 25.51 ± 4.04 26.23 ± 4.70 0.50
Parity 0.48 ± 0.92 0.34 ± 0.81 0.61 ± 0.85 0.33
Smoker 0 2 (4) 2 (4) 0.34
Abbreviation: IVF, in vitro fertilization.
a Values are given as mean ± SD or number (percentage), unless indicated otherwise.
b Analysis of variance.
c Calculated as weight in kilograms divided by the square of height in meters.
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counseling ismore important forwomen older than 40 yearswho choose
oocyte donation, youngerwomen should be informed of the risks [24,25].
Furthermore, obstetricians need to be aware of the increased pregnancy
risks for this group of women, who should be managed appropriately
during the pregnancy, delivery, and puerperium period [25].
In conclusion, oocyte donation should be treated as an independent
risk factor for hypertensive disorders in pregnancy. Women should be
fully informed of the risks before undergoing fertility treatment.
Womenwho select conception using donor oocytes should bemanaged
in high-risk obstetric clinics with appropriate surveillance andmanage-
ment strategies for obstetric complications. There is currently limited
evidence to attribute complications to an immunologic origin; further
research is needed to explain the pathogenesis and risks involved in
donor oocyte pregnancies.
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Background Observational studies showed that women with a
donor oocyte (DO) pregnancy have an increased risk of pregnancy
complications.
Objectives Systematic review and meta-analysis to compare
pregnancy complications of DO pregnancy with autologous oocyte
in vitro fertilisation (IVF), and whether DO pregnancy acts as an
independent risk factor.
Search strategy Online searches of databases from 1 January 1980
to 31 January 2015 were performed using a set of relevant
keywords.
Selection criteria All studies comparing pregnancy complications
of women with donor oocyte IVF and autologous oocyte IVF
were included.
Data collection and analysis Data collected included
demographics and pregnancy complications. Methodological
quality assessment was performed using the Newcastle–Ottawa
scale. Statistical analysis was performed using REVIEW
MANAGER 5.3 and STATA 13.0. Meta-regression was performed
for age.
Main results In total, 11 studies (n = 81 752) were included. Ten
studies (n = 11 539) examined the primary outcome. The risk of
developing hypertensive disorders in pregnancy was significantly
higher for DO pregnancy (odds ratio, OR 3.92; 95% confidence
interval, 95% CI 3.21–4.78). Further subgroup analysis for
singleton and twin pregnancies showed that the risk was
significantly higher for DO pregnancy in each group. Secondary
outcomes including small for gestational age (OR 1.81), caesarean
section (OR 2.71), and preterm delivery (OR 1.34) were
significantly higher with DO pregnancy. Meta-regression for the
covariate of age suggested that risk was independent of age.
Author’s conclusions Donor oocyte pregnancy acts as an
independent risk factor for pregnancy complications, including
hypertensive disorders, small for gestational age, and preterm
delivery. Women should be counselled carefully before undergoing
DO-assisted conception.
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Introduction
Donor oocyte (DO) conception has allowed many women
of advanced age to achieve successful pregnancies. The
demand has grown steadily with the trend of delayed child-
bearing. This phenomenon of increased maternal age is
likely to continue in the years to come.1 The recent rise in
DO pregnancies is reported by all European countries.2 In
addition to advanced maternal age there are various other
indications for DO conception, which include primary or
secondary ovarian failure, diminished ovarian reserve, mul-
tiple failures of in vitro fertilisation (IVF), and diagnoses of
genetic conditions.3 The treatment option of egg sharing,
which involves a woman sharing her eggs with another in
exchange for free or reduced-cost fertility treatment, has
been regulated in the UK since 1998, and is viewed
positively by the egg-sharing donors and recipients.4
Advanced maternal age in itself is associated with preg-
nancy complications, including hypertensive disorders, ges-
tational diabetes, preterm labour, and intrauterine growth
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restriction.5,6 A recent report from the Human Fertilization
and Embryonic Authority (HFEA) showed that over half of
women receiving IVF aged 45 years and older used donated
oocytes, but that there has also been a substantial increase
in recipients aged under 35 years.7 The most common
complication noted in DO pregnancies is pregnancy-
induced hypertension and pre-eclampsia, ranging from 16
to 40% of women.8–13 Pre-eclampsia affects 3–5% of all
pregnancies, and is estimated to result in 60 000 maternal
deaths annually worldwide.14 Although obstetric complica-
tions have been attributed to advanced maternal age in
these women, the risk is reported to be independent of
age.13 Placental pathology as a result of immunological
pathogenesis is suggested to be the reason for obstetric
complications in DO pregnancy. The study by Kim et al.15
showed that the incidence of hypertensive disorders is sig-
nificantly higher if the oocyte donor is unrelated to the
recipient, compared with a related sibling donor. It is sug-
gested that immunologic intolerance between the mother
and the fetus may play an important role in the pathogene-
sis of pre-eclampsia.16–18 Pregnancies achieved by IVF or
by intracytoplasmic sperm injection (ICSI) are at a higher
risk for pregnancy complications compared with sponta-
neous pregnancies.19 Therefore, it would be more appropri-
ate to use autologous-oocyte IVF pregnancy as a control
group to study outcome in DO pregnancies.
The aim of this systematic review and meta-analysis is to
study the obstetric outcome of DO pregnancies compared
with autologous-oocyte IVF pregnancy. We aim to discover
whether DO pregnancy acts as an independent risk factor
for pregnancy complications.
Methods
A literature search was performed using Ovid MEDLINE
(1980–January 2015), EMBASE (1980–January 2015), Ovid
OLDMEDLINE, Pre-MEDLINE, in-process and other
non-indexed citations database consists of in-process
and PubMed-not-MEDLINE records from NLM, HaPI
(1985–January 2015), Google scholar, Web of Sciences
(1980–2015), and the Cochrane Library. The conference
proceedings citation index was also searched with no lan-
guage restriction applied. A combination of medical sub-
ject headings and keywords were used to generate a
subset of: citations for oocyte* (‘ovum’, ‘ova’, ‘egg*’);
citations including donor and oocyte; citations including
assisted conception techniques (‘ART* or IVF* or ICSI*’);
and citations including various pregnancy complications
(‘gestational hypertension or pregnancy-induced hyperten-
sion or pre-eclampsia*’ ‘fetal growth restriction* or
IUGR* or small baby or birthweight’, ‘preterm labour’,
‘intrauterine death*’, ‘caesarean section*’). These subsets
were combined using ‘AND’ or ‘OR’, as appropriate, to
generate a set of results addressing the research question.
Duplicates were removed. The reference list of all pub-
lished articles including review articles was examined to
check for missed citations. No author was contacted. This
review was registered in the PROSPERO database
(CRD42015023739).
Data collection and analysis
Two review authors (YJ and NP) independently screened
the titles and abstracts. Studies that met the predefined and
explicit criteria were selected for inclusion in the review.
The electronic searches were scrutinised and the full texts
of all citations that were likely to meet the predefined selec-
tion criteria were obtained. The quality of included cita-
tions was independently examined and data extraction was
performed. Where disagreements occurred, they were
resolved by the consensus of both authors.
Criteria for including studies in the review
Types of study
Inclusion criteria: all observational studies comparing preg-
nancy outcomes in DO pregnancies with a predefined con-
trol group of pregnancies achieved with autologous oocyte
IVF or ICSI only. Studies comparing outcome of DO sin-
gleton and twin gestations were included. All published
data were used in the review. We have included both
prospective and retrospective cohort and case–control stud-
ies.
Exclusion criteria: all observational studies reporting out-
come in only DO pregnancies without any control group
were excluded. Studies with incomplete data or with a
heterogeneous control group were excluded. All studies
with a spontaneous conception group used as the control
group, donor sperm conception, case reports, and DO con-
ception for Turner syndrome were also excluded, as Turner
syndrome itself carries an additional risk for obstetric com-
plications.
Types of participants
Women who conceived as a result of DO-assisted concep-
tion and delivered at 24 weeks of gestation, or later, were
included in the analysis. The control group included
women who had assisted conception using IVF or ICSI
with autologous oocytes.
Types of outcome measures
The primary outcome was any hypertensive disorder in
pregnancy, which included pregnancy-induced hypertension
(PIH) and pre-eclampsia (PET). PIH was defined as a
blood pressure of ≥140/90 mmHg on two or more occa-
sions, at least 6 hours apart, without proteinuria, and later
than 20 weeks of gestation. PET was defined as a blood
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pressure of ≥140/90 mmHg on two or more occasions, at
least 6 hours apart, with proteinuria of ≥0.3 g/day, and
later than 20 weeks of gestation. This definition was consis-
tent with the definition set by the International Society for
the Study of Hypertension in Pregnancy (ISSHP).20 Sub-
group analysis was performed for PIH and PET separately
in singleton DO pregnancies.
Secondary outcome measures included risk of caesarean
section, development of gestational diabetes, small for ges-
tational age, preterm delivery, and intrauterine death
(IUD). Small for gestational age (SGA) was defined as a
birthweight of less than tenth centile. For the purpose of
standardisation, we have used the term SGA. The terms
fetal growth restriction (FGR) or intrauterine growth
restriction (IUGR) have been used by some authors,
although all of these fulfil the criteria for SGA based on
birthweight. Preterm labour was defined as delivery before
37 completed weeks of gestation.
Quality and risk of bias of the included studies
All studies included were cohort and case–control studies.
Quality assessment was performed using the internationally
accepted Newcastle–Ottawa scale.21 The Newcastle–Ottawa
scale evaluates the quality of non-randomised studies, and
focuses on the design, content, and ease of use for incorpo-
rating the quality of assessments in the interpretation of
meta-analytic results. This scale is useful to evaluate poten-
tial biases at selection, comparability, exposure, and out-
come stages. The selected studies were assessed for
methodological quality using the domain-based risk for
bias assessment tool, as recommended by the Cochrane
Collaboration.22 A risk-of-bias table was produced in
REVMAN 5.3,23 using the biases described by the Newcastle–
Ottawa scale.
Statistical analysis
The study characteristics and outcomes were assembled in
tabular form. A formal meta-analysis was performed using
REVMAN 5.3.23 A fixed-effect model (using the Mantel–Haen-
szel method) was used when the I2 statistic showed hetero-
geneity of <50%, whereas a random-effect model was used
when the I2 statistic showed heterogeneity >50%. The effect
estimate was expressed as an odds ratio (OR) with a 95%
confidence interval (95% CI), represented graphically by for-
est plots. Clinical heterogeneity was examined by assessing
the participants, intervention used, study quality, and out-
come measures. Statistical heterogeneity was examined using
the v2 test, with P < 0.05 taken as suggestive of heterogene-
ity. Publication bias was assessed visually using a funnel plot
and by formal testing. Meta-regression was performed using
STATA 13.0 to determine whether age at conception was a lim-
iting factor between studies (Figure S1).
Results
The process of literature search and study selection
for the quantitative meta-analysis is shown in Figure 1.
We reviewed 43 full-text articles after the screening
search and excluded 32 articles, with the most com-
mon reason for exclusion being inappropriate con-
trol group. A total of 11 studies including 81 752
cycles were included in the review and meta-analysis.
The characteristics of the included studies are shown in
Table S1.
Meta-analysis
Primary outcome
The primary outcome measure was hypertensive disorders
of pregnancy, which included PIH and PET. We found
that the risk of developing hypertensive disorders in preg-
nancy was significantly higher in the DO pregnancy group
than in autologous oocyte IVF pregnancy. The fixed-effect
model for ten studies showed women with DO pregnancy
(N = 970) had a significant risk of developing hyperten-
sive disorders in pregnancy [n/N = 341/970 (35%) in the
DO group versus n/N = 1831/10569 (17%) in the autolo-
gous IVF group; OR 3.92, 95% CI 3.21–4.78, I2 = 10%;
Figure 2]. We performed subgroup analysis for four stud-
ies with twin pregnancies,13,24–26 and the fixed-effect
model showed that hypertensive disorders of pregnancy
were significantly higher in DO twin pregnancy than in
the autologous twin pregnancy group [n/N = 89/229
(38%) versus n/N = 948/5630 (16%), OR 3.69, 95% CI
2.62–5.19, I2 = 0%; Figure 2]. The subgroup analysis for
PET in singleton DO pregnancies included four stud-
ies,18,24,27,28 and the fixed-effect model showed that the
risk of PET was significantly higher in singleton DO preg-
nancy [n/N = 66/606 (10%) versus n/N = 333/10193 (3%),
OR 2.90, 95% CI 1.98–4.24, I2 = 0%; Figure 3]. The
fixed-effect model meta-analysis of five studies showed
that the risk of PIH in singleton DO pregnancy is signifi-
cantly higher when compared with singleton IVF preg-
nancy [n/N = 99/577 (17%) versus n/N = 522/10211 (5%),
OR 3.08, 95% CI 2.26–4.19, I2 = 0%; Figure 3].11,24,26,28,29
Additionally, the subgroup analysis fixed-effect model of
two studies of women older than 40 years of age showed
that the risk for hypertensive disorders was still signifi-
cantly higher with DO pregnancy compared with IVF
pregnancy [n/N = 30/129 (23%) versus n/N = 18/168
(10%), OR 2.33, 95% CI 1.21–4.49, I2 = 2%; Fig-
ure 3].29,30 Meta-regression for the covariate of age
showed that between-study variance was minimal
(s2 = 0.008), and that the occurrence of hypertensive
disorders in the studies was independent of age, with P
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values above the level of significance (P = 0.473, 95% CI
0.90–1.05).
As both cohort and case–control studies were included
in the meta-analysis, to assess the robustness of the results
we performed sensitivity analysis after the exclusion of the
case–control studies. Six cohort studies were included in
the meta-analysis for the primary outcome measure of
hypertensive disorders of pregnancy (Figure S2).18,24,25,30–32
The analysis showed that the risk of hypertensive disorders
was significantly raised in all DO pregnancies (OR 3.63,
95% CI 2.92–4.51, I2 = 0%). This effect was significant for
singleton (OR 3.05, 95% CI 2.19–4.24, I2 = 0%) as well as
twin pregnancies (OR 3.64, 95% CI 2.57–5.16, I2 = 0%).
Risk for PET in the singleton DO subgroup also showed a
significant difference (OR 2.62, 95% CI 1.75–3.93
I2 = 0%).
Secondary outcome
Secondary outcome measures included SGA, preterm deliv-
ery, risk of caesarean section, gestational diabetes, and
intrauterine death (IUD). Meta-analysis of six studies
showed that the risk of SGA was significantly raised in DO
pregnancy [n/N = 58/630 (9%) versus n/N = 594/11262
(5%), OR 1.81, 95% CI 1.26–2.60, I2 = 21%].11,18,24,27,31,32
As a result of uncertainty about the definition used to
define SGA in the original papers, however, subgroup
analysis was performed for three studies with consistent
definition, and the results gave OR 1.44 [n/N = 34/422
versus n/N = 585/11 044, OR 1.44, 95% CI 0.93–2.23,
I2 = 0%].11,18,24 Because of the discrepancy in the defini-
tions used for identifying FGR, IUGR, and SGA, these
results should be interpreted with caution. Birthweight
reported in six studies showed no significant difference
(Figure 4).11,24,29,32–34 The risk of preterm delivery was
analysed in nine studies, and the fixed-effect model showed
that the risk of preterm birth was significantly higher
in DO pregnancy compared with autologous IVF preg-
nancy [n/N = 194/1011 (19%) versus n/N = 1078/11
651 (9%), OR 1.34, 95% CI 1.08–1.66, I2 = 38%; Fig-
ure 4].18,24,26,29–32,35–37 The risk of caesarean section was
significantly increased in DO pregnancy [n/N = 435/690
(88%) versus n/N = 3452/10 283 (33%), OR 2.71, 95% CI
2.23–3.30, I2 = 43%; Figure 4].11,18,24,26,37,38 Neither the
increased risk of IUD, analysed in two studies [n/N = 4/
303 (1.3%) versus n/N = 3/346 (0.8%), OR 1.39, 95% CI
0.32–6.15],35,37 nor the increased risk of developing gesta-
tional diabetes for the mother, analysed in five studies
[n/N = 58/524 (11%) versus n/N = 52/519 (10%),
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OR 1.25, 95% CI 0.68–2.30],11,18,26,32,37 was statistically sig-
nificant.
Discussion
Main findings
The results of the meta-analysis described above show that
the risk of developing hypertensive disorders in pregnancy is
significantly higher with DO pregnancy when compared
with autologous IVF pregnancy. The studies included single-
tons as well as twins; therefore, we studied the effect in sin-
gleton and multiple pregnancies separately. The increased
risk was found in all subgroups, including women of
advanced maternal age. When the risk of hypertensive disor-
ders in pregnancy was subdivided into two groups, PIH and
PET, the risk of both complications was higher in DO preg-
nancies. These findings are consistent with some previous
observational studies.8–12,29,30 Multiple pregnancy is a
known risk factor for developing hypertensive disorders;
however, our analysis suggested that DO pregnancy is inde-
pendent of multiple pregnancies for the development of
hypertensive disorders. The risks of SGA and preterm deliv-
ery are significantly higher in DO pregnancy. Our meta-ana-
lysis showed that the chances of caesarean delivery for
singletons are significantly higher with DO pregnancy. Simi-
lar findings are reported by other authors.3,9,10,12
Strengths and limitations
This is the first meta-analysis and meta-regression to quan-
tify the risk of pregnancy complications in women with
DO pregnancy. A previous systematic review by van der
Hoorn focused on the immunological pathogenesis of com-
plications, but did not include meta-analysis.39 We have
quantified the risk taking into account potential confound-
ing factors; therefore, this meta-analysis provides evidence-
based information for the clinical care of women with DO
pregnancy. The outcomes of DO IVF pregnancies have
been compared with autologous oocyte IVF pregnancies in
various subgroups, adjusting for maternal age, multiple ges-
tation, and the assisted reproductive technique. The meta-
analysis showed small values for I2 and narrow confidence
intervals. This suggests that the accuracy of the meta-analy-
sis is of good quality, and that the estimated value is rela-
tively stable. Low statistical heterogeneity is a major
strength of our meta-analysis. A previous systematic review
and meta-analysis performed by Pecks showed that DO is a
risk factor for the development of PIH; however, the con-
trol group included all types of conventional reproductive
therapy, including spontaneous conception.40 Shanis
showed that IVF itself increases the risk of PET.41 The
systematic review by van-der Hoorn concluded that the
higher risk of maternal morbidity in DO pregnancy is
Hypertensive disorders in DO pregnancy  
Hypertensive disorders in twin pregnancy  
Figure 2. Primary outcome- Hypertensive disorders in DO pregnancy.
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linked to the high degree of antigenic dissimilarity.17 In
original publications the definitions of FGR, IUGR, or SGA
are not standardised. These definitions have evolved over a
period of time. We have performed sensitivity analysis to
address this limitation. We have used the term SGA, which
covers all babies with birthweights of less than the tenth
centile. Although we made every attempt to neutralise the
effects of confounding factors such as age by performing
subgroup analysis and meta-regression, it is difficult to
prove that the risk is totally independent of these variables
from any meta-analysis and systematic review. It requires a
multivariate analysis on an original data set. Ideally, indi-
vidual participant data (IPD) meta-analysis would be the
best design to assess the effect of various other confound-
ing factors. The secondary outcomes of preterm delivery,
SGA, and caesarean section may be the result of hyperten-
sive disorders in pregnancy. It is not possible to identify
the magnitude of these complications independent of
hypertensive disorders. Analysis of any complication as an
outcome depends upon prevention and management strate-
gies. The information was not available on preventative
measures such as the use of low-dose aspirin or ultrasound
assessment for fetal growth.
Interpretation
Donor oocyte (DO) IVF provides the opportunity of preg-
nancy for many women, but at the same time increases the
risks associated with pregnancy. Multiple gestations,
advanced age, and underlying polycystic ovary syndrome
are constant confounding factors for all studies examining
the association between assisted reproductive techniques
(ARTs) and hypertensive disorders in pregnancy.42 Tho-
mopoulos showed that ART pregnancies, especially IVF
techniques, are accompanied by increased risks for gesta-
tional hypertension and PET, as compared with non-ART
pregnancies, even after adjustment for confounding
factors.42
The success of pregnancy depends upon an appropriate
implantation and placental function. Any insult during the
process of implantation and placentation leads to obstetric
complications, including spontaneous miscarriage, SGA,
preterm birth, and PET.43 The risk of hypertensive disor-
Pregnancy-induced hypertension and singleton DO pregnancy 
Pre-eclampsia and singleton DO pregnancy 
Hypertensive disorders in pregnancy with maternal age > 40 years 
Figure 3. Primary outcome – subgroup analysis.
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ders of pregnancy in DO pregnancies can be explained on
the basis of an immunological mechanism.44,45 In DO
pregnancies the fetus is allogeneic to the gestational carrier.
Therefore, the mother has to cope with a higher degree of
antigenic dissimilarity compared with spontaneously con-
ceived pregnancies.46,47 Increased immunological activity
and fibrinoid deposition was noted at the maternal–fetal
interface in DO pregnancies.
Small for Gestational Age and DO pregnancy 
Birth weight and DO pregnancy 
Caesarean section and DO pregnancy 
Preterm delivery and DO pregnancy 
Figure 4. Secondary outcomes.
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This represents a host versus graft rejection-like phe-
nomenon.48 Parental human leukocyte antigen sharing
plays a role in the aetiology of PET.49 Considering the
immunologic mechanisms at work in DO, it might be
worthwhile performing human leukocyte antigen (HLA)
typing of the donor and the recipient in order to select
haplo-identical combinations that would be more compara-
ble with spontaneously conceived pregnancies than fully
HLA mismatched combinations.39 This makes DO preg-
nancies at higher risk of perinatal complications. Further
research is required to explain the pathogenesis of DO
pregnancies and placental complications.
Although the DO technique proved to be an excellent
treatment option for many women to achieve pregnancy, it
exposes them to higher risks of many maternal complica-
tions, including maternal death.50–52 Women undergoing
DO conception should be counselled before conception
about the increased risks during DO pregnancy, and that
the risk is independent of age or multiple pregnancies.51,52
Obstetricians should be aware of the increased pregnancy
risks in this particular group of patients, and appropriate
surveillance strategies should be in place during antenatal,
intrapartum, and postnatal care.51 The use of serial growth
scans to diagnose SGA has resource implications. Therefore,
an individualised surveillance and management strategy
should be considered. The use of low-dose aspirin in DO
pregnancy in the absence of any other risk factors requires
further evaluation. Oocyte cryopreservation for future fertil-
ity is suggested as an alternative for avoiding DO in selected
cases;34 however, data on success rates, the effect on contin-
uing pregnancy, and adverse effects are limited.53
Conclusion
In the light of current evidence, DO pregnancy should be
considered as an independent risk factor for pregnancy
complications, including hypertensive disorders of preg-
nancy, SGA, preterm delivery, and caesarean section.
Women should be counselled carefully about these risks
before undergoing DO-assisted conception. These women
should be managed in high-risk obstetric clinics with indi-
vidualised monitoring and management strategies to reduce
complications. The role of low-dose aspirin in DO preg-
nancy in the absence of any other risk factors requires fur-
ther research. The use of serial growth scans in DO
pregnancies needs further evaluation. Limited evidence
attributed these complications to immunological origin;
further research is required to explain the pathogenesis
involved in donor oocyte pregnancies.
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ABSTRACT
Successful fertilisation is one of the key steps determining success of assisted conception.
Various factors including sperm or oocyte pathology and environmental factors have a signifi-
cant impact on fertilisation rates. This systematic review is aimed to evaluate the existing evi-
dence about factors affecting fertilisation and strategies to improve fertilisation rates. A literature
search was performed using Ovid MEDLINE VR (Jan 1950–April 2016), EMBASE (Jan 1950–April
2016), Ovid OLDMEDLINE VR , Pre-MEDLINE (Jan 1950–April 2016) and the Cochrane Library.
Relevant key words were used to combine sets of results and a total 243 papers were screened.
Only qualitative analysis was performed, as there was major heterogeneity in study design and
methodology for quantitative synthesis. Factors affecting fertilisation were divided into sperm-
and oocyte-related factors. The methods to improve fertilisation rates were grouped together
based on the approach used to improve fertilisation rates. Optimising laboratory condition and
procedural effects in techniques is associated with improved fertilisation rates. Various techni-
ques are described to improve fertilisation rates including assisted oocyte activation, physio-
logical intracytoplasmic sperm injection (PICSI) and intracytoplasmic morphologically selected
sperm injection (IMSI). This review highlights the promising strategies under research to enhance
fertilisation rates. Adequately powered multicentre randomised trials are required to evaluate
these techniques before considering clinical application.
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Introduction
Fertilisation is defined as the process resulting from
the fusion of the two parental gametes: the oocyte
and the spermatozoon. It induces a cascade of critical
events that result in the development of the zygote.
For assisted conception, fertilisation is aided by proce-
dures such as IVF and ICSI. Total fertilisation rate is cal-
culated as the total number of zygotes divided by the
total number of mature oocytes inseminated (Buffone,
Schindler, & Schultz, 2009). Over the last 40 years,
since the inception of IVF, fertilisation rates of 60%
or over are expected (Braude & Rowell, 2003).
Undoubtedly, the live birth rates are related to the fer-
tilisation rates and subsequent development of the
zygote to the embryo stage. Structural and functional
defects in gametes and laboratory factors can result in
reduced fertilisation rates. Fertilisation rates are consid-
ered surrogate indicators of the quality of services and
laboratory environment (Heitmann et al., 2015).
If all mature oocytes fail to fertilise, it is called total
failed fertilisation (TFF). Total failure of fertilisation may
occur due to undetected sperm or oocyte abnormal-
ities (Braude & Rowell, 2003). Sperm-related activation
deficiency is seen in globozoospermia and extreme oli-
goasthenoteratozoospermia (Heindryckx, Van der Elst,
De Sutter, & Dhont, 2005). Intracytoplasmic sperm
injection (ICSI) has overcome many gamete defects,
but total fertilisation failure still occurs in 2–3% of ICSI
cycles (Kang et al., 2015; Palermo, Neri, Takeuchi, &
Rosenwaks, 2009). Lack of viability, inability of the
sperm nucleus to decondense, and chromatin abnor-
malities can be reasons behind failed fertilisation after
ICSI (Nasr-Esfahani, Deemeh, & Tavalaee, 2010). Various
sperm function tests are proposed and endorsed by
different researchers in addition to the routine semen
analysis (Oehninger, Franken, & Ombelet, 2014; Talwar
& Hayatnagarkar, 2015). However, sperm function tests
are not part of routine fertility investigations as they
are complex, expensive, not rigorously tested, do not
always provide clinically useful information and typic-
ally do not affect treatment outcome (Talwar &
Hayatnagarkar, 2015). The most reliable predictor of
failed fertilisation is failed fertilisation in the previous
CONTACT Yadava Bapurao Jeve drybjeve@gmail.com Leicester Fertility Centre, University Hospitals of Leicester, Leicester LE1 5WW, UK
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IVF cycle (Roest, Van Heusden, Zeilmaker, & Verhoeff,
1998).
Different strategies have been investigated to over-
come gamete dysfunction to improve fertilisation
rates. This review is aimed to study the factors affect-
ing fertilisation and strategies to improve fertilisation
rates.
Materials and methods
A literature search was performed using Ovid MEDLINE
VR (Jan 1950–April 2016), EMBASE (Jan 1950–April
2016), Ovid OLDMEDLINE VR , Pre-MEDLINE, in-Process &
Other Non-Indexed Citations database consists of In-
Process and PubMed-not-MEDLINE records from NLM,
Google scholar, Web of Sciences (Jan 1950–April 2016)
and the Cochrane Library. Searches were conducted
using various combinations of the keywords, ‘IVF’,
‘ICSI’, ‘Fertilisation rates’, ‘sperm’ ‘Oocyte’, ‘laboratory’,
‘assisted oocyte activation’, ‘IMSI’ and ‘PICSI’. These
subsets were combined using ‘AND’ or OR as appropri-
ate to produce sets of results relevant to the research
question. The duplicates were removed and searches
were limited to human participants and restricted to
English language. The reference list of all published
articles including review articles was examined for
missed citations. No author was contacted. Titles were
screened first and then relevant abstracts were
obtained. Full text of the articles addressing research
question were reviewed. Two reviewers assessed the
quality of the evidence (Y. J. and T. G.) and extracted
data. Inclusion criteria involved all studies analyzing
factors affecting fertilisation and strategies to improve
the fertilisation rates. The population was couples
undergoing IVF or ICSI cycles. Interventions were vari-
ous strategies used for improving fertilisation rates.
The comparison group was those cycles with no inter-
vention. Primary outcome measure was fertilisation
rates. No secondary outcome measure analysis was
planned. All types of study designs including case con-
trol, cohort and randomized studies were included.
Case reports and studies with no comparison group
were excluded from qualitative analysis. Quantitative
synthesis of suitable studies was planned. This
review was registered with PROSPERO database
(CRD42016043931).
Results
The search generated 243 articles, which were
screened. Total of 51 studies used various methods to
improve fertilisation rates (Table 1) and were included
in the qualitative analysis. The studies were grouped
based on the different strategies used to improve
fertilisation rate. Studies included in the qualitative
analysis were not found to be suitable for quantitative
synthesis due to extensive heterogeneity in study
design and methodology. The factors affecting fertilisa-
tion were classified into two groups: (i) sperm- and
(ii) oocyte-related factors. Each has been discussed in
detail below.
Sperm-related factors affecting fertilisation rates
Sperm origin
Conflicting results for fertilisation are available in the
literature after use of ejaculated or surgically retrieved
sperm for male factor infertility (Esteves & Agarwal,
2013; Oron et al., 2014). It is important to compare
type of sperm abnormality while comparing the source
of sperm. Lower fertilisation rates are reported with
surgically retrieved sperm from non-obstructive azoo-
spermia men compared with those from obstructive
azoospermia (Esteves & Agarwal, 2013; Oron et al.,
2014). Few studies show similar fertilisation rate
between surgically retrieved sperm and ejaculated
spermatozoa (Amirjannati et al., 2012; Jamal et al.,
2012). The combination of enzymatic digestion, density
gradient centrifugation and stimulation of motility
(where indicated) is suggested to improve fertilisation
rates (58.4% verses 45%) in testicular sperm extraction
(Wober et al., 2015). However, evidence is not
adequate to recommend these methods. A recent
study suggested that neither the source of spermato-
zoa nor the aetiology of severe male infertility has any
relevant impact on the results of ICSI cycles as long as
fresh motile, morphologically normal spermatozoa are
used (Gnoth et al., 2015).
Sperm structural defects
The role of sperm morphology for the prediction of
fertilisation rate is debated in the literature (Demir
et al., 2012; Figueiredo, Tavares, Ferras, Couceiro, &
Chaves, 1996). A global impairment of spermatogen-
esis is supposed to be the origin of the morphological
alterations (Perdrix et al., 2011). There is a strong cor-
relation between high relative vacuole area and poor
sperm morphology (Perdrix et al., 2012). Sperm head
vacuoles were related to impaired fertilisation rate
after IVF (Fekonja et al., 2014). In 2001, Bartoov,
Berkovitz, and Eltes (2001) introduced the motile
sperm organelle morphology examination (MSOME), in
which the fine nuclear morphology of motile sperma-
tozoa was examined in real time with an inverted light
microscope equipped with high-power differential
2 Y. B. JEVE ET AL.
Ta
bl
e
1.
St
ra
te
gi
es
to
im
pr
ov
e
fe
rt
ili
sa
tio
n
ra
te
s.
M
et
ho
d
St
ud
y
D
es
ig
n
an
d
po
pu
la
tio
n
In
te
rv
en
tio
n
Co
m
pa
ris
on
Re
su
lts
O
pt
im
iz
in
g
la
bo
ra
to
ry
co
nd
iti
on
an
d
pr
oc
ed
ur
al
ef
fe
ct
s
in
te
ch
ni
qu
es
O
pe
ra
to
r
de
pe
nd
en
t
Sh
en
et
al
.(
20
03
)
Re
tr
os
pe
ct
iv
e
co
ho
rt
w
ith
fir
st
tim
e
IC
SI
(n
¼
44
1)
W
el
l-t
ra
in
ed
op
er
at
or
s
w
ith
>
5
ye
ar
s’
ex
pe
rie
nc
e
in
IC
SI
O
pe
ra
to
rs
co
m
pa
re
d
am
on
g
th
em
se
lv
es
Si
gn
ifi
ca
nt
di
ffe
re
nc
es
in
th
e
2P
N
ra
te
am
on
g
th
e
fo
ur
IC
SI
op
er
at
or
s
IC
SI
te
ch
ni
qu
e
Eb
ne
r
et
al
.(
20
04
)
Co
ho
rt
st
ud
y
w
ith
pr
ev
io
us
IC
SI
fa
ilu
re
s
(n
¼
12
7)
M
od
ifi
ed
IC
SI
te
ch
ni
qu
e
St
an
da
rd
IC
SI
M
od
ifi
ed
IC
SI
le
d
to
si
gn
ifi
-
ca
nt
fe
rt
ili
sa
tio
n
ra
te
s
Im
pr
ov
em
en
t
in
la
bo
ra
to
ry
en
vi
ro
nm
en
t
H
ei
tm
an
n
et
al
.(
20
15
)
Re
tr
os
pe
ct
iv
e
co
ho
rt
,f
irs
t
au
to
lo
go
us
IV
F
or
IC
SI
(n
¼
82
0)
Im
pr
ov
em
en
t
in
la
bo
ra
to
ry
en
vi
ro
nm
en
t
an
d
ai
r
qu
al
ity
Pr
ev
io
us
fa
ci
lit
y
Si
gn
ifi
ca
nt
ly
im
pr
ov
ed
ou
tc
om
e
Ch
an
ge
in
cu
ltu
re
m
ed
ia
H
ua
ng
et
al
.(
20
16
)
RC
T
(n
¼
75
0)
Sy
nt
he
tic
se
ru
m
su
bs
tit
ut
e
(S
SS
)
Va
rio
us
co
nc
en
tr
at
io
n
of
SS
S
Su
pp
le
m
en
ta
lp
ro
te
in
co
n-
ce
nt
ra
tio
n
in
th
e
ET
m
ed
iu
m
do
es
no
t
af
fe
ct
th
e
tr
ea
tm
en
t
ou
tc
om
es
Ce
sc
hi
n
et
al
.(
20
16
)
RC
T
(n
¼
60
)
G
1-
PL
U
ST
M
/G
2-
PL
U
ST
M
se
qu
en
tia
l
G
V
BL
AS
TT
M
so
le
N
o
di
ffe
re
nc
e
As
si
st
ed
oo
cy
te
ac
tiv
at
io
n
Ch
em
ic
al
m
et
ho
ds
N
ak
ag
aw
a
et
al
.(
20
01
)
Co
ho
rt
st
ud
y,
oo
cy
te
s
th
at
sh
ow
ed
no
ev
id
en
ce
of
no
rm
al
fe
rt
ili
sa
tio
n
18
h
af
te
r
IC
SI
(n
¼
17
0)
Ca
lc
iu
m
io
no
ph
or
e
A2
31
87
(A
23
18
7)
an
d
pu
ro
m
yc
in
Pr
ev
io
us
ly
fa
ile
d
fe
rt
ili
sa
tio
n
Th
e
se
qu
en
tia
lt
re
at
m
en
t
of
ca
lc
iu
m
io
no
ph
or
e
A2
31
87
an
d
pu
ro
m
yc
in
ac
tiv
at
es
un
fe
rt
ili
se
d
oo
cy
te
s
af
te
r
IC
SI
M
oa
z
et
al
.(
20
06
)
Co
ho
rt
st
ud
y,
co
ns
ec
ut
iv
e
cy
cl
es
w
ith
di
ffe
re
nt
ab
no
rm
al
sp
er
m
m
or
ph
-
ol
og
y,
pr
ev
io
us
fa
ile
d
or
lo
w
fe
rt
ili
sa
tio
n
ra
te
(n
¼
56
)
10
lm
ol
/l
io
no
ph
or
e
Co
nt
ro
lg
ro
up
w
ith
ou
t
AO
A
Si
gn
ifi
ca
nt
ly
im
pr
ov
ed
fe
rt
il-
is
at
io
n
ra
te
s
N
as
r-
Es
fa
ha
ni
et
al
.(
20
08
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
,
IC
SI
fo
r
se
ve
re
te
ra
to
zo
o-
sp
er
m
ia
(n
¼
87
)
10
lM
Io
no
m
yc
in
fo
r
10
m
in
N
o
AO
A
Si
gn
ifi
ca
nt
in
cr
ea
se
in
fe
rt
il-
is
at
io
n
ra
te
Bo
rg
es
et
al
.(
20
09
)
RC
T,
IC
SI
fo
r
m
al
e
fa
ct
or
(n
¼
31
4)
Ca
lc
iu
m
io
no
ph
or
e
A2
31
87
Co
nt
ro
lg
ro
up
w
ith
ou
t
AO
A
N
o
si
gn
ifi
ca
nt
di
ffe
re
nc
e
H
ei
nd
ry
ck
x
et
al
.(
20
05
)
RC
T,
G
lo
bo
zo
os
pe
rm
ia
an
d
ol
ig
oa
st
he
no
te
ra
to
zo
o-
sp
er
m
ia
(n
¼
30
).
Ca
lc
iu
m
io
no
ph
or
e
A2
31
87
an
d
in
je
ct
io
n
of
Ca
Cl
2
Co
nt
ro
lg
ro
up
w
ith
ou
t
AO
A
Fe
rt
ili
sa
tio
n
ra
te
im
pr
ov
ed
Eb
ne
r
et
al
.(
20
12
)
Co
ho
rt
st
ud
y,
IC
SI
fo
r
cr
yp
-
to
zo
os
pe
rm
ia
an
d
az
oo
-
sp
er
m
ic
(n
¼
66
)
Re
ad
y-
to
-u
se
Ca
2þ
io
no
-
ph
or
e
so
lu
tio
n
Pr
ec
ed
in
g
cy
cl
e
w
ith
ou
t
ac
tiv
at
io
n
Bo
th
az
oo
sp
er
m
ic
(6
4.
4%
)
an
d
cr
yp
to
zo
os
pe
rm
ic
(4
8.
4%
)
m
en
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
ly
im
pr
ov
ed
fe
rt
ili
sa
tio
n
M
on
ta
g
an
d
va
n
de
r
Ve
n
(2
01
2)
Co
ho
rt
st
ud
y,
po
or
fe
rt
ili
sa
-
tio
n
(<
50
%
)
in
a
pr
ev
i-
ou
s
IC
SI
cy
cl
e
(n
¼
27
)
Re
ad
y-
to
-u
se
Ca
2þ
io
no
ph
or
e
so
lu
tio
n
Pr
ec
ed
in
g
cy
cl
e
w
ith
ou
t
ac
tiv
at
io
n
H
ig
he
r
fe
rt
ili
sa
tio
n
ra
te
s
fo
r
pr
ev
io
us
po
or
fe
rt
ili
sa
tio
n
ra
te
s
Va
nd
en
M
ee
rs
ch
au
t
et
al
.
(2
01
2)
RC
T,
hi
st
or
y
of
TF
F
or
lo
w
fe
rt
ili
sa
tio
n
Ca
lc
iu
m
io
no
ph
or
e
(c
al
ci
m
y-
ci
n)
co
m
bi
ne
d
w
ith
Ca
Cl
in
je
ct
io
n
N
o
AO
A
Im
pr
ov
e
fe
rt
ili
sa
tio
n
ra
te
s
Ef
te
kh
ar
et
al
.(
20
13
)
RC
T,
IC
SI
fo
r
te
ra
to
os
pe
rm
ia
(n
¼
38
)
O
oc
yt
e
ac
tiv
at
io
n
w
ith
ca
l-
ci
um
io
no
ph
or
e
N
o
AO
A
N
o
si
gn
ifi
ca
nt
di
ffe
re
nc
e
Ca
gl
ar
Ay
ta
c
et
al
.(
20
15
)
RC
T,
no
rm
al
sp
er
m
,d
im
in
-
is
he
d
ov
ar
ia
n
re
se
rv
e
(n
¼
29
6)
Ca
lc
iu
m
io
no
ph
or
e
so
lu
tio
n
N
o
AO
A
60
.7
%
an
d
55
.4
%
no
di
ffe
re
nc
e
(c
on
tin
ue
d)
HUMAN FERTILITY 3
Ta
bl
e
1.
Co
nt
in
ue
d
M
et
ho
d
St
ud
y
D
es
ig
n
an
d
po
pu
la
tio
n
In
te
rv
en
tio
n
Co
m
pa
ris
on
Re
su
lts
Eb
ne
r
et
al
.(
20
15
)
Co
ho
rt
st
ud
y,
pr
ev
io
us
<
50
%
fe
rt
ili
sa
tio
n
ra
te
w
ith
IC
SI
(n
¼
10
1)
Re
ad
y-
to
-u
se
Ca
2þ
io
no
ph
or
e
so
lu
tio
n
(A
23
18
7)
Pr
ec
ed
in
g
cy
cl
e
w
ith
ou
t
ac
tiv
at
io
n
Th
e
fe
rt
ili
sa
tio
n
ra
te
of
48
%
in
th
e
st
ud
y
cy
cl
es
w
as
si
gn
ifi
ca
nt
ly
hi
gh
er
co
m
-
pa
re
d
w
ith
th
e
25
%
in
th
e
co
nt
ro
lc
yc
le
s
Li
u
et
al
.(
20
14
)
RC
T,
fa
ile
d
to
fe
rt
ili
ze
,
m
at
ur
e
oo
cy
te
s
(n
¼
38
6)
AO
A
w
ith
7%
an
hy
dr
ou
s
al
co
ho
l
N
o
AO
A
N
o
ef
fe
ct
El
ec
tr
ic
al
m
et
ho
ds
Zh
an
g
et
al
.(
19
99
)
RC
T,
fa
ile
d-
to
-f
er
til
iz
e
oo
cy
te
s
(n
¼
10
4)
El
ec
tr
ic
al
ac
tiv
at
io
n
IC
SI
w
ith
no
ac
tiv
at
io
n
Im
pr
ov
e
fe
rt
ili
sa
tio
n
ra
te
s
M
an
ip
al
vi
ra
tn
et
al
.(
20
06
)
RC
T,
fa
ile
d-
to
-f
er
til
iz
e
oo
cy
te
s
(n
¼
10
0)
El
ec
tr
ic
al
ac
tiv
at
io
n
IC
SI
w
ith
no
ac
tiv
at
io
n
Im
pr
ov
e
fe
rt
ili
sa
tio
n
ra
te
s
M
an
so
ur
et
al
.(
20
09
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
,
te
ra
to
sp
er
m
ia
or
to
ta
lly
im
m
ot
ile
sp
er
m
at
oz
oa
(n
¼
24
1)
El
ec
tr
o
ac
tiv
at
io
n
an
d
IC
SI
IC
SI
w
ith
no
ac
tiv
at
io
n
Th
e
fe
rt
ili
sa
tio
n
ra
te
w
as
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
ly
hi
gh
er
in
th
e
el
ec
tr
o
ac
ti-
va
te
d
gr
ou
p
Ba
lta
ci
et
al
.(
20
10
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
,
on
e
pr
ev
io
us
TF
F
(n
¼
71
)
El
ec
tr
ic
al
ac
tiv
at
io
n
IC
SI
w
ith
no
ac
tiv
at
io
n
Im
pr
ov
ed
fe
rt
ili
sa
tio
n
M
ec
ha
ni
ca
lm
et
ho
ds
Te
sa
rik
et
al
.(
20
02
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
(n
¼
6)
M
ec
ha
ni
ca
lm
an
ip
ul
at
io
n
th
at
fa
ci
lit
at
ed
en
tr
y
of
ca
lc
iu
m
in
to
th
e
oo
cy
te
St
an
da
rd
IC
SI
Im
pr
ov
ed
fe
rt
ili
sa
tio
n
TE
SE
an
d
se
le
ct
io
n
of
m
ot
ile
sp
er
m
in
co
m
pl
et
e
as
th
en
oz
oo
sp
er
m
ia
,n
ec
ro
zo
os
pe
rm
ia
or
cr
yp
to
zo
os
pe
rm
ia
Se
le
ct
io
n
of
sp
er
m
us
in
g
hy
po
-o
sm
ot
ic
sw
el
lin
g
te
st
El
-N
ou
r,
Al
M
ay
m
an
,
Ja
ro
ud
i,
an
d
Co
sk
un
(2
00
1)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
,
IC
SI
cy
cl
es
w
ith
no
m
ot
ile
sp
er
m
(n
¼
30
)
Sp
er
m
se
le
ct
io
n
us
in
g
hy
po
-
os
m
ot
ic
sw
el
lin
g
te
st
(H
O
ST
)
N
o
H
O
ST
N
o
st
at
is
tic
al
si
gn
ifi
ca
nc
e
Sa
lla
m
,F
ar
ra
g,
Ag
am
ey
a,
El
-
G
ar
em
an
d
Ez
ze
ld
in
,
(2
00
5)
Co
ho
rt
st
ud
y,
im
m
ot
ile
te
s-
tic
ul
ar
sp
er
m
at
oz
oa
tr
ea
te
d
w
ith
IC
SI
(n
¼
79
)
Sp
er
m
at
oz
oa
us
ed
fo
r
in
je
c-
tio
n
w
er
e
se
le
ct
ed
us
in
g
th
e
m
od
ifi
ed
H
O
S
te
st
Sp
er
m
at
oz
oa
w
er
e
se
le
ct
ed
on
th
e
ba
si
s
of
th
ei
r
m
or
ph
ol
og
y
Fe
rt
ili
sa
tio
n
ra
te
w
as
si
gn
ifi
-
ca
nt
ly
hi
gh
er
in
th
e
H
O
S
te
st
gr
ou
p
(4
3.
6%
)
co
m
-
pa
re
d
w
ith
th
e
no
-H
O
S
te
st
gr
ou
p
(2
8.
2%
)
Se
le
ct
io
n
of
sp
er
m
us
in
g
la
se
r
Ak
ta
n
et
al
.(
20
04
)
Co
ho
rt
st
ud
y,
hu
m
an
-e
ja
cu
-
la
te
d
sp
er
m
at
oz
oa
/T
ES
E
fr
om
pa
tie
nt
s
w
ith
co
m
-
pl
et
e
as
th
en
oz
oo
sp
er
m
ia
(n
¼
10
)
A
si
ng
le
la
se
r
sh
ot
ap
pl
ie
d
at
th
e
en
d
of
th
e
ta
il
Se
le
ct
io
n
us
in
g
hy
po
-
os
m
ot
ic
sw
el
lin
g
te
st
La
se
r
se
le
ct
io
n
ga
ve
si
gn
ifi
-
ca
nt
ly
hi
gh
er
fe
rt
ili
sa
tio
n
ra
te
s
(4
5.
4%
ve
rs
us
20
.4
%
;p
<
0.
00
01
)
Se
le
ct
io
n
of
sp
er
m
us
in
g
m
ec
ha
ni
ca
lT
ou
ch
de
O
liv
ei
ra
et
al
.(
20
04
)
Co
ho
rt
st
ud
y,
IC
SI
cy
cl
es
us
in
g
fr
oz
en
-t
ha
w
ed
te
s-
tic
ul
ar
sp
er
m
(n
¼
17
)
M
ot
ile
sp
er
m
se
le
ct
ed
us
in
g
m
ec
ha
ni
ca
lt
ou
ch
M
or
ph
ol
og
ic
al
ly
no
rm
al
ap
pe
ar
an
ce
Si
gn
ifi
ca
nt
in
cr
ea
se
in
fe
rt
il-
is
at
io
n
ra
te
U
se
of
pe
nt
ox
ify
lli
ne
Ko
va
ci
c
et
al
.(
20
06
)
Co
ho
rt
st
ud
y,
su
rg
ic
al
ly
re
tr
ie
ve
d
sp
er
m
s
(n
¼
77
)
Sh
or
t
ex
po
su
re
of
te
st
ic
ul
ar
sa
m
pl
es
w
ith
on
ly
im
m
o-
til
e
sp
er
m
to
pe
nt
ox
ify
l-
lin
e
(P
F)
-s
pe
rm
m
ot
ili
ty
st
im
ul
at
or
U
nt
re
at
ed
im
m
ot
ile
sp
er
m
PF
gr
ou
p
ha
d
a
hi
gh
er
fe
r-
til
is
at
io
n
ra
te
(6
6%
ve
rs
us
50
.9
%
;p
<
0.
00
5)
U
se
of
IC
SI
an
d
re
sc
ue
IC
SI
Be
ck
-F
ru
ch
te
r
et
al
.(
20
14
)
Sy
st
em
at
ic
re
vi
ew
,m
et
a-
an
al
ys
is
(n
¼
18
63
)
Ea
rly
re
sc
ue
IC
SI
,i
n
fa
ile
d
fe
rt
ili
sa
tio
n
Pr
ev
io
us
ly
fa
ile
d
or
po
or
fe
rt
ili
sa
tio
n
Im
pr
ov
ed
fe
rt
ili
sa
tio
n
ra
te
s
H
ua
ng
et
al
.(
20
15
)
Re
tr
os
pe
ct
iv
e
co
ho
rt
st
ud
y,
ea
rly
re
sc
ue
IC
SI
(n
¼
13
,2
32
)
Ea
rly
re
sc
ue
IC
SI
,i
n
fa
ile
d
fe
rt
ili
sa
tio
n
Pl
an
ne
d
IC
SI
Si
m
ila
r
fe
rt
ili
sa
tio
n
an
d
pr
eg
na
nc
y
ra
te
s
as
pl
an
ne
d
IC
SI
.N
o
in
cr
ea
se
d
m
al
fo
rm
at
io
n
Ca
o
et
al
.(
20
16
)
Co
ho
rt
st
ud
y,
cy
cl
es
w
ith
a
fe
rt
ili
sa
tio
n
ra
te
of
<
50
%
to
co
nv
en
tio
na
lI
VF
(n
¼
31
3)
Re
sc
ue
IC
SI
Co
nv
en
tio
na
li
n
vi
tr
o
fe
rt
il-
is
at
io
n
cy
cl
e
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
im
pr
ov
ed
.
Im
pr
ov
ed
ra
te
of
re
sc
ue
IC
SI
fo
r
fe
rt
ili
sa
tio
n
ra
te
s
of
<
25
%
(c
on
tin
ue
d)
4 Y. B. JEVE ET AL.
Ta
bl
e
1.
Co
nt
in
ue
d
M
et
ho
d
St
ud
y
D
es
ig
n
an
d
po
pu
la
tio
n
In
te
rv
en
tio
n
Co
m
pa
ris
on
Re
su
lts
U
se
of
PI
CS
I
Pa
rm
eg
ia
ni
et
al
.(
20
12
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
(n
¼
10
0)
H
A
cu
ltu
re
di
sh
(P
IC
SI
Sp
er
m
Se
le
ct
io
n
D
ev
ic
e)
Vi
sc
ou
s
m
ed
iu
m
co
nt
ai
ni
ng
H
A
(S
pe
rm
Sl
ow
)
N
o
di
ffe
re
nc
e
in
fe
rt
ili
sa
tio
n
ra
te
s
W
or
ril
ow
et
al
.(
20
13
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
(n
¼
80
2)
H
ya
lu
ro
na
n-
bo
un
d
sp
er
m
se
le
ct
io
n
Vi
su
al
se
le
ct
io
n
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
M
aj
um
da
r
an
d
M
aj
um
de
r
(2
01
3)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
(n
¼
15
6)
PI
CS
I
Vi
su
al
se
le
ct
io
n
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
M
ok
an
sz
ki
et
al
.(
20
14
)
N
on
ra
nd
om
iz
ed
st
ud
y
co
m
-
pa
re
d
co
nv
en
tio
na
lI
CS
I
(n
¼
14
0)
to
PI
CS
I
(n
¼
11
0)
PI
CS
I
Vi
su
al
se
le
ct
io
n
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
si
gn
ifi
-
ca
nt
ly
im
pr
ov
ed
Ch
oe
et
al
.(
20
12
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
(n
¼
21
9)
H
A-
bo
un
d
Vi
su
al
se
le
ct
io
n
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
U
se
of
IM
SI
Ba
rt
oo
v
et
al
.(
20
02
)
Co
ho
rt
st
ud
y,
m
ot
ile
sp
er
m
or
ga
ne
lle
m
or
ph
ol
og
y
ex
am
in
at
io
n
(n
¼
10
0)
M
SO
M
E
Co
nv
en
tio
na
lI
CS
I
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
si
gn
ifi
-
ca
nt
ly
im
pr
ov
ed
.
Ba
rt
oo
v
et
al
.(
20
03
)
Co
ho
rt
st
ud
y
w
ith
of
le
as
t
tw
o
pr
ev
io
us
co
ns
eq
ue
nt
pr
eg
na
nc
y
fa
ile
d
IC
SI
cy
cl
es
,s
ub
je
ct
ed
to
IM
SI
(n
¼
11
2)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
G
at
im
el
et
al
.(
20
16
)
Re
tr
os
pe
ct
iv
e
co
m
pa
ra
tiv
e
st
ud
y
w
ith
tw
o
pr
ev
io
us
IC
SI
fa
ilu
re
s
(n
¼
21
6)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
Lu
na
et
al
.(
20
15
)
Co
ho
rt
st
ud
y
(n
¼
31
)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
La
Sa
la
et
al
.(
20
15
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
,
in
fe
rt
ile
co
up
le
s
sc
he
d-
ul
ed
fo
r
th
ei
r
fir
st
IC
SI
cy
cl
e
(n
¼
12
1)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
Se
tt
ie
t
al
.(
20
11
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
(n
¼
50
0)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
Kn
ez
et
al
.(
20
12
)
Ra
nd
om
iz
ed
co
nt
ro
ls
tu
dy
(n
¼
12
2)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
D
e
Vo
s
et
al
.(
20
13
)
Pr
os
pe
ct
iv
e
si
bl
in
g-
oo
cy
te
st
ud
y
(n
¼
70
0)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
El
Kh
at
ta
bi
et
al
.(
20
13
)
Pr
os
pe
ct
iv
e
no
n-
ra
nd
om
iz
ed
ob
se
rv
at
io
na
ls
tu
dy
(n
¼
47
8)
IM
SI
IC
SI
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
U
se
of
po
la
riz
at
io
n
m
ic
ro
sc
op
y
Sp
er
m
se
le
ct
io
n
M
al
go
rz
at
a
et
al
.(
20
07
)
Co
ho
rt
st
ud
y
(n
¼
49
)
El
ec
tr
on
m
ic
ro
sc
op
ic
sp
er
-
m
at
oz
oa
m
or
ph
ol
og
y
ch
ec
k
Co
nv
en
tio
na
lI
VF
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
si
gn
ifi
-
ca
nt
ly
im
pr
ov
ed
w
ith
no
rm
al
ul
tr
as
tr
uc
tu
re
sp
er
m
at
oz
oa
pe
rc
en
ta
ge
G
ia
na
ro
li
et
al
.(
20
08
)
Pr
os
pe
ct
iv
e
ra
nd
om
iz
ed
st
ud
y
(n
¼
23
1)
Bi
re
fr
in
ge
nt
sp
er
m
at
oz
oa
se
le
ct
ed
us
in
g
po
lo
sc
op
e
fo
r
IC
SI
Co
nv
en
tio
na
lI
CS
Ic
yc
le
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
no
t
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
G
ho
sh
et
al
.(
20
12
)
Co
ho
rt
st
ud
y
of
IC
SI
cy
cl
es
fo
r
az
oo
sp
er
m
ia
an
d
Bi
re
fr
in
ge
nt
sp
er
m
at
oz
oa
se
le
ct
ed
us
in
g
po
lo
sc
op
e
IC
SI
us
in
g
Th
e
fe
rt
ili
sa
tio
n
ra
te
s
si
gn
ifi
-
ca
nt
ly
im
pr
ov
ed
in
(c
on
tin
ue
d)
HUMAN FERTILITY 5
interference contrast (Nomarski/DIC) optics (magnifica-
tion,150) enhanced by digital imaging (magnifica-
tion,44) which achieved a total magnification of over
6000. This is much higher magnification than routinely
used for ICSI procedure. MSOME can identify a motile
spermatozoon with a normal nucleus and a normal
nuclear content (with<4% of the nucleus occupied by
vacuoles) (Bartoov, Berkovitz, & Eltes, 2001). Although,
few studies have showed improved fertilisation and
pregnancy rates with MSOME, its clinical use remains
unclear (Perdrix & Rives, 2013). Again, no consensus
has been established concerning normal or abnormal
MSOME criteria (Perdrix et al., 2012). Large-headed
spermatozoa are commonly associated with a lower
chance of pregnancy and ICSI is advised in these cases
(Guthauser et al., 2011). Globozoospermia is character-
ized by round-headed spermatozoa lacking an acro-
some and is found in 0.1% of infertile men (Karaca,
Akpak, Oral, Durmus, & Yilmaz, 2015). Similarly, oli-
goasthenozoospermic men were reported to have
lower fertilisation rates, poor embryo quality and lower
pregnancy rates (Zhu et al., 2015). Necrozoospermia is
defined as sperm viability5 to45%. The aetiological
factors include infections, epididymis dysfunction;
however, in many cases, no aetiology can be found
(Nduwayo, Barthelemy, Lansac, Tharanne, & Lecomte,
1995). Few authors suggest that testicular sperm
should be favoured over ejaculated sperm in cases of
persistent necrozoospermia (Negri et al., 2014;
Tournaye et al., 1996).
Sperm motility and progression
Normal structural appearance of sperm on light
microscopy cannot not rule out functional deficiencies.
Sperm motility disorder associated with bronchiectasia
called immotile cilia syndrome (ICS), or primary ciliary
dyskinesia (PCD), shows morphologically normal immo-
tile spermatozoa on light microscopy but ultra-struc-
tural studies reported a wide spectrum of axonemal
defects (Rossman, Forrest, Lee, Newhouse, &
Newhouse, 1981). Severe asthenozoospermia or total
immotility have also been reported in men with dys-
plasia of the fibrous sheath (DFS), a multigenic disease
with common pattern of flagellar abnormalities
(Chemes, Brugo, Zanchetti, Carrere, & Lavieri, 1987;
Chemes et al., 1998). Therefore, it is vital to identify
truly immotile sperm as it is possible that the sperm
may be dead.
The role of ion channels in human sperm function
was studied by Brown et al. (2016) found that
impaired potassium channel conductance and/or rest-
ing membrane potential (Vm) regulation is bothT
ab
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common and complex in human spermatozoa and
importantly is associated with impaired fertilisation
capacity when the Vm of cells is completely depolar-
ized. The practical implication of this knowledge would
be to develop novel diagnostic tools to assess semen
quality using membrane permeable voltage-sensitive
dyes.
In human spermatozoa, Ca2þ influx induced by pro-
gesterone is mediated by CatSper, a sperm-specific
Ca2þ channel. A suboptimal Ca2þ influx is significantly
associated with abnormal semen parameters and failed
fertilisation. Functional failure of CatSper compromises
fertility of human sperm. Such defects are rare. Sperm
with a near absence of CatSper current fail to respond
to activation of CatSper by progesterone. It is associ-
ated with fertilisation failure at IVF (Williams et al.,
2015). CatSper is a suitable and specific target for
further studies.
Premature chromosomal condensation (PCC)
Sperm PCC is one of the prevalent causes of fertilisa-
tion failure in both IVF and ICSI (Schmiady, Sperling,
Kentenich, & Stauber, 1986). It has been observed that
ICSI is associated with higher rate of PCC and higher
variations in the degree of condensation as compared
with IVF (Schmiady & Kentenich, 1989). When the
sperm nucleus can act with the chromosome condens-
ing factors and the oocyte does not become activated,
this will lead to the induction of PCC. When a cell,
with chromosomes in MII, fuses with an inter-phase
cell, the nuclear membrane of the cell in the inter-
phase dissolves and its chromatin condenses. This is
known as PCC (Johnson & Rao, 1970). The cytogenetic-
cytological data on unfertilised human oocyte follow-
ing ICSI have led to two predominant results including
presence of non-activated sperm head in the cyto-
plasm and PCC (Schmiady, Tandler-Schneider, &
Kentenich, 1996). PCC was also observed in fertilised
eggs that had formed two or three pronuclei which
resulted either from distinct pronuclear asynchrony or
interchromosomal asynchrony within the chromosome
set (Schmiady & Kentenich, 1989).
Sperm deoxyribonucleic acid (DNA) damage
Sperm DNA integrity tests have been proposed as a
mean to assess sperm competence. Several methodol-
ogies have been developed to assess sperm DNA frag-
mentation including the SCSA (Sperm chromatin
structure assay) (Evenson, Darzynkiewicz, & Melamed,
1980), sperm chromatin dispersion (SCD) assays
(Fernandez et al., 2005) and TUNEL (terminal deoxynu-
cleotidyl transferase dUTP nick end labelling) assay
(Gorczyca, Traganos, Jesionowska, & Darzynkiewicz,
1993). There is insufficient evidence to recommend the
routine use of sperm DNA integrity tests in the evalu-
ation and treatment of the infertile couple (Barratt
et al., 2010). Recent meta-analysis suggests high sperm
DNA damage is related to lower pregnancy rates in
IVF but not in ICSI cycles, whereas it is associated with
higher miscarriage rates in both IVF and ICSI cycles
(Zhao, Zhang, Wang, & Li, 2014). Oxidative stress is a
major cause of defective sperm function and DNA
fragmentation in cases of male infertility (Aitken,
Jones, & Robertson, 2012). Potential contribution of
antioxidant therapy in the clinical management of this
condition is under investigation (Lewis et al., 2013). A
Cochrane review found low-quality evidence synthes-
ised from four small randomised controlled trials sug-
gesting that antioxidant supplementation in sub fertile
males may improve live birth rates (Showell et al.,
2014).
Oocyte-related factors affecting fertilisation rates
Oocyte morphology
Oocyte selection based on morphology has been dis-
cussed in the literature (Van Blerkom & Henry, 1992).
Oocyte grading based on the three factors of first
polar body, size of perivitelline space and cytoplasmic
inclusions is found to be significantly related to fertil-
isation rate and embryo quality after ICSI (Xia, 1997).
However, the presence of one or two abnormal factors
such as large perivitelline space, spots, vacuoles or
refractile bodies did not correlate with fertilisation rate
(Dozortsev, De Sutter, & Dhont, 1994). Delayed cyto-
plasmic maturation with unsynchronized nuclear
maturity can lead to morphological changes in oocyte.
It has been suggested that oocytes with extreme mor-
phological abnormalities should not be discarded as
ICSI may overcome the barriers to fertilisation and
cleavage (Esfandiari, Burjaq, Gotlieb, & Casper, 2006;
Esfandiari, Ryan, Gotlieb, & Casper, 2005).
Oocyte maturity
Oocyte maturity influences fertilisation rates
(Esfandiari, Javed, Gotlieb, & Casper, 2005). Fifteen per-
cent of the oocytes obtained remain at prophase I
(10%) and MI (5%) stage (Cha & Chian, 1998; De
Vos, Van de Velde, Joris, & Van Steirteghem, 1999;
Schultz, 2002). It would be logical to hypothesise that
the potential use of these oocytes may increase the
number of available embryos. Rescue in vitro matur-
ation (IVM) is currently not a routine procedure.
Previous literature evaluated the clinical outcomes
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derived from short-term in vitro cultured MI oocytes
that progressed to MII oocytes. Majority of studies
showed significantly reduced fertilisation rates for MI
oocytes compared with MII oocytes (Balakier, Sojecki,
Motamedi, & Librach, 2004; De Vincentiis, De Martino,
Buffone, & Brugo-Olmedo, 2013; De Vos et al., 1999;
Huang et al., 1999; Shin et al., 2013; Strassburger et al.,
2004, 2010; Vanhoutte, De Sutter, Van der Elst, &
Dhont, 2005). Few authors suggested higher fertilisa-
tion rates (up to 60%) in these oocytes (De Vincentiis,
De Martino, Buffone, & Brugo-Olmedo, 2013; Huang
et al., 1999; Strassburger et al., 2004). Safety is a major
concern for embryos derived after in vitro maturation
of MI oocyte. In one study, nearly 80% of embryos
from MI oocytes were genetically abnormal. The rate
of aneuploidy falls with the duration of incubation,
with 40% after 2 h of incubation period (Strassburger
et al., 2010). Current evidence does not support use of
MI oocytes.
Oocyte activation
Oocyte activation is a series of events triggered by the
fertilising spermatozoon and necessary for the begin-
ning of the zygote development (Tesarik, 1994). Few
oocytes fail to get activated during fertilisation. During
IVF cycles, the majority of oocytes (60–90%) that fail to
fertilise do not contain sperm nuclei. This suggests fer-
tilisation failure is due to failure of sperm to penetrate
or sperm ejection (Mahutte & Arici, 2003). After ICSI,
the majority of unfertilised MII oocytes show swollen
sperm head which suggests failed oocyte activation.
Oocyte activation failure could account for 40–70% of
unfertilised oocytes exposed to ICSI (Heindryckx et al.,
2005; Mahutte & Arici, 2003; Yanagida, 2004).
Globozoospermia results in oocyte activation failure
due to abnormalities in acrosome formation and
oocyte activation capacity (Dam et al., 2007). Even
morphologically normal sperm can fail to activate the
oocyte. Assisted oocyte activation (AOA) is discussed
below.
Strategies to improve fertilisation rates
Optimising laboratory condition and procedural
effects in techniques
The technique of performing ICSI procedure is a sig-
nificant predictor of fertilisation (Shen, Khabani, Klein,
& Battaglia, 2003). Immobilization of the spermatozoon
and rupture of the oolemma are the two key steps for
successful fertilisation (Svalander, Forsberg, Jakobsson,
& Wikland, 1995; Van den Bergh, Bertrand, Biramane, &
Englert, 1995). Aspiration of the ooplasm is always
used to make sure that the oocyte membrane is bro-
ken during injection. Injection of motile sperm
without immobilization leads to poor fertilisation rates
(Vanderzwalmen et al., 1996). The degeneration of
oocytes after ICSI may be due to a faulty ICSI tech-
nique. It has been suggested that sperm-borne and
oocyte-borne oocyte activation failures can be over-
come by modifying the ICSI technique (Tesarik, Rienzi,
Ubaldi, Mendoza, & Greco, 2002). Pushing the needle
tip close to the membrane opposite the puncture site,
aspirating the cytoplasm at this point and releasing
the sperm in the centre of oocyte are the modifica-
tions suggested to improve the fertilisation rates in
oocyte-dependent activation failure (Ebner, Moser,
Sommergruber, Jesacher, & Tews, 2004). Laser-medi-
ated ICSI has been suggested to overcome technical
difficulty of passing the zona pellucida. A micro-hole
with diameter 5–10lm can be created in the zona pel-
lucida by a laser beam just prior to ICSI and this will
allow the injection pipette to pass without any trauma.
Laser-mediated ICSI has shown to improve fertilisation
rates by a few authors (Choi et al., 2011; Demirol,
Benkhalifa, Sari, & Gurgan, 2006). It has been proposed
that performing ICSI through a laser-drilled hole in the
zona pellucida reduces the risk of oocyte damage
related to deformation during the initial phase of the
microinjection procedure. This technique appears to
be suitable for patients whose oocyte show inherent
fragility and high degeneration rates after the standard
ICSI procedure (Rienzi et al., 2001). Improvements in
IVF laboratory conditions and air quality have pro-
found positive effects on outcomes (Heitmann et al.,
2015). A recent review suggested that successful and
consistent outcomes are associated with optimization
of each procedure associated with the collection and
processing of gametes (Balaban, Sakkas, & Gardner,
2014). Change in culture media did not show any dif-
ference in fertilisation rate (Ceschin et al., 2016). A
recent randomised trial suggested supplemental pro-
tein concentration in the embryo transfer medium
does not affect the treatment outcomes (Huang et al.,
2016). In contrast, a review of the literature suggested
that out of 11 studies five studies showed that the cul-
ture medium not only influences immediate outcome
but also has influence on phenotypic characteristics
such as birthweight (Zandstra, Van Montfoort, &
Dumoulin, 2015). However, recently published large
retrospective cohort study of 7295 singletons showed
no difference in birthweight despite of changes in clin-
ical care and laboratory practice (Maas, Galkina,
Thornton, Penzias, & Sakkas, 2016). There are various
limitations of these studies including retrospective
design with consecutive use of different culture media,
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different composition, limited human studies and lim-
ited sample sizes in those studies. There is insufficient
evidence on the impact of culture media on birth-
weight. Culture medium or oxygen concentration used
in in vitro culture does not have significant effect on
the global gene expression profile of preimplantation
embryos (Mantikou et al., 2016). External pH of culture
media influences sperm binding, motility (Dale,
Menezo, Cohen, DiMatteo, & Wilding, 1998; Emmens,
1947) oocyte maturation (Bagger, Byskov, &
Christiansen, 1987; Downs & Mastropolo, 1997) and
embryo development. Improper intracellular pH
impedes sperm function (Hamamah & Gatti, 1998;
Marquez & Suarez, 2007) frequent fluctuations in envir-
onmental conditions, including pH of media, could be
harmful. They can be transduced into deleterious intra-
cellular perturbations (Phillips, Leveille, Claman, &
Baltz, 2000). Embryos have a limited ability to regulate
their internal pH (pHi), oocytes lack robust mecha-
nisms (Swain, 2010). Therefore, careful attention to
external pH (pHe) of culture media is imperative in
IVF. Optimal pHe conditions needed for oocyte matur-
ation, fertilisation and various stages of developing
embryos may vary. Increasing buffering capacity of
media, using combination buffers or some other novel
approach may be beneficial during fertilisation (Swain,
2010).
Spindles are formed from microtubules. They are
exquisitely sensitive to changes in temperature. The
maintenance of temperature at 37 C during in vitro
manipulation is important for spindle integrity, normal
fertilisation and subsequent embryo development
(Wang, Meng, Hackett, Odenbourg, & Keefe, 2001).
They get rapidly depolymerised even after a slight
reduction in temperature to 33 C. Damage to the mei-
otic spindle may be the cause of aneuploidembryos
(Mandelbaum et al., 2004; Zenzes, Bielecki, Casper, &
Leibo, 2001). Optimization of laboratory condition and
techniques is the most important factor and the only
practically controllable method of improving fertilisa-
tion rates. Unfortunately, these factors are not studied
widely with robust study designs. Therefore, what are
optimal laboratory conditions required to maximise
the fertilisation rates is an unanswered question.
Assisted oocyte activation (AOA)
Several methods of AOA have been described, which
employ mechanical, electrical or chemical stimuli. The
use of chemical oocyte activation is the most popular
method. Calcium plays a pivotal role in triggering all
downstream nuclear and cytoplasmic changes in fertil-
ised oocytes, leading to successful oocyte activation
and the onset of embryogenesis (Ramadan, Kashir,
Jones, & Coward, 2012; Tesarik, 1994). Chemical AOA
could be performed for predominantly sperm-related
or oocyte-related activation failures. Commonly used
agents are calcium ionophores. These agents are lipid
soluble and they transport calcium ions across the
oocyte cell membrane inducing a single transient
surge in intracellular calcium concentration (Swann &
Ozil, 1994). Calcium ionophores such as ionomycin and
calcimycin (A23187, GM508) are used successfully for
oocyte activation (Borges, de Almeida Ferreira Braga,
de Sousa Bonetti, Iaconelli, & Franco, 2009; Heindryckx
et al., 2005; Moaz, Khattab, Foutouh, & Mohsen, 2006;
Montag & van der Ven, 2005, Reply: Auer &
Schwaerzler, 2005; Nasr-Esfahani et al., 2010; Vanden
Meerschaut et al., 2012).
Various randomised and non-randomised studies
have shown significantly improved fertilisation rates
following AOA using calcium ionophore A23187 (Moaz
et al., 2006; Nakagawa et al., 2001; Vanden Meerschaut
et al., 2012) whereas some studies failed to find signifi-
cant improvement (Borges et al., 2009; Caglar Aytac
et al., 2015; Eftekhar, Aflatoonian, Mohammadian, &
Eftekhar, 2013). AOA with Ca2þ ionophore (GM508
Cult-Active) showed significantly better fertilisation
rates for both azoospermic and cryptozoospermic men
(Ebner et al., 2012). Systematic review showed that
oocyte activation (with calcium ionophore) improved
pregnancy rate significantly with globozoospermia
(Chansel-Debordeaux, Dandieu, Bechoua, & Jimenez,
2015).
The electrical activation with direct current voltage
leads to rearrangement of the proteins of the cell
membrane, which allow the influx of extracellular cal-
cium (Mansour & Buckett, 2008; Yanagida et al., 1999).
Electrical activation significantly increases the fertilisa-
tion rates (Manipalviratn et al., 2006; Mansour et al.,
2009; Zhang et al., 1999). Mechanical oocyte activation
includes advancing the microinjection pipette and
aspirating peripheral cytoplasm, followed by depos-
ition of the aspirated cytoplasm and the spermatozoon
in the centre of the oocyte. The peripheral cytoplasm,
which is rich in mitochondria, increases the energy
source at the central site of subsequent pronuclear for-
mation (Ebner et al., 2004). Failed oocyte activation
can be overcome by modifying the ICSI technique
with mechanical stimulation (Tesarik et al., 2002). The
meta-analysis by Sfontouris et al., (2015) concluded
that the evidence available from the current RCTs is
not sufficient to judge the efficacy or safety of ICSI-
AOA on key reproductive outcomes, therefore, these
interventions should be further examined by
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well-designed RCTs before the introduction of ICSI-
AOA as a standard treatment.
AOA has been studied for fertilisation of aged
oocyte. It has been suggested that 3-d-old unfertilised
human oocytes after IVF or ICSI could be activated by
the calcium ionophore A23187 or strontium chloride
(Liu et al., 2014). In another study using combination of
calcium ionophore A23187 with puromycin, the best
results of AOA were achieved in unfertilised oocytes
20 h after ICSI, which exhibited an activation rate of
91.2% (31/34), a cleavage rate of 64.7% (22/34) and
44.1% (15/34) high-quality embryos (Lu et al., 2006). A
live birth is reported after calcium ionophore A23187
activation on 1-d-old unfertilised oocytes in a patient
with repeated near-total fertilisation failure after ICSI
(Lu et al., 2012). A recent study demonstrated that acti-
vating post-ICSI aged human unfertilised oocytes with
a combination of a calcium ionophore and a cytokine
can produce good-morphology euploid blastocysts
(Economou et al., 2016). Current evidence on oocyte
activation shows early promise but no sufficient clinical
evidence to make recommendation for practice.
TESE and selection of motile sperm in complete
asthenozoospermia, necrozoospermia or
cryptozoospermia
Absolute immotile spermatozoa is one of the most
important causes of reduced fertilisation and preg-
nancy rates after ICSI. In total necrozoospermia, TESE
is the only possible option, but retrieving motile or
viable spermatozoa for ICSI may not be possible
(Tournaye et al., 1996). Although TESE yields more
viable sperm, testicular sperm are immotile immedi-
ately after biopsy. There are various techniques
described to differentiate between immotile and non-
viable sperm. Live spermatozoa with normal mem-
brane function show swelling of the cytoplasm and
curling of the tail due to water influx when exposed
to hypo-osmotic conditions. Mechanical touch tech-
nique or the sperm tail flexibility test (STFT) is an easy
and cost-effective way for selecting viable immotile
spermatozoa. The principle of this technique is to
evaluate the tail flexibility by touching it with the ICSI
pipette (Soares et al., 2003). Pentoxifylline (PTX) is a
3050-nucleotidase phosphodiesterase inhibitor of the
methylxantine group that enhances sperm motility by
increasing intracellular c-AMP. Its short exposure does
not affect early embryo development (Ortega et al.,
2011). Short exposure of testicular samples with immo-
tile sperm to pentoxifylline (PTX)-sperm motility stimu-
lator showed higher fertilisation rate (Kovacic,
Vlaisavljevic, & Reljic, 2006). A laser is used to
discriminate between viable and dead immotile sper-
matozoa, curling of the sperm tail seen in viable
sperm. Laser-assisted immotile sperm selection showed
higher fertilisation rate as compared with hypo-
osmotic swelling test (HOS) (Aktan et al., 2004).
However, it remains unclear which is the best tech-
nique to improve the pregnancy outcomes in cases
with absolute immotile spermatozoa (Ortega et al.,
2011).
Use of ICSI and rescue ICSI
A retrospective cohort study of 1,395,634 fresh IVF
cycles showed that the use of ICSI increased from
36.4% in 1996 to 76.2% in 2012 in the United States,
with the largest relative increase among cycles without
male factor infertility. However, ICSI use was not asso-
ciated with improved post fertilisation reproductive
outcomes, irrespective of male factor infertility diagno-
sis when compared with conventional IVF. On the con-
trary, among cycles without male factor infertility
(n¼ 317,996), ICSI use was associated with lower rates
of implantation, live births, as compared with conven-
tional IVF (Boulet et al., 2015). Fertilisation rates were
not reported in this study. The systematic review and
meta-analysis of 11 studies with well-defined unex-
plained infertility showed marginally higher true fertil-
isation rate with ICSI as compared with conventional
IVF (RR 1.49, 95% confidence interval [CI] 1.35–1.65).
The number of subjects needed to be treated with
ICSI to prevent one case of TFF was five (Johnson,
Sasson, Sammel, & Dokras, 2013). The use of ICSI in
the absence of a male factor can adversely affect
reproductive outcome when used for poor responders.
Probably because of aging-related defects overcoming
the advantage of sperm selection, the choice of IVF
technique is not relevant to reproductive success
when oocyte quality is compromised by reproductive
aging (Artini et al., 2013). Early rescue ICSI is proposed
as a safe alternative method for couples with total fer-
tilisation failure or near total fertilisation failure when
compared with conventional IVF treatment. The fertil-
isation rates were improved with rescue ICSI but the
rate of polyploidy was high; therefore, rescue ICSI is
not recommended for patients with a fertilisation rate-
>25% as the procedure is associated with a greater
risk and low returns (Cao et al., 2016). Systematic
review on rescue ICSI analysed 38 studies including
1863 patients with failed fertilisation showed
pooled pregnancy rate of 14.4% per cycle and rate
of malformations was not elevated (Beck-Fruchter,
Lavee, Weiss, Geslevich, & Shalev, 2014). However, res-
cue ICSI is not permitted in the United Kingdom due
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to safety concerns. There is a risk of injecting sperm
into unfertilised oocyte with prior insemination, which
may already contain sperm head. Further evidence on
safety and efficacy is required before recommending
rescue ICSI.
Use of physiological intracytoplasmic sperm
injection (PICSI)
PICSI is based on the uses of hyaluronic acid to
select mature sperm for injection. The formation of
hyaluronic-acid (HA)-binding sites on the sperm
plasma membrane is one of the signs of sperm
maturity. PICSI-selected sperm show less DNA dam-
age, and fewer chromosomal aneuploidies (Huszar
et al., 2007). A small non-randomised study reported
significantly improved fertilisation rates with PICSI
(Mokanszki et al., 2014). Other studies did not show
any difference in fertilisation rate following the selec-
tion of hyaluronan-bound (HB) sperm for ICSI (Choe
et al., 2012; Majumdar &. Majumdar, 2013; Worrilow
et al., 2013). A Cochrane review concluded that the
evidence is insufficient to support sperm selection
by hyaluronanic acid binding (McDowell et al.,
2014). Results from multicentre trial in the United
Kingdom, HABSelect, are awaited (Trial registration
ISRCTN99214271). This study will provide further evi-
dence on the use of PICSI.
Use of intracytoplasmic morphologically selected
sperm injection (IMSI)
IMSI is a technique of selecting a spermatozoon after
use of 6000 or higher magnification. The MSOME
was significantly and positively associated with both
fertilisation rate and pregnancy outcome (Bartoov
et al., 2002). The use of MSOME method for ICSI pro-
cedure led to the development of IMSI. It is suggested
that IMSI improves clinical outcome (Shalom-Paz et al.,
2015) but other authors failed to find any difference in
fertilisation rates (Bartoov et al., 2003). Observational
studies did not find any improvement in clinical out-
come after the use of IMSI for two previous ICSI fail-
ures (Gatimel, Parinaud, & Leandri, 2016; Luna et al.,
2015). Results from many randomised and non-rando-
mised studies suggest that the fertilisation rates are
not significantly different with IMSI as compared with
ICSI (De Vos et al., 2013; El Khattabi et al., 2013; Knez,
Tomazevic, Zorn, Vrtacnik-Bokal, & Virant-Klun, 2012;
La Sala et al., 2015; Setti, Figueira, Braga, Iaconelli, &
Borges, 2011; Teixeira et al., 2013). Further trials are
required to before recommending IMSI in clinical
practice.
Use of polarization microscopy
Transmission electron microscope studies have shown
that the presence of birefringence in the sperm head
indicates a normal sperm structure with the highest
potential of development. The use of birefringent sper-
matozoa is associated with higher fertilisation rate
(Malgorzata et al., 2007) and higher clinical pregnancy
rates (Gianaroli et al., 2008). Selection of birefringent
spermatozoa with the aid of polarised light micro-
scope, called polscope (Polscope, CRi Oosight imaging
system, model: MA20511 Cambridge Research
Instrumentation, Woburn, MA), shows promising
results in asthenozoospermic men and men under-
going TESA or TESE before ICSI (Ghosh et al., 2012).
Polarization microscopy to identify the meiotic spindle
in oocytes is suggested to improve fertilisation rates
(Cohen et al., 2004; Wang, Meng, Hackett, & Keefe,
2001). This may result in potential deleterious impact
on embryo development due to additional oocyte
handling (Picinato et al., 2014; Rienzi et al., 2003).
Therefore, no significant difference in clinical preg-
nancy, or live-birth rates was found (Picinato et al.,
2014). Polarization microscopy is not a widely prac-
ticed method and there is insufficient evidence of its
usefulness to improve the fertilisation rates.
Postacrosomal WW binding protein (PAWP)
Increased levels of PAWP in sperm are correlated with
higher fertilisation rates independently of age, DNA
fragmentation index and other sperm parameters.
Considering its proposed role in the initiation of
oocyte activation, PAWP could have potential applica-
tions in the diagnosis and treatment of infertility
(Aarabi et al., 2014).
Micro electrophoresis
Selection of negatively charged sperm through micro-
electrophoresis has the potential to isolate sperm
relatively free of DNA damage to be used in ICSI. The
percentage of negatively charged sperm is positively
associated with fertilisation rate and blastocyst devel-
opment and inversely associated with embryo arrest
(Simon et al., 2015). Further evidence is awaited on
this sperm selection method.
Magnetic activated cell sorting (MACS)
MACS is a novel sperm preparation technique that
separates apoptotic and non-apoptotic spermatozoa
based on the expression of phosphatidylserine
(Makker, Agarwal, & Sharma, 2008). Externalization of
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phosphatidylserine (PS) in the inner plasma membrane
is one of the earliest signs of apoptosis (Lee, Meng,
Flatten, Loegering, & Kaufmann, 2013). Annexin-V
magnetic-MACS is based on the binding of superpara-
magnetic Annexin-microbeads to externalized phos-
phatidylserine at the outer leaflet of the plasma
membrane of sperm with activated apoptosis signal-
ling or membrane damage (Grunewald & Paasch,
2013). The spermatozoa prepared by density gradient
centrifugation (DGC) and further processed by MACS
showed a reduced level of apoptotic markers and a
high fertilisation potential (Lee et al., 2010). In recent
study, when the MACS ART annexin V reagent kit
(Miltenyi Biotec, Auburn, CA) was used to filter apop-
totic sperm using a binding protein with high affinity
for PS, annexin V conjugated to microbeads, combined
with DCG, was shown to be an effective method to
isolate high-quality sperm with progressive motility,
non-apoptosis, high DNA integrity, and low protamine
deficiency for clinical use (Chi et al., 2016). It has been
suggested that this technique could be a potential
tool to improve sperm quality on cryopreserved sper-
matozoa of cancer patient and improve ICSI outcome
(Herrero et al., 2013). A meta-analysis of five studies
(total n¼ 499) showed sperm selection using MACS
resulted in higher clinical pregnancy rates. However,
this analysis was based on poor-quality studies (Gil,
Sar-Shalom, Melendez Sivira, Carreras, & Checa, 2013).
A randomised triple blinded controlled trial involving
237 infertile couples undergoing ICSI as part of an
oocyte donation programme showed its use for unse-
lected males does not improve the reproductive out-
come (Romany et al., 2014). MACS did not show any
clinically relevant adverse effects on obstetric and peri-
natal outcomes (Romany et al., 2017). The use of this
technology for males with suspected cell damage and
poor semen quality would be an area for future
research.
Conclusion
The commonest cause of failed fertilisation is non-
availability of appropriate sperm or failed oocyte
activation. Repeated ICSI attempts may result in 85%
fertilisation rates. Optimization of laboratory environ-
ment and techniques is associated with improved fer-
tilisation rates. Assisted oocyte activation and sperm
selection using IMSI and PICSI are widely studied
methods to improve assisted conception outcome.
Various other novel approaches such as polarised
microscopy and micro-electrophoresis are suggested
to improve the fertilisation rates. However, multicentre
randomized controlled trial are needed to generate
conclusive evidence to support any of these methods
before routine clinical application.
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ABSTRACT
Objectives To evaluate, by systematic review of the
literature, the accuracy of first-trimester ultrasound in
diagnosing early embryonic demise.
Methods We searched MEDLINE (1951–2011), Embase
(1980–2011) and the Cochrane Library (2010) for
relevant citations. The reference lists of all known primary
and review articles were examined. Language restrictions
were not applied. Studies which evaluated the accuracy
of first-trimester ultrasonography in pregnant women for
the diagnosis of early embryonic demise were selected
in a two-stage process and their data extracted by
two reviewers. Accuracy measures including sensitivity,
specificity and likelihood ratios (LRs) for abnormal and
normal test results were calculated for each study and for
each test threshold.
Results Eight primary articles with four test categories
(18 2 × 2 tables), involving 872 women, evaluated the
accuracy of ultrasound in diagnosing early embryonic
demise. The lower limit of the 95% CI for specificity was
> 0.95 in only two tests. These were an empty gestational
sac with mean diameter of ≥ 25 mm and absent yolk
sac with a mean gestational sac diameter of ≥ 20 mm
(specificity, 1.00; 95% CI, 0.96–1.00 for both).
Conclusions There is a paucity of high-quality, prospec-
tive data on which to base guidelines for the accurate
diagnosis of early pregnancy demise. The findings are
limited by the small number of studies and patients,
the age of the studies, inclusion of symptomatic and
asymptomatic women and variable reference standards
for diagnosis of early pregnancy demise. Before guidelines
for the safe management of threatened miscarriage can be
formulated, there is an urgent need for an appropriately
powered, prospective study using current ultrasound tech-
nology and an agreed reference standard for pregnancy
success or loss. Copyright  2011 ISUOG. Published by
John Wiley & Sons, Ltd.
INTRODUCTION
Ultrasound examination is the method of choice in the
diagnosis of early embryonic demise1. One in three
women miscarries at some time during reproductive life
and the incidence of early embryonic demise is high
compared with other early pregnancy complications2. The
diagnosis of failed pregnancy has implications for further
management, with associated emotional impact on the
mother. Most of the current recommendations regarding
the diagnosis of early embryonic demise arose as a result
of the public enquiry report investigating the misdiagnosis
of the death of embryos3.
Recommendations regarding the ultrasound criteria
for the diagnosis of pregnancy failure in the first
trimester vary. The American College of Radiologists
(ACR) recommends a diagnosis of early embryonic
demise when the embryo has a crown–rump length
(CRL) > 5 mm without cardiac activity4. In the UK,
the joint report of the Royal College of Obstetricians
and Gynaecologists (RCOG) and the Royal College of
Radiologists (RCR) recommends using the following
criteria to diagnose pregnancy of ‘uncertain viability’:
an intrauterine gestational sac of < 20 mm in mean
diameter with no obvious yolk sac, or presence of a
fetus or fetal echo of < 6 mm CRL with no obvious fetal
heart activity5,6. The Society of Gynaecologists of Canada
(SOGC) recommends diagnosis of early embryonic demise
with certainty when the mean gestational sac diameter
exceeds 8 mm without a yolk sac or when the mean
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gestational sac diameter exceeds 16 mm without an
embryo on transvaginal scan7. The evidence for all of the
above recommendations came from very small studies.
We undertook a systematic review of the literature to
assess the accuracy of the various ultrasound criteria in
diagnosing early embryonic demise.
METHODS
This review was carried out with a prospective protocol
using well accepted methodology8.
Search strategy
We searched MEDLINE (1951–2011), Embase (1980–
2011) and the Cochrane Library (2010) for relevant
citations. We used a combination of MeSH and
text words to generate two subsets of citations, one
indexing ultrasound (‘ultrasound’, ‘ultrasonography’,
‘exp ultrasound’) and the other indexing outcomes
(‘miscarriage’, ‘abortion’, ‘pregnancy loss’, ‘early’ AND
‘pregnancy’ AND ‘failure’, ‘fetal OR foetal OR fetus
OR foetus’ AND ‘death OR demise’). These two subsets
were then combined with ‘AND’ to generate a subset of
citations relevant to our research question. The reference
lists of all known primary and review articles were
examined to identify cited articles not captured by
the electronic searches. Language restrictions were not
applied. A comprehensive database of relevant articles
was constructed.
Study selection
Primary studies which evaluated the accuracy of first-
trimester ultrasonography in pregnant women for the
diagnosis of early embryonic demise were selected in
a two-stage process. We included studies that assessed
patients symptomatic or asymptomatic of threatened
miscarriage in the first trimester. First, the electronic
searches were scrutinized and full manuscripts of all
citations that were likely to meet the predefined selection
criteria were obtained. Second, final inclusion or exclusion
decisions were made by the reviewers (Y.J. and S.T.) after
examination of these manuscripts. Studies which met
the predefined and explicit criteria regarding population,
tests, outcomes and study design were selected for
inclusion in the review. When disagreements occurred,
they were resolved by consensus (Y.J. and S.T.). In
cases of duplicate publication, the most recent and
complete version was selected. Subjective ultrasound
criteria for diagnosis of early embryonic demise were
not included.
From each selected article we extracted information
on study characteristics, quality and accuracy results.
Accuracy data were used to construct 2 × 2 tables of
ultrasound findings and pregnancy outcomes.
Methodological quality assessment
All manuscripts meeting the selection criteria were
assessed for their methodological quality. Quality was
defined as the confidence that the study design, conduct
and analysis minimized bias in the estimation of test
accuracy. Based on existing checklists, quality assessment
involved scrutinizing the study design and relevant
features of the population, test and outcomes of the
study. A study was considered to be of good quality if
it used a prospective design, consecutive enrolment, full
verification of the test result with reference standard, and
had adequate description of the test.
Data synthesis
Accuracy measures, including sensitivity, specificity and
likelihood ratios (LRs) for abnormal and normal test
results, were calculated for each study, separately for
each test threshold. Heterogeneity of diagnostic odds
ratio was assessed graphically using forest plot and
statistically using chi-square test to aid in decisions
regarding how to proceed with quantitative synthesis.
Because, for some tests and outcomes, there was either
graphical or statistically significant heterogeneity, we
planned to use random effects model meta-analysis.
When a quantitative approach was not appropriate due
to significant clinical heterogeneity, we refrained from
pooling and described the results narratively and reported
the accuracy measures estimated in each study. All
statistical analyses were performed using the Meta Disc
statistical package9.
RESULTS
From 720 citations, 23 were reviewed in detail. Eight
primary articles with four different categories of tests (18
2 × 2 tables) involving 872 women were included in this
systematic review10–17 (Figure 1).
Clinical characteristics of the included studies
Four primary articles included women symptomatic of
threatened miscarriage10–13, three included both symp-
tomatic and asymptomatic women14–16 and one included
only asymptomatic women17 in the first trimester. It
was not possible to separate the data of asymptomatic
women from those who were symptomatic of threat-
ened miscarriage. The sonographic criteria for diagnosis
of early embryonic demise included varied CRL mea-
surements with absent cardiac activity, size of empty
gestational sac, absent yolk sac with varied gestational
sac sizes and combined criteria (Table 1). The refer-
ence standard for pregnancy loss included diagnosis of
miscarriage on further scan, clinically diagnosed miscar-
riage, histopathology, failure of embryo development,
falling levels of beta-human chorionic gonadotropin (β-
hCG) and evaluation of fetal status on second-trimester
ultrasound.
Copyright  2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 489–496.
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Study quality
Six of the eight (75%) primary articles were prospective
cohort studies which recruited consecutive women
(Figure 2). In no study was the operator blinded to the
test and in only one study was the operator blinded
to ascertainment of reference standard. The test was
described in sufficient detail in three of the eight (37%)
primary studies. The follow-up was adequate in all studies.
Accuracy of ultrasound
The sensitivity of the included studies for early pregnancy
demise ranged from 14% to 100% (Table 2). The highest
sensitivity (1.00; 95% CI, 0.54–1.00) was observed
in studies using the sonographic criteria of absence of
embryo or cardiac activity in gestational sac with a mean
diameter of or above 16 mm15.
Fourteen of the 18 evaluations had specificity > 90% in
diagnosing early pregnancy demise (Figure 3, Table 2).
The lower limit of the 95% CI for specificity was
> 0.95 for only two sonographic criteria: an empty
gestational sac with mean diameter ≥ 25 mm (specificity,
1.00; 95% CI, 0.96–1.00) and absent yolk sac with mean
gestational sac diameter ≥ 20 mm (specificity, 1.00; 95%
CI, 0.96–1.00).
The positive LR for the sonographic diagnosis of
early embryonic demise was > 10 in 13/18 (72.2%)
of the studies and the negative LR was < 0.1 in
3/18 (16.7%). Table 2 provides the accuracy estimates
sensitivity, specificity and positive and negative LRs and
false-positive rates for various cut-off levels of ultrasound
features.
Citations excluded after screening titles and/or
abstracts (n = 697)
Total citations identified by electronic searches (n = 720)
Articles evaluating use of different ultrasound criteria in
diagnosing early embryonic demise in the first trimester (n = 23)
-
-
-
-
-
Articles excluded (n = 15)
Inappropriate population (n = 3)
Inappropriate outcome (n = 2)
Data not extractable (n = 1)
Lack of original data e.g. letters, review (n = 4)
Inappropriate test (n = 5)
Primary articles included in systematic review (n = 8)
Figure 1 Flow chart of study selection in this systematic review of
accuracy of ultrasound examination in diagnosing early embryonic
demise.
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Table 2 Accuracy of early pregnancy sonographic features in diagnosing early embryonic demise
Sonographic criteria Study (year)
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR− (95% CI) FPR
No cardiac activity
With CRL < 4 mm Goldstein17
(1992)
0.50 (0.01–0.99) 0.59 (0.41–0.75) 1.21 (0.28–5.14) 0.85 (0.21–3.50) 0.41
Levi et al.16
(1990)
0.64 (0.41–0.83) 0.82 (0.63–0.94) 3.56 (1.52–8.38) 0.44 (0.25–0.79) 0.18
With CRL < 5 mm Goldstein17
(1992)
0.50 (0.12–0.88) 0.65 (0.48–0.79) 1.43 (0.58–3.53) 0.77 (0.34–1.77) 0.35
Levi et al.16
(1990)
0.65 (0.45–0.81) 0.88 (0.73–0.96) 5.16 (2.19–12.20) 0.41 (0.25–0.66) 0.12
With CRL > 5 mm Goldstein17
(1992)
0.50 (0.12–0.88) 1.00 (0.90–1.00) 36.00 (2.08–622.64) 0.51 (0.24–1.07) 0
With CRL > 6 mm Goldstein17
(1992)
0.50 (0.07–0.93) 1.00 (0.87–1.00) 27.00 (1.51–482.2) 0.51 (0.21–1.23) 0
Empty gestational sac (GS)
Diameter > 26 mm Scott et al.11
(1987)
0.46 (0.35–0.56) 1.00 (0.69–1.00) 10.05 (0.66–152.18) 0.57 (0.45–0.71) 0
MSD ≥ 25 mm Nyberg et al.14
(1987)
0.20 (0.08–0.39) 1.00 (0.93–1.00) 22.65 (1.32–388.50) 0.80 (0.66–0.96) 0
Nyberg et al.10
(1986)
0.29 (0.19–0.40) 1.00 (0.96–1.00) 50.17 (3.10–811.70) 0.71 (0.62–0.82) 0
Largest diameter > 20 mm Ismail and
Kishk12
(1991)
0.81 (0.70–0.89) 0.57 (0.29–0.82) 1.88 (1.02–3.48) 0.34 (0.18–0.65) 0.43
MSD ≥ 17 mm Tongsong
et al.13 (1994)
0.50 (0.43–0.58) 1.00 (0.88–1.00) 31.17 (1.99–489.13) 0.51 (0.43–0.59) 0
MSD ≥ 16 mm Levi et al.15
(1988)
0.50 (0.12–0.88) 1.00 (0.88–1.00) 30.00 (1.74–516.92) 0.51 (0.24–1.07) 0
Absent yolk sac
With MSD ≥ 20 mm Nyberg et al.14
(1987)
0.14 (0.04–0.33) 1.00 (0.93–1.00) 16.76 (0.93–300.55) 0.85 (0.73–1.00) 0
Nyberg et al.10
(1986)
0.41 (0.30–0.52) 1.00 (0.96–1.00) 70.64 (4.40–1133.7) 0.59 (0.50–0.71) 0
With MSD ≥ 13 mm Tongsong
et al.13 (1994)
0.96 (0.92–0.99) 1.00 (0.69–1.00) 21.12 (1.41–316.93) 0.04 (0.02–0.10) 0
With MSD ≥ 8 mm Levi et al.15
(1988)
0.67 (0.38–0.88) 1.00 (0.92–1.00) 59.06 (3.67–951.17) 0.35 (0.18–0.69) 0
Combined criteria
No cardiac activity
in GS MSD ≥ 16 mm
Levi et al.15
(1988)
1.00 (0.54–1.00) 1.00 (0.88–1.00) 55.71 (3.54–877.02) 0.07 (0.01–1.05) 0
No embryo or
cardiac activity in GS
MSD ≥ 16 mm
Levi et al.15
(1988)
1.00 (0.54–1.00) 1.00 (0.88–1.00) 55.71 (3.54–877.02) 0.07 (0.01–1.05) 0
CRL, crown–rump length; FPR, false-positive rate; LR+, positive likelihood ratio; LR−, negative likelihood ratio; MSD, mean gestational
sac diameter.
DISCUSSION
For the diagnosis of early embryonic demise there are
various ultrasound criteria used which have relatively
high specificity and poor sensitivity. The ultrasound
features of an empty gestational sac with mean diameter
≥ 25 mm and absent yolk sac with mean gestational sac
diameter ≥ 20 mm were the thresholds with the highest
and most precise estimates of specificity for diagnosing
early embryonic demise.
Specificity versus sensitivity
Most pregnancy screening tests, such as Down syndrome
or gestational diabetes screening, strive for optimal
sensitivity whilst tolerating a low false-positive rate.
With threatened early pregnancy loss, it is imperative
to have a highly specific test with a zero false-positive
rate, as the diagnosis of early embryonic demise leads to
evacuation of the uterus. While it would be ideal to have
both a highly sensitive and highly specific test for early
pregnancy loss, it is critical to realize that a false-positive
diagnosis of early embryonic demise is likely to result
in inadvertent termination of pregnancy. Positive results
from highly specific tests would rule in a diagnosis of
early pregnancy demise (Specific, Positive, In = SpPIn)18.
The application of this rule and test performance in the
diagnosis of early pregnancy demise will be affected
by the following: spectrum bias of different stages of
Copyright  2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 489–496.
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Figure 2 Quality of primary studies (n = 8) included in this review
evaluating accuracy of ultrasound examination in diagnosing early
embryonic demise. , Yes; , No.
pregnancy demise, differential verification bias due to
varied application of different reference standards for
confirmation of the diagnosis and the small number of
included studies18. The power to rule in a diagnosis of
early pregnancy demise will depend on both specificity
and sensitivity.
Ultrasound criteria for diagnosis of early pregnancy
demise
This review has identified a number of studies and varied
criteria for the identification of inevitable early pregnancy
demise. An empty gestational sac of ≥ 25 mm diameter
and a missing yolk sac with a gestational sac diameter of
≥ 20 mm appear to be the most accurate thresholds for the
diagnosis of early embryonic demise, with an estimated
specificity of 1.00. However, it should be noted that
both thresholds had a 95% CI of 0.96–1.00, indicating
that up to four in every 100 diagnoses may be a false-
positive one. Although other criteria may have equally
high specificities reported, all of these studies involved
very few patients.
There was a fair amount of inconsistency among the
reported specificities. For instance, empty gestational sacs
≥ 16 mm and ≥ 17 mm were reported to have a high
specificity in two studies13,15, but the use of a more con-
servative threshold (> 20 mm) gave very poor specificity
for the diagnosis of early embryonic demise12. None of the
studies evaluated the reproducibility and repeatability of
these early pregnancy measurements. Furthermore, only
half had access to an endovaginal probe. The latter two
criteria are relevant when considering the very small mea-
surements that are taken to make the diagnosis of early
pregnancy demise. In clinical practice, operator error is
Goldstein 1992
Goldstein 1992
Levi 1990
Goldstein 1992
Goldstein 1992
Scott 1987
Nyberg 1987
Nyberg 1986
Ismail 1991
Tongsong 1994
Levi 1988
Nyberg 1987
Nyberg 1986
Tongsong 1994
Levi 1988
Levi 1988
Levi 1988
Sensitivity
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
0.50 (0.01–0.99)
0.50 (0.12–0.88)
0.65 (0.45–0.81)
0.50 (0.12–0.88)
0.50 (0.07–0.93)
0.46 (0.35–0.56)
0.20 (0.08–0.39)
0.29 (0.19–0.40)
0.81 (0.70–0.89)
0.50 (0.43–0.58)
0.50 (0.12–0.88)
0.14 (0.04–0.33)
0.41 (0.30–0.52)
0.96 (0.92–0.99)
0.67 (0.38–0.88)
1.00 (0.54–1.00)
1.00 (0.54–1.00)
Sensitivity (95% CI)
Specificity
0.59 (0.41–0.75)
Levi 1990 0.64 (0.41–0.83) 0.82 (0.63–0.94)
0.65 (0.48–0.79)
0.88 (0.73–0.96)
1.00 (0.90–1.00)
1.00 (0.87–1.00)
1.00 (0.69–1.00)
1.00 (0.93–1.00)
1.00 (0.96–1.00)
0.57 (0.29–0.82)
1.00 (0.88–1.00)
1.00 (0.88–1.00)
1.00 (0.93–1.00)
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1.00 (0.69–1.00)
1.00 (0.92–1.00)
1.00 (0.88–1.00)
1.00 (0.88–1.00)
Specificity (95% CI)Study yearSonographic criteria
No cardiac activity
CRL < 4mm
CRL < 4mm
CRL < 5mm
CRL < 5mm
Empty gestational sac (GS)
CRL > 6mm
CRL > 5mm
Diameter > 26mm
MSD ≥ 25mm
Largest diameter > 20mm
MSD ≥ 25mm
MSD ≥ 17mm
MSD ≥ 16mm
Absent yolk sac
MSD ≥ 20mm
MSD ≥ 20mm
No cardiac activity in
   GS MSD ≥ 16mm
MSD ≥ 13mm
MSD ≥ 8mm
Combined criteria
No embryo or cardiac
   activity in GS
   MSD ≥ 16mm
Figure 3 Sensitivity and specificity of first-trimester ultrasound criteria in diagnosing early embryonic demise. CRL, crown–rump length;
MSD, mean sac diameter.
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common and it is not unusual for small embryos to be
missed by inexperienced examiners. The reviewed studies
did not stipulate if a policy of two independent examiners
confirming the diagnosis was undertaken routinely.
Reference standards
The main problem with these studies is the use of varied
reference standards. The only conclusive criterion to
diagnose miscarriage is documentation of spontaneous
expulsion of histologically confirmed pregnancy tissue or
the finding of retained products in the uterus in a woman
with previous evidence of intrauterine gestational sac on
ultrasound examination. The patient follow-up in such
studies needs to be of sufficient length to allow a conclusive
diagnosis of early pregnancy demise to be made. This will
depend on many factors, such as presumed gestational
age, growth of gestational sac, presence of intragestational
sac structures and presence of an embryo. It is possible
that some abnormal pregnancies will develop much more
slowly than do normal pregnancies and that the heartbeat
will eventually appear at a much later gestation than
normal. Finally, a biochemical threshold, such as a decline
in serum hCG on follow-up measurements, may be a
powerful predictor of miscarriage, but does not preclude
laboratory error or a physiological drop in hCG late
in the first trimester. Most studies did not use rigorous
standards for the diagnosis of early pregnancy demise,
relying rather on medical chart reviews or subsequent
ultrasound thresholds to ‘confirm’ early pregnancy loss,
thereby potentially biasing the results.
Conclusion
This review is the first to comprehensively collate evidence
of the role of ultrasound in diagnosing early embryonic
demise. The review is strengthened by its broad search
strategy without language restrictions and assessment
of quality of the included studies. The findings were
limited by the small number and poor quality of
the studies, small number of patients evaluated and
heterogeneity in the tests and outcome assessment. Most
studies were also conducted some two decades ago and
changes in ultrasound technology and the introduction of
transvaginal probes would have affected the accuracy
and generalizability of the findings. An appropriately
powered study using current ultrasound technology, a
transvaginal approach and the appropriate reference
standard for pregnancy success or loss is urgently
required before setting future standards for the accurate
diagnosis of early embryonic demise. In order for these
studies to be successful, however, a consensus about an
appropriate methodological approach should be reached
before embarking on further projects.
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ABSTRACT
Recurrent miscarriages are postimplantation failures in natural conception; they are also 
termed as habitual abortions or recurrent pregnancy losses. Recurrent pregnancy loss is 
disheartening to the couple and to the treating clinician. There has been a wide range of 
research from aetiology to management of recurrent pregnancy loss. It is one of the most 
debated topic among clinicians and academics. The ideal management is unanswered. 
This review is aimed to produce an evidence‑based guidance on clinical management of 
recurrent miscarriage. The review is structured to be clinically relevant. We have searched 
electronic databases (PubMed and Embase) using different key words. We have combined 
the searches and arranged them with the hierarchy of evidences. We have critically 
appraised the evidence to produce a concise answer for clinical practice. We have graded 
the evidence from level I to V on which these recommendations are based.
KEY WORDS: Aspirin, antiphospholipids syndrome, immunotherapy, low molecular 
weight heparin, recurrent pregnancy loss, recurrent miscarriage, unexplained
to generate most relevant results. The 
evidence was searched using individual 
subclass of etiology of recurrent pregnancy 
loss. Different key words were used such as 
recurrent miscarriage, recurrent pregnancy 
loss, habitual abortions, pregnancy failures, 
unexplained, and idiopathic miscarriage; 
and these words were combined with 
various factors known to cause or treat 
miscarriages. The search results were 
combined and most relevant results were 
grouped together for critical appraisal. 
The evidence was sought for all current 
recommendations as well as all unanswered 
questions on investigating and managing 
recurrent miscarriages. The good‑quality 
meta‑analysis was critically apprised 
and accepted. The recommendations are 
based on evidence. The evidence is graded 
as (I‑IV).
I. High‑quality meta‑analyses, systematic 
reviews of randomized controlled trials 
or randomized controlled trials with a 
very low risk of bias
II. Meta‑analyses, systematic reviews 
of randomized controlled trials or 
randomized controlled trials with a high 
risk of bias or high‑quality case–control 
or cohort studies
INTRODUCTION
Spontaneous miscarriage is a major loss 
for all pregnant women. It affects 1% of all 
women.[1] The incidence of spontaneous 
miscarriage may be much greater than 
is clinically recognized. Spontaneous 
miscarriage occurs in 12% to 15% of all 
pregnancies. Thirty percent pregnancies are 
lost between implantation and sixth week. 
Maternal age and previous miscarriages 
increases risk of subsequent miscarriages.[2] 
The management of recurrent miscarriages 
is an unsolved problem; up to 50% of cases 
of recurrent losses will not have a clearly 
defined etiology. The investigations and 
management of recurrent miscarriages is one 
of the most debated topics. This review is 
aimed to provide evidence‑based approach 
to manage recurrent pregnancy loss. This 
review is structured to be clinically relevant.
MATERIALS AND METHOD
Literature search was performed using 
e lectronic  databases ,  Embase ,  and 
PubMed (1950 to Jan 2014). We have used 
different keywords and MeSH terms to 
generate set of results with were combined 
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III. Well‑conducted case–control or cohort studies with risk 
of confounding, bias
IV. Nonanalytical studies, e.g. case reports, case series
V. Expert opinion
Clinical Guideline
Definition
Recurrent miscarriages are defined as three or more 
consecutive miscarriages.[1] The Practice Committee of the 
American Society for Reproductive Medicine[3] defines 
recurrent pregnancy loss as by two or more failed clinical 
pregnancies. The risk of recurrent spontaneous miscarriage 
is much higher in patients with previous losses. The risk 
of miscarriage after two consecutive losses is 17% to 25% 
and the risk of miscarrying fourth pregnancy after three 
consecutive losses is between 25% and 46%. The risk gets 
worse with increasing maternal age.[4] The evidence suggests 
higher frequency of spontaneous miscarriages amongst 
subfertile couples and a higher prevalence of subfertility 
in women with recurrent spontaneous miscarriages when 
compared with the general population.[5] Self‑reported losses 
by patients may not be accurate. In one study, only 71% of 
self‑reported clinical pregnancy losses could be verified in 
hospital records.[6] It is important to define pregnancy as 
a clinical pregnancy documented by ultrasonography or 
histo‑pathological examination (Evidence level IV).
Investigations
Genetic
The prevalence of chromosome abnormalities in women 
facing a single sporadic miscarriage is to be 45%.[7] 
Approximately 50% to 60% of early spontaneous miscarriages 
are associated with a chromosomal anomaly of conceptus. 
Most common abnormality is aneuploidy, with autosomal 
trisomy accounting for more than 50% of chromosomally 
abnormal abortuses.[8] A strong family history of recurrent 
miscarriage or genetic anomaly suggests a parental 
karyotypic abnormality, and a chromosomal analysis of the 
affected partner is appropriate in the primary evaluation. 
Chromosomal analysis of the miscarriage offers an 
explanation in at least 50% of cases.[9] Parental karyotyping 
is not predictive of a subsequent miscarriage.[10] Routine 
karyotyping of couples with recurrent miscarriage is not 
recommended. Cytogenetic analysis may be performed on 
products of conception to avoid unnecessary evaluation and 
treatment and because an aneuploid conceptus indicates a 
somewhat greater likelihood of success with a subsequent 
pregnancy[10] (Evidence Level III).
Anatomical defects
Women with recurrent pregnancy loss have a 3.2% to 6.9% 
likelihood of having a major uterine anomaly and 1.0% to 
16.9% chance of having an arcuate uterus.[11] Ultrasound is 
quick, readily available, economical, and lacks radiation. 
2D US can only identify about half of the congenital 
uterine anomalies present, but it has very low false positive 
rate.[12] Some authors consider that this combination of 
hysteroscopy and laparoscopy can be the gold standard 
in evaluating congenital uterine anomalies.[13‑16] However, 
these are invasive tests. Three‑dimensional ultrasound by 
experienced hands is a more accurate than two‑dimensional 
ultrasound and equal to MRI at assessing uterine anomaly.[17] 
Sonohysterography is a noninvasive, cost‑effective method 
with 95% accuracy in identifying uterine anomalies.[18] 
MRI is a highly sensitive and specific method available 
because of its superior ability to reliably visualize complex 
uterovaginal anatomy.[19] Two‑dimensional ultrasound can 
be used as an initial screening tool. Combined hysteroscopy 
and laparoscopy, sonohysterography, MRI, and 3D US can 
be used for a definitive diagnosis (Evidence level II).
Infections
Bacterial vaginosis is a risk factor for preterm delivery 
and a strong risk factor for late miscarriages.[20] Vaginal 
swabs should be considered as screening tests during 
pregnancy in high risk women with previous history of late 
miscarriages.[21] TORCH test is not recommended (Evidence 
level II).
Haematological disorders
Acquired thombophilia
Antiphospholipid syndrome (APS) is the only proven 
thrombophilia that is associated with adverse pregnancy 
outcomes.[22] Five to fifteen percent of women with recurrent 
miscarriage have clinically significant antiphospholipid 
antibody titres, as compared with 2% to 5% of unselected 
obstetrical patients.[23] Antiphospholipid syndrome (APS) 
is an autoimmune disease with the presence of 
antiphospholipid autoantibodies (aPL) formed against 
the person’s own tissues. These autoantibodies interfere 
with coagulation. Recurrent pregnancy loss will test 
positive for antiphospholipid antibodies (aPLs), the actual 
reported range varies between 8% and 42%.[24,25] Laboratory 
testing for aPL Abs should generally be limited to patients 
who present with the thrombotic and/or the pregnancy 
manifestations of the disorder. Weak positive test results 
for aPL immunoassays are unlikely to have any clinical 
significance. The two assays that were preferred were the 
dilute Russell viper venom time (dRVVT) panel, which 
is widely used in clinical laboratories and is believed to 
be specific for detecting LA in those patients at high risk 
of thrombosis,[26] and an LA‑insensitive aPTT.[27] Testing 
positive for aCL Abs does not necessarily mean that a 
patient has APS. The positive test may be triggered by a 
preceding infection, such as syphilis, Lyme disease, EBV, 
CMV, HIV, and hepatitis C virus. These patients do not 
have LA or elevated Abs against β2GPI.[28] Anti‑β2GPI 
immunoassays are more specific but less sensitive for APS 
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than aCL Ab assays.[29] The antiphospholipid syndrome 
should be diagnosed only when two tests performed 
12 or more weeks apart are positive (Evidence level I). 
International Consensus classification criteria for diagnosis 
of the antiphospholipid syndrome is based on the presence 
of at least one of the clinical criteria and one of the laboratory 
criteria.[25,30] Laboratory criteria includes the presence of 
Lupus anticoagulant (LA) or Anticardiolipin (aCL) antibody 
of IgG and/or IgM isotype in serum or plasma, present 
in medium or high titer Anti‑β2 glycoprotein‑I antibody 
of IgG and/or IgM isotype in serum or plasma on two 
or more occasions, at least 12 weeks apart, measured by 
a standardized ELISA. Clinical criteria include vascular 
thrombosis or pregnancy morbidity. One or more 
unexplained deaths of a morphologically normal fetus at or 
beyond the 10th week of gestation, severe pre‑eclampsia or 
eclampsia, or recognized features of placental insufficiency 
before 34 weeks gestation and three or more unexplained 
consecutive spontaneous abortions before the 10th week of 
gestation are features of pregnancy morbidity. The presence 
of any one of these clinical features plus abnormal laboratory 
test diagnose antiphospholipid syndrome (Evidence level 
I). When a patient has the clinical appearance of APS but 
negative standard aPL assay results, there is possibility 
of seronegative APS. Noncriteria tests such as aCL and 
anti‑β2GPI IgA Abs and antiphosphatidylserine Abs may 
help to clarify the picture[28] (Evidence level II) Ruffatti 
showed that pregnant women with APS reported that 
patients with triple aPL Ab‑positivity (ie, positivity 
for LA, aCL, and anti‑β2GPI Abs) and/or previous 
thromboembolism had an increased likelihood of poor 
neonatal outcomes than patients with double or single 
aPL Ab positivity and no thrombosis history.[31] However, 
other study showed that lupus anticoagulant is the primary 
predictor of adverse pregnancy outcome in aPL‑associated 
pregnancies[32] (Evidence level III).
Inherited Thrombophilia: Antithrombin activity, 
Protein C activity, Protein S levels, Factor V Leiden (F5), 
and/or prothrombin G20210A (F2)
Inherited thrombophilias such as factor V Leiden mutation, 
prothrombin gene mutation (PT 20210A), and deficiencies 
of natural anticoagulants protein C, protein S, and 
antithrombin are associated with recurrent miscarriage.[33] 
The existence of a causal role for heritable thrombophilia 
and pregnancy failure is controversial.[22] A combination 
of risk factors, including multiple inherited thrombophilic 
defects are associated with secondary hypercoagulable 
states.[34] Case–control studies have shown a modest 
association (odds ratios of 2 to 3) between recurrent 
miscarriage and thrombophilias such as the factor V Leiden 
mutation and the prothrombin G20210A mutation.[35] This 
association is stronger for fetal deaths, such as stillbirths 
after 20 weeks’ gestation, than for recurrent early losses. 
Many other large prospective cohort studies have not 
shown significant associations between thrombophilias and 
sporadic pregnancy loss.[36‑38] However, the strength of the 
association between inherited thrombophilia and recurrent 
miscarriage is not very strong, and more importantly, no 
evidence indicates that the use of anticoagulants improves 
the chance of live birth in these women.[39] A disadvantage 
of testing patients with a VTE for thrombophilia is the 
high costs of testing. Thrmbophilia testing should not be 
performed routinely in women with recurrent miscarriage 
except in the context of scientific studies[39] (Evidence level I).
MTHFR mutation
M T H F R  ( E C  1 . 5 . 1 . 2 0 )  i s  a  k e y  e n z y m e  i n 
one‑carbon metabolism. The enzyme catalyzes the 
conversion of 5,10‑methylenetetrahydrofolate into 
5‑methyltetrahydrofolate, the predominating circulating 
form of folate.[40] MTHFR gene polymorphisms are 
commonly associated with hyperhomocysteinemia[41,42] 
Thus, hyperhomocysteinemia is considered as a risk 
factor for neural tube defects (NTD)[43,44] and recurrent 
embryo loss[44,45] Homocysteine levels vary, depending on 
an individual’s state when measured (intake of folic acid, 
vitamin B12); therefore, it is difficult to achieve representative 
results. Mild hyperhomocysteinaemia has been identified 
as a risk factor for arterial disease and venous thrombosis. 
The evidence is conflicting on hyperhomocysteinaemia as a 
risk factor for recurrent miscarriage.[46,47] Therefore, testing 
for MTHFR mutation is not a part of routine evaluation for 
recurrent miscarriage. (Evidence level II).
Thromboelastography
The test is not recommended as routine investigation for 
recurrent miscarriage currently as little evidence to support 
it (Evidence level III). It is argued that thromboelastography 
identifies a proportion of women with recurrent early 
miscarriages who are in a pro‑thrombotic state outside of 
pregnancy.[48] Thromboelastography, a “near patient” test 
of whole blood hemostasis by dynamically assessing the 
kinetics, strength and stability of the fibrin clot.[49]
Endocrine:
PCO, elevated LH, and insulin resistance
Polycystic ovaries (PCO) is the most commonly identified 
ultrasound abnormality amongst women with recurrent 
miscarriages.[50] The prevalence of PCO is 40% among 
women with recurrent miscarriage; however, polycystic 
ovarian morphology is not predictive of pregnancy loss 
amongst ovulatory women with recurrent miscarriage 
conceiving spontaneously. The ultrasound diagnosis of 
PCO in women with a history of recurrent miscarriage 
does not necessarily predict a poor outcome in subsequent 
pregnancy and therefore it is not recommended[51] (Evidence 
level III).
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It has been reported that hypersecretion of basal LH 
with or without polycystic ovaries is a risk factor for 
miscarriage. Women with elevated LH, a frequent feature 
of the polycystic ovary syndrome, are at increased risk for 
miscarriage after either spontaneous or assisted conception. 
However, suppression of endogenous LH release before 
conception, in women with elevated circulating LH 
concentrations and a history of recurrent miscarriage, did 
not improve the live birth rate. Neither an elevated serum 
luteinizing hormone concentration (>10 IU/l) nor an elevated 
serum testosterone concentration (>3 nmol/l) was associated 
with an increased miscarriage rate.[52]
Insulin resistance plays a significant role in recurrent 
pregnancy loss.[53] Insulin resistance can be independent of 
polycystic ovarian status. Women with a history of recurrent 
miscarriage are at an increased risk for insulin resistance 
during the first trimester of a new pregnancy.[54,55] Recent 
meta‑analysis concluded that insulin resistance is associated 
with the susceptibility to recurrent miscarriages, and it may 
contribute to the occurrence of recurrent miscarriages.[56] 
Therefore, insulin resistance might be one of the direct 
causes that lead to recurrent miscarriage.[57]
Luteal Phase defect
The shortened luteal phase has been associated with 
pregnancy loss but the assessment and interpretation of 
a putative luteal phase defect is problematic. The use of 
histological and biochemical endpoints as diagnostic criteria 
for endometrial dating are unreliable (Evidence level III).
Diabetes Mellitus
Evaluation for diabetes is advised with clinical suspicion. 
Glycated hemoglobin test is advised to screen diabetes. 
The best test is the oral glucose tolerance test (OGTT), but 
it is the most expensive, is inconvenient. Fasting plasma 
glucose would miss people with impaired glucose tolerance. 
Glycated hemoglobin does not require fasting, and may be 
the best compromise[58] (Evidence level III).
Thyroid Disorders
Thyroid Function Tests and Thyroid antibody (Thyroid 
Peroxidase Antibody ‑TPO) Tests: Recurrent miscarriages 
are associated with clinical and sub clinical thyroid 
disorders. Thyroid function tests are recommended based 
on clinical history while evaluating miscarriages. Evidence 
is controversial about role of TPO antibodies.[59] Pregnant 
women with subclinical hypothyroidism or thyroid 
antibodies have an increased risk of recurrent miscarriage.[60,61] 
TPO antibody screening is not recommended[62] (Evidence 
level II).
Immunology
A significant proportion of recurrent pregnancy loss is 
associated with immune aetiologies.[63] Various mechanisms 
are suggested. Peripheral natural killer (pNK) and uterine 
NK (uNK) cells have been associated with reproductive 
failure. Abnormally functioning immunocompetent cells, 
including natural killer (NK) cells, in the endometrium, are 
thought to be responsible and treatment trials including 
oral prednisolone and intravenous immunoglobulins are 
now underway.[64] Peripheral immunological dysfunction is 
observed with recurrent miscarriage.[65] Chronic histiocytic 
intervillositis is a rare type of placental pathology that is 
associated with reproductive loss. It is considered to be an 
immunologic origin.[66] Many studies have suggested that 
women with recurrent miscarriages have signs of generally 
exaggerated inflammatory immune responses both before 
and during pregnancy and signs of breakage of tolerance 
to autoantigens and fetal antigens.[67] There is neither an 
adequate standardization of counting uterine NK cells nor 
consensus as to what constitutes an abnormal level.[64] The 
prognostic value of measuring pNK or uNK cell parameters 
is uncertain. Further evidence is required to confirm or 
refute the role of NK cell assessments as a predictive test for 
screening women who may benefit from immunotherapy.[68] 
No immunological test is currently recommended in the 
recurrent miscarriage work up (Evidence level I).
Male factors
Sperm samples from recurrent pregnancy loss couples 
have an increase in their sperm DNA fragmentation.[69‑71] 
Meta‑analysis showed a significant increase in miscarriage 
in patients with high DNA damage compared with those 
with low DNA damage.[72] The associating sperm quality 
with recurrent pregnancy loss emphasizes the importance 
of evaluating male factor by tests. Several different tests are 
available, but no consensus has yet been reached as to which 
tests are most predictive. Among terminal uridine nick‑end 
labeling assay (TUNEL), sperm chromatin structure 
assay (SCSA), sperm chromatin dispersion (SCD), and 
alkaline Comet assays, the alkaline COMET assay showed 
better prediction for male infertility.[73] A chromosomal 
abnormality was found in 15.2% men with azoospermia and 
in 2.3% nonazoospermic men. Male factors abnormality is a 
significant cause for recurrent pregnancy loss after assisted 
conception. The number of azoospermic men who needs 
to be screened to prevent one miscarriage is 80–88 and the 
number need to screen is 315–347 in the nonazoospermic 
group.[74] Although there is some evidence of association 
between DNA defragmentation and recurrent miscarriage, 
well‑designed prospective studies are needed before 
using these tests in clinical practice.[75] Routine testing for 
spermploidy (e.g. fluorescence in situ hybridization [FISH]) 
or DNA fragmentation is not recommended (Evidence 
level II).
Management
Referral to recurrent miscarriage clinic and expert advice 
help us improve the reproductive outcome
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Tender loving care and lifestyle advice
A cause for recurrent miscarriage can be identified 
approximately 50–60% of the time. There is tremendous 
psychological impact of recurrent miscarriage. [76] 
Psychological support in the form of frequent discussions 
and sympathetic counseling are crucial to the successful 
evaluation and treatment of the anxious couple. When 
no etiologic factor is identified, no treatment started 
at 60% to 80% fetal salvage rate still may be expected. 
Therefore, couples with unexplained recurrent miscarriage 
should be offered appropriate emotional support and 
reassurance[77] (Evidence level III). Obesity,[78] cigarette 
smoking,[79] alcohol use,[80] and moderate‑to‑heavy caffeine 
use[81] may be associated with sporadic miscarriage, but 
its association with recurrent miscarriage is uncertain. 
Cigarette smoking has been suggested to have an adverse 
effect on trophoblastic function and is linked to an increased 
risk of sporadic pregnancy loss.[82] The Cochrane review 
concludes that any vitamin supplements prior to pregnancy 
or in early pregnancy do not prevent women experiencing 
miscarriage or stillbirth.[83] Lifestyle modification and stress 
reduction should be emphasized by pointing out that a 
healthier lifestyle, free from tobacco, alcohol, illicit drugs, 
and undue stress cannot hurt and may significantly improve 
the couple’s chances for a successful pregnancy (Evidence 
level III).
Genetic anomalies
In vitro fertilization (IVF) plus prenatal genetic testing is 
a suggested strategy in the management of couples with 
chromosomal abnormalities and recurrent miscarriages.[84] 
It is proposed as a faster method of conceiving a live child 
than natural conception, at least for translocation carriers 
with recurrent miscarriages.[85] However, this evidence is 
being questioned. Systematic reviews showed that there is 
no conclusive evidence to support prenatal genetic screening 
for unexplained recurrent miscarriages as well as structural 
chromosome abnormality.[84,86,87] The new technologies such 
as trophectoderm‑laser‑assisted blastocyst biopsy and 
molecular karyotyping via whole genome amplification 
and either comparative genomic hybridization (CGH) or 
single nucleotide polymorphism (SNP) arrays helped to 
revitalize the concept of preimplantation genetic screening. 
The evidence from these newer technologies is awaited. 
Because of the lack of evidence, assisted conception 
with preimplantation genetic screening as a treatment of 
recurrent miscarriage is not recommended (Evidence level 
II).
Anatomical defects
Almost 65% to 85% of patients with bicornuate or 
septate uteri have a successful pregnancy outcome after 
metroplasty. However, 59.5% of the patients with such 
anomalies have a successful subsequent pregnancy 
without surgery, with a cumulative live birth rate of 78.0%. 
Further evidence is needed to recommend metroplasty 
surgery in these women[11] (Evidence level II). The clinical 
management of pregnancy‑loss patients with Asherman 
syndrome/intrauterine synechiae, uterine fibroids, and 
uterine polyps is also controversial, and there is no 
conclusive evidence that surgical treatment reduces the 
risk of pregnancy loss. Minimally invasive surgeries are 
the better option for the treatment of structural defects. 
Cervical incompetence is treated with cervical encirclage; 
however, the CERVO trial demonstrated no added benefit 
of circlage.[88] Trans‑vaginal Ultrasound examination 
in subsequent pregnancy is indicated with history of 
midterm loss due to cervical incompetence, The current 
data suggest that emergency cerclage is associated with 
a longer latency and period better pregnancy outcomes 
when compared with bed rest.[89] (Evidence level III). The 
accuracy of cervical length in predicting preterm delivery 
is relatively poor.[90] Compared to the McDonald technique, 
the Shirodkar technique was more effective in prolonging 
pregnancy in patients with singleton pregnancies 
undergoing ultrasound‑indicated cerclage[91] (Evidence level 
III). Cerclage, vaginal progesterone, or pessary are equally 
efficacious in the prevention of preterm birth in women with 
a short cervix detected on sonogrphy at the midtrimester 
in singleton gestation[92,93] (Evidence level II).
Infection
Treatment of asymptomatic abnormal vaginal flora and 
bacterial vaginosis with oral clindamycin early in the second 
trimester significantly reduces the rate of late miscarriage 
and spontaneous preterm birth in a general obstetric 
population[20,94] (Evidence II).
Endocrine disorders
It  is  generally agreed that maternal endocrine 
disorders (e.g. diabetes, thyroid dysfunction) should be 
evaluated and treated.[95,96] Though elevated LH is associated 
with increased risk of miscarriage suppression of LH 
secretion with GnRH agonist prior to ovulation induction 
yielded no difference in outcome. Hyperprolactinemia 
may be associated with recurrent pregnancy loss through 
alterations in the hypothalamic‑pituitary‑ovarian 
axis, resulting in impaired folliculogenesis and oocyte 
maturation, and/or a short luteal phase. Normalization 
of prolactin levels with a dopamine agonist improved 
subsequent pregnancy outcomes in patients with recurrent 
pregnancy loss Hyper‑prolactinemia is treated with 
dopamine agonist.[97] Thyroid disorders can be treated 
medically to achieve euthyroid status and medications 
should be modified with pregnancy appropriately. There 
is lack of consensus regarding the definition of a normal 
upper limit of TSH. A consensus is emerging that TSH 
values more than 2.5 mIU/L are outside the normal range.[3] 
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Thyroid hormone requirement in early pregnancy is higher. 
The aim is to maintain baseline TSH < 2.5 mU/L. Some 
evidence suggests association of raised thyroid (TPO) 
antibodies with recurrent miscarriage.[62,98] Levothyroxine 
50 µg daily for the women with raised TPO antibodies with 
normal TSH is suggested intervention. Observational study 
suggest TPO Ab‑positive status does not have a prognostic 
value regarding the outcome of a subsequent pregnancy, 
and empirical thyroxine therapy in those who tested 
positive did not seem to improve outcome.[59] The thyroid 
antibodies and levothyroxine study (TABLET) study is a 
randomized controlled trial of the efficacy and mechanism 
of levothyroxine treatment on pregnancy and neonatal 
outcomes in women with thyroid antibodies. This study 
will help to find the role of thyroxin treatment for women 
with normal thyroid function tests but raised thyroid 
peroxidase antibody (TPO) (http://www.controlled‑trials.
com/ISRCTN15948785/). Until robust evidence is available, 
thyroxine treatment is not recommended in raised 
thyroid antibody status with normal thyroid function 
tests (Evidence level III).
Progesterone supplementation
The progesterone act as immmunomodulator and it 
shift from proinflammatoryTh‑1 cytokine responses 
to anti‑inflammatory Th‑2 cytokine response which 
is more favorable and pregnancy protective. [99,100] 
Dihydrogesterone is a potential immunomodulator, it 
produces progesterone‑induced blocking factors (PIBF) 
which is protein produced by pregnancy lymphocyte 
following exposure to progestorene. PIBF inhibits 
cell‑mediated cytotoxicity and natural killer cell 
activity. Thus, it is immunoprotective for pregnancy. 
Administration of progesterone to women with sporadic 
miscarriages is ineffective.[97,101] However, in patients 
with three or more consecutive miscarriages immediately 
preceding their current pregnancy, empiric progestogen 
administration may be of some potential benefit.[97,101‑103] 
A large multicenter study called promise study (http://
www.medscinet.net/promise) is currently underway to 
assess the benefit of progesterone supplementation in 
women with unexplained recurrent miscarriages. Most 
commonly used regime is micronized progesterone tablets 
400 mg daily. The route of administration may be either 
vaginal or oral. The argument for use of progesterone is 
that there is no evidence of harm and some evidence of 
benefit, although not coming from huge multicentric trials. 
The decision should be based on clinician’s discretion 
until strong evidence is available to recommend routine 
use (Evidence level III).
Metformin
Data on the use of metformin to decrease the chance of 
miscarriage are contradictory as no adequately powered 
trials have been published. Insulin resistance is an 
independent risk factor for spontaneous miscarriage in 
spontaneous pregnancy. Patients with insulin resistance 
should be advised to improve their insulin sensitivity 
through lifestyle change or medical intervention 
before infertility treatment to reduce their risk of 
spontaneous miscarriage. Nonrandomized studies 
have shown that the reduction in insulin levels with 
metformin in insulin‑resistant individuals may reduce 
miscarriage risk by restoring normal hemostasis and 
improving the endometrial milieu[104,105] Metformin is not 
recommended as a treatment of recurrent miscarriage 
(Evidence level III).
Hematological disorders:
Antiphospholipid syndrome
Low doses of acetylsalicylic acid and low molecular weight 
heparin (LMWH) are the best solution in women suffering 
from recurrent spontaneous miscarriage. This treatment 
combination of low dose aspirin and low molecular weight 
heparin reduces the miscarriage rate by 54%.[106] The role 
of low molecular weight heparin and aspirin treatment 
specifically for the prevention of recurrent miscarriage 
remains controversial. The meta‑analysis showed the 
combination of unfractionated heparin and aspirin confers 
a significant benefit in live births. However, the efficacy 
of low molecular weight heparin plus aspirin remains 
unproven as LMWH data were based on only two trials. 
These trials were criticized as studies were not blinded and 
the randomization procedure had been criticized in one of 
the trials and inclusion criteria were very different. Third 
trial showed no significant difference in live birth rate with 
LMWH treatment versus aspirin or a combination of both 
versus aspirin in women with recurrent miscarriage.[107] 
A small trial showed comparable results with LMWH 
plus aspirin as an alternative to unfractionated heparin 
and aspirin in the management of recurrent miscarriage 
secondary to APS.[108] The consensus is combination of 
low molecular weight heparin and aspirin is superior to 
aspirin alone in achieving more live births. Therefore, 
it is recommended treatment for recurrent miscarriages 
with antiphospholipid syndrome[109,110] (Evidence level I). 
Glucocorticoids should not be given in antiphospholipid 
antibodies syndrome without connective tissue disorder. 
Low‑dose prednisone is given when lupus is present 
and with the advice of rheumatologist. Prednisone 
does not prevent recurrent fetal death in women with 
antiphospholipid antibody.[111] Women with a history of 
thrombosis in whom the antiphospholipid syndrome or 
a heritable thrombophilia is diagnosed should receive 
an appropriate dose of unfractionated heparin or 
low‑molecular‑weight heparin[23] (Evidence level I). A third 
trial could not find that heparin/aspirin was better than 
aspirin alone.
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Inherited Thrombophilia
Role of anticoagulation therapy in the treatment of 
recurrent miscarriages with hereditary thrombophilia is 
debatable. Few studies suggested low molecular weight 
heparin therapy during pregnancy may improve the live 
birth rate of women with second‑trimester miscarriage 
associated with inherited thrombophilia.[112‑114] However, 
there is currently no evidence supporting treatment, because 
observational research is hampered by poor methodology 
or inconsistent results.[115] Recent meta‑analysis showed that 
the use of LMWH in women with inherited thrombophilia 
with recurrent pregnancy loss is not indicated.[116] Women 
with thrombophilia should be followed closely without 
routine prophylactic low molecular weight heparin other 
than for prevention of venous thromboembolism in limited 
circumstances (Evidence level I).
Hyperhomocysteinemia and MTHFR mutation
High‑dose folic acid (5 mg) and vitamin B12 (0.5 mg) once 
daily has been reported to reduce levels of homocysteine; 
however, a randomized‑controlled trial on the effect of 
variable doses of both vitamins on pregnancy has yet to be 
conducted. High‑dose folic acid is considered with women 
with high BMI and diabetes. There is no evidence to support 
usage of 5 mg folic acid from pre‑pregnancy stage purely to 
reduce the risk of recurrent miscarriage (Evidence level III).
Fibrinolytic anomalies
Activators and inhibitors of the fibrinolytic system are 
frequently abnormal in recurrent miscarriage.[117] Plasma 
levels of tissue factor activity, thrombomodulin activity, 
and procoagulant phospholipids were significantly higher 
in recurrent miscarriage group.[118] Clinical evaluation 
of recurrent miscarriage does not include investigating 
fibrinolytic anomalies. It is limited to the research interest.
Immunotherapy
Both organ‑specific and systemic autoimmunity are 
associated with an increased prevalence of recurrent 
miscarriage. Immune modulating therapies have been 
mooted as potential therapeutic strategies. There is no 
specific immunological test or clinical method, which will 
predict the need for treatment. Mechanisms of possible 
efficacy of high dose of intravenous immunoglobulin 
therapy for recurrent miscarriage may include enhancement 
of CD94 expression and subsequent suppression of NK 
cell cytotoxicity.[119] Evidence does not support routine use 
of intralipid therapy.[120] The Cochrane review analyzed 
various strategies including paternal cell immunization, 
third‑party donor leukocytes, trophoblast membranes, and 
intravenous immune globulin. None of these interventions 
proved beneficial over placebo in improving the live birth 
rate.[121] This Cochrane review has been widely criticized for 
not making the necessary sub‑analyses between primary and 
secondary recurrent miscarriage. Meta‑analysis showed that 
IVIG increased the rates of live birth in secondary recurrent 
miscarriage, but there was insufficient evidence for its use in 
primary recurrent miscarriage.[122] There is risk of possible 
complications such as undesirable immune responses 
and the possibility of transmitting infectious diseases 
like cytomegalovirus. The risk of transmitting infections 
disease with intravenous immunoglobulin is extremely 
small. Most recent systematic review and meta‑analysis 
concludes that NK cell analysis and immune therapy should 
be offered only in the context of clinical research.[123] The 
current recommendation is immunotherapy should not be 
advised.[121] (Evidence level II)
Unexplained recurrent miscarriage
• Psychological support: Stress itself is a risk factor for 
miscarriage[124] and recurrent miscarriage is a stressful 
condition so that the vicious cycle can be broken by 
strong psychological support. Women should be 
reassured for a successful future pregnancy with 
supportive care.[125,126] (Evidence level III)
• Aspirin 75 mg OD: Evidence is debatable. There is 
paucity of evidence to make any recommendation on 
aspirin for treating recurrent miscarriage in women 
without antiphospholipid syndrome.[115] Few RCT 
suggested clear benefit of using aspirin for such 
women.[127] Recent trial failed to support any role of 
Aspirin in unexplained recurrent miscarriage.[128] 
Aspirin helps in improving uterine perfusion.[129] Aspirin 
is useful in many undiagnosed implantation failure 
patients. However, in the absence of strong evidence, 
routine use of Aspirin is not recommended (Evidence 
level II)
• Progesterone: Meta‑analysis of 4 randomized trials 
and only 132 women in total showed a statistically 
significant reduction in miscarriages.[130] Further, the 
evidence is awaited before making recommendation on 
use of progesterone in explained miscarriage. (Evidence 
level III)
• LMWH: Use of LMWH to prevent miscarriage is not 
recommended in the absence of antiphospholipid 
syndrome (Evidence level II)
• Human chorionic gonadotrophin (hCG): Recent 
Cochrane review failed to find quality evidence to 
support use of hCG for preventing miscarriage.[131] A 
well‑designed randomized controlled trial of adequate 
power and methodological quality is required. Therefore, 
the use of hCG is not recommended (Evidence level II)
• Steriods: The effect of prednisolone therapy for some 
women with recurrent miscarriage may be due to altered 
endometrial angiogenic growth factor expression and 
reduced blood vessel maturation.[132] The role is mostly 
limited to recurrent miscarriage with known connective 
tissue disorders. Rheumatologic advice should be taken 
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with patients diagnosed having recurrent pregnancy 
loss and connective tissue disorder. The results from 
the Prednisolone Trial are awaited; it is a randomized 
controlled trial of prednisolone for women with 
idiopathic recurrent miscarriage and raised uNK cells 
in the endometrium.[133] There is no robust evidence 
to recommend steroid use for unexplained recurrent 
miscarriage (Evidence level III)
• Immunoglobulins: IVIG administration for treatment of 
recurrent miscarriage is not justified outside the context 
of research as discussed earlier (Evidence level II)
• Intravenous intralipid solution: No evidence of benefit 
with use of intralipid. Well controlled, large‑scale, 
and confirmatory studies required before it can be 
recommended for routine use[118,120] (Evidence level III)
CONCLUSION
Recurrent miscarriage is one of most the widely researched 
areas in medicine. Recurrent miscarriage may be the 
first presentation of some of the hematological or 
endocrine disorders. Many investigations such as genetic 
thrombophilia screening are not based on strong evidence. 
The management of unexplained miscarriage is a challenge. 
Role of aspirin and low molecular weight heparin is 
controversial in genetic thrombophilias. Any form of 
immunotherapy is not recommended until further evidence 
is available. We look forward for results of various ongoing 
multicentre trials to produce an answer.
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